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Summary 
Phosphodiesterase type 5 (PDE5) is highly expressed in vascular smooth muscle cells, and its 
inhibition is a primary target for the treatment of erectile dysfunction and pulmonary 
hypertension. Besides, PDE5 plays a pivotal role in disease progressions such as, cardiac 
hypertrophy and ventricular remodeling, myocardial ischemia, aortic stenosis, end stage 
congestive heart failure and atherosclerosis.  
Several PDE5 inhibitors are approved for clinical use or have been introduced in preclinical 
development. Vardenafil, sildenafil, tadalafil, RPP07 (PF-5), JC4712, and RBQ05 are among 
the many to mention few that have been shown to possess avid PDE5 inhibitory activity and 
are in clinical use and/or at development stage.  
Positron emission tomography (PET) is a non-invasive molecular imaging modality that 
uniquely allows exploration of biochemical processes and can quickly be translated from the 
laboratory to clinical application.  Hence, the use of radiolabeled PDE5 inhibitors with short 
lived radionuclides such as carbon-11 and fluorine-18 could potentially enable localization 
and quantification of PDE5 expression in vivo. Exploitation of a suitable PDE5 specific PET 
radioligand(s) would allow quantifying and evaluating changes in PDE5 expression, select 
patients that would benefit from PDE5 inhibitor treatment early during disease progression 
and assess PDE5 occupancy and optimize dose regimens in patients treated with PDE5 
inhibitors. 
In order to realize this goal, PDE5 inhibitors reported in literature to have high in vitro PDE5 
inhibitory activity and specificity were selected and synthesized, radiolabeled and biologically 
evaluated for their suitability to non-invasively visualize PDE5 expression. The binding and 
specificity of radiolabeled radiotracers were evaluated by in vivo and in vitro studies in mice 
and rats. Binding of radiolabeled tracers to PDE5 was initially evaluated by comparing the 
lung retention of the radiotracers in mice and subsequently their specificity for PDE5 was 
verified with a pre-blocking study by pre-treating mice with a structurally different PDE5 
inhibitor. In addition, radiolabeled tracers were evaluated in transgenic mice with 
cardiomyocyte specific PDE5 over-expression.  
In conclusion, four classes of PDE5 inhibitors were radiolabeled and biologically evaluated 
among which the imidazotriazine family ([11C]NMVardenafil and [18F]Fluorovardenafil) and 
pyridopyrazinone family ([11C]RPP07B and [18F]FRPP07) showed the highest in vivo 
retention in the lungs of healthy mice where the enzyme is abundantly expressed. Although 
 XIII 
 
the pyrazolopyrimidinone derivative [11C]JC4714 showed favorable properties in initial 
biological evaluation in healthy mice, further investigation in PDE5 TG mice showed 
moderate to low in vivo binding of the tracer to PDE5. The other investigated compounds 
[11C]PVardenafil, [11C]sildenafil, [11C]RBQ08 and [11C]JC4687 showed low in vivo binding 
and/or specificity for PDE5 rendering them unsuitable for in vivo visualization and/or 
quantification of PDE5. Based on preclinical evaluation of our studies [11C]NMVardenafil has 
been selected for further clinical investigation in selected patients with end-stage heart failure 
awaiting cardiac transplantation. 
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Samenvatting 
Het enzym fosfodiesterase type 5 (PDE5) is verantwoordelijk voor de hydrolyse van cyclisch 
guanosinemonofosfaat (cGMP) naar guanosinemonofosfaat (GMP). PDE5 heeft een hoge 
expressie in de gladde spiercellen van bloedvaten en verschillende PDE5 inhibitoren (zoals 
Viagra) werden geregistreerd voor farmacologische behandeling van erectiele dysfunctie en 
pulmonaire hypertensie. Daarnaast speelt PDE5 ook een belangrijke rol bij aandoeningen 
zoals myocardiale ischemie en hypertrofie, ventriculaire remodeling, aorta stenose, 
eindstadium van congestief hartfalen en atherosclerose.  
Verschillende structureel uiteenlopende PDE5 inhibitoren (o.a. Vardenafil, Sildenafil, 
Tadalafil, RPP07 (PF-5), JC4712 en RBQ05) werden reeds goedgekeurd voor humaan 
gebruik of zijn in het stadium van preklinische of klinische ontwikkeling.  
Positronemissie tomografie (PET) is een niet-invasieve moleculaire beeldvormingstechniek 
die gebruik maakt van radioactieve verbindingen en toelaat biochemische processen in vivo te 
visualiseren en te kwantificeren. Daar er slechts een uiterst kleine massahoeveelheid van een 
radioactieve tracerverbinding voor beeldvorming moet worden toegediend kan een nieuwe 
PET tracerverbinding relatief snel translationeel toegepast worden bij de mens. 
Het gebruik van PDE5 inhibitoren gemerkt met een radionuclide dat met een korte 
halveringstijd vervalt via positronemissie zoals koolstof-11 of fluor-18 laat mogelijk toe om 
de PDE5 expressie in vivo in beeld te brengen en te kwantificeren. 
De toepassing van een gevalideerde PDE5 specifieke PET radioligand zou dus toelaten 
patiënten te selecteren met een lokaal pathologisch verhoogde PDE5 expressie (bij voorbeeld 
na myocardinfarct) die baat kunnen hebben van farmacologische behandeling met een PDE5 
inhibitor. Bovendien zou een geschikte PDE5 tracerverbinding ook toelaten de relatie tussen 
de plasmaconcentratie van een PDE5 inhibitor en de effectieve PDE5 bezetting te 
kwantificeren zodat aan de hand van deze relatie de dosering met PDE5 inhibitoren kan 
worden geoptimaliseerd. 
Verschillende in de literatuur beschreven PDE5 inhibitoren werden geselecteerd voor merking 
met koolstof-11 of fluor-18. De benodigde precursoren en referentieverbindingen werden 
gesynthetiseerd en de radioactief gemerkte verbindingen werden geëvalueerd in proefdieren 
met betrekking tot hun PDE5 specifieke binding. 
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Initieel werden de verschillende onderzochte tracerverbindingen vergeleken aan de hand van 
hun PDE5 specifieke longretentie in muizen daar PDE5 een hoge expressiegraad in dit orgaan 
heeft. Daarnaast werden de verbindingen ook geëvalueerd in transgene muizen met myocard 
specifieke PDE5 overexpressie.  
Uit de biologische evaluatie van radioliganden uit vier onderzochte structurele klassen van 
PDE5 inhibitoren bleek dat verbindingen van de imidazotriazine familie ([11C]NMVardenafil 
en [18F]fluorovardenafil) en de pyridopyrazinon familie ([11C]RPP07B en [18F]FRPP07) de 
hoogste retentie in longen vertoonden bij muizen. 
Op basis van de preklinische evaluatie werd [11C]NMVardenafil geselecteerd voor verdere 
klinische evaluatie in patiënten met eindstadium hartfalen cardiomyopathie die in aanmerking 
komen voor harttransplantatie. Een beperkte toxiciteitsstudie volgens de “microdosing” 
benadering toonde aan dat [11C]NMVardenafil veilig kan gebruikt worden als PET 
tracerverbinding bij klinische studies. 
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Tadalafil   β-carboline  
Vardenafil   imidazotriazine  
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Phosphodiesterase inhibitors have been used for more than two thousand years since the 
advent of coffee in East Africa (Ethiopia) but only in the last 60 years their targets have been 
identified. The active ingredient caffeine inhibits the degradation of cyclic nucleotide second 
messengers [1].  
Second messengers are molecules that relay signals from receptors on the cell surface to 
target molecules inside the cell, in the cytoplasm or nucleus. They relay the signals of 
hormones like adrenaline, growth factors, light, natriuretic peptides (NPs), nitric oxide (NO) 
and others, and cause a change in the activity of the cell. They greatly amplify the strength of 
the signal and are a component of signal transduction cascades. Some examples of second 
messengers include cyclic adenosine monophosphate (cAMP), cyclic guanosine 
monophosphate (cGMP), Ca2+, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
[2, 3]. 
1. Cyclic nucleotides (cNs) 
A cyclic nucleotide (cN) or a cyclic nucleoside monophosphate (cNMP) is a 
single phosphate nucleotide with a cyclic bond arrangement between the sugar and the 
phosphate group. Cyclic nucleotides are composed of three functional groups: a sugar, 
a nitrogenous base, and a single phosphate group (figure 1). cAMP and cGMP are currently 
the most well documented cyclic nucleotides. They are ubiquitous second messengers 
responsible for transducing effects of various extracellular mediators including hormones, 
light and neurotransmitters [2, 3]. cAMP is formed from adenosine triphosphate (ATP) by the 
catalytic action of adenylyl cyclases (ACs). There are two types of AC: (a) transmembrane 
AC (tmAC) which is activated/regulated by heterotrimeric G proteins, which transduce 
extracellular signals via G protein-coupled receptors and can also be activated by forskolin 
and (b) soluble AC (sAC) which is regulated by the intracellular signaling molecules 
bicarbonate and calcium. The effector proteins of cAMP include protein kinase A (PKA), 
exchange proteins activated by cAMP (Epac), cyclic nucleotide gated ion channels and 
potentially phosphodiesterase type 10 (PDE10). cAMP modulates physiological responses 
such as learning and memory, cardiac myocyte function, olfaction, sperm activation, pH 
regulation in epididymis, and tumor necrosis factor (TNF) activation of granulocytes [4]. 
cGMP is formed from guanosine triphosphate (GTP) by the catalytic action of guanylyl 
cyclases (GCs). There are two subtypes of guanylyl cyclases: particulate GC (pGC), a 
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membrane bound protein which is activated by natriuretic peptides and soluble GC (sGC), a 
cytosolic protein which is activated by nitric oxide (NO) [5]. 
 
Figure 1. Structures of cAMP (left) and cGMP (right). 
1.1. Natriuretic peptide-mediated biosynthesis of cGMP 
Natriuretic peptides are a family of three structurally related hormone/paracrine factors. Atrial 
natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted from the cardiac 
atria and ventricles, respectively. ANP signals in an endocrine and paracrine manner to 
decrease blood pressure and cardiac hypertrophy. BNP acts locally to reduce ventricular 
fibrosis. C-type natriuretic peptide (CNP, secreted by the vascular endothelium) primarily 
stimulates long bone growth. ANP and BNP activate the transmembrane guanylyl cyclase, 
natriuretic peptide receptor-A (NPR-A). CNP activates a related cyclase, natriuretic peptide 
receptor-B (NPR-B). Both receptors catalyze the synthesis of cGMP, which mediates most 
known effects of natriuretic peptides. A third natriuretic peptide receptor, natriuretic peptide 
receptor-C (NPR-C), clears natriuretic peptides from the circulation through receptor-
mediated internalization and degradation [6]. 
1.2. Nitric oxide-mediated biosynthesis of cGMP 
Nitric oxide, also known as endothelium-derived relaxing factor (EDRF) and proclaimed 
''Molecule of the Year'' in 1992 (also an area of research for the Nobel prize award in 1998) is 
a simple but the only known gaseous neuromessenger molecule that readily crosses cell 
membranes [7]. It is synthesized by the catalytic action of nitric oxide synthases (NOS) from 
L-arginine, oxygen, and NADPH (figure 2) [8, 9]. There are three isoforms of NOS: neuronal 
NOS (nNOS or Type I, NOS-I) being the isoform first found in the neuronal tissue; inducible 
NOS (iNOS, Type II, NOS-II) being the isoform which is inducible in a wide range of cells 
and tissues; and endothelial NOS (eNOS, Type III, NOS-III) being the isoform first found in 
vascular endothelial cells. eNOS and nNOS are calcium dependent for their activation 
whereas iNOS is calcium independent [9]. The NOS isoforms were named by order of their 
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discovery and initially reported expression pattern. However, all three isoforms have been 
detected in vascular smooth muscle cells (VSMCs) and vascular endothelial cells [10]. 
The biosensor of NO is soluble guanylyl cyclase (sGC) which is a heterodimer with an α and 
β subunit. The amino-terminal of the cyclase contains a heme domain to which nitric oxide 
binds with distinct specificity [11].  
1.3. Physiological role of cAMP and cGMP 
The second messengers cAMP and cGMP are important regulators of various physiological 
processes. The main effectors of cAMP are cAMP dependent protein kinase A (PKA) and 
cyclic nucleotide-gated ion channels [5]. cAMP and its associated kinases play a role in 
several biochemical processes, including the regulation of glycogen, sugar and lipid 
metabolism. Other functions of cAMP and PKA include activation of calcium channels, 
providing a minor pathway by which growth hormone-releasing hormone causes a release 
of growth hormone. However, the view that the majority of the effects of cAMP are 
controlled by PKA is outdated. In 1998 a family of cAMP-sensitive proteins with guanine 
nucleotide exchange factor (GEF) activity was discovered. These are termed ‘exchange 
proteins directly activated by cAMP (Epac)’ and the family comprises Epac1 and Epac2. 
Upon binding of cAMP, the GEF domain becomes active allowing Epac to activate small 
Ras-like GTPase proteins, such as Ras-related protein 1(Rap1) [4]. 
The main effectors of cGMP are cGMP dependent protein kinase G (PKG), cyclic nucleotide-
gated ion channels and phosphodiesterases (PDEs, figure 2). Three isotypes of PKGs have 
been identified, two of which are splice variants of a single gene. PKG type I (PKG-I), which 
consists of an α and a β isoform (76 kDa), is the prominent isotype in the cardiovascular 
system. It is expressed at very high levels (> 0.1μM) in vascular smooth muscle cells (both 
PKG-Iα and PKG-Iβ) and endothelial cells (PKG-Iβ) and at lower levels in cardiac myocytes 
(PKG-Iα). PKG type II (PKG-II, 86 kDa) is mainly expressed in the kidney, brain, and 
intestines. Both PKG-I and PKG-II exist as homodimers with identical structures. Each 
subunit consists of three functional domains, i.e. an N-terminal domain, a regulatory domain, 
and a kinase domain. The N-terminal domain mediates PKG homodimerization, suppresses 
kinase domain activity in the absence of cGMP, and interacts with target substrate proteins 
[10]. Upon cGMP binding to specific sites in the regulatory domain, PKG undergoes a 
conformational change, resulting in the release of the N-terminus inhibition of the kinase 
domain. The kinase domain then catalyzes the phosphorylation of a serine/threonine side 
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chain of the target substrate protein [10]. The other main effector proteins of cGMP are the 
phosphodiesterases which are a superfamily of intracellular enzymes involved in the 
degradation of cNs. This will be discussed in the next section.  
2. Phosphodiesterases 
Early studies by Sutherland and colleagues demonstrated that tissue extracts contained a PDE- 
activity that could ablate the biological actions of cAMP. This was subsequently identified as 
PDE catalytic activity, which was increased in the presence of divalent cations and inhibited 
by methylxanthines such as caffeine and theophylline [12, 13]. 
Based on differences in primary structure of known PDEs, they have been subdivided into 
three classes (Class I, II, and III). Class I contains the largest number of PDEs and includes all 
known mammalian PDEs. Each class I PDE contains a conserved segment of ~250 - 300 
amino acids in the C-terminal portion of the proteins (which show high affinity for cAMP 
and/or cGMP), and this segment has been demonstrated to include the catalytic site of these 
enzymes. All known class I PDEs are contained within cells and vary in subcellular 
distribution, with some being primarily associated with the particulate fraction or the 
cytoplasmic fraction of the cell, others being more evenly distributed in both compartments 
[13]. 
Twenty-one classes of genes and diverse spliced transcriptional variants for the PDE class I of 
humans, rats and mice have been identified. They have been classified into 11 families based 
on particular subcellular distributions, structural similarities, mechanisms of regulation, amino 
acid sequences, proteic domains and enzymatic properties among which are specificity for the 
substrate, kinetic properties, and sensitivity to endogenous regulators and inhibitors [3]. 
According to the nomenclature used for each PDE isozyme (e.g., HsPDE5A1), the first two 
letters indicate the animal species (Humans) and the first Arabic number after PDE designates 
the PDE gene family. This number is followed by a single capital letter indicating a distinct 
subfamily gene. The last Arabic number indicates a specific splice variant or a specific 
transcript generated from a unique transcription initiation site [13]. 
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Figure 2. Schematics of PDE regulation of NOS–NO generated cGMP in a vascular smooth muscle 
cell and cardiac myocyte. Small molecule inhibitors and signal-activators for each PDE are shown at 
the top. Smooth muscle cell: NOS3-derived NO diffuses from neighboring endothelial cells (EC) 
interacting with soluble guanylate cyclase (sGC) to convert GTP to cGMP. cGMP can be hydrolyzed 
by PDE1 in the presence of Ca2+/calmodulin (Ca/CM) stimulation, and PDE1 may also hydrolyze 
cAMP. PDE3 hydrolyzes primarily cAMP, but this can be inhibited competitively by cGMP. PDE5 
selectively hydrolyzes cGMP, and cGMP and its distal effector kinase-protein kinase G (PKG) also 
activate the enzyme. Activation of PKG results in phosphorylation of myosin light chain phosphatases 
(MLCP), RhoA, regulator of g-protein signaling (RGS-2), inositol 1,4,5-trisphosphate receptor-
associated PKG substrate; IRAG, and calcium-sensitive potassium channels (BKca) that serve to 
reduce smooth muscle tone.  Cardiac myocyte: NO possibly derived from several intracellular NOS 
isoforms (eNOS being coupled to β3 adrenergic receptors) stimulates cGMP synthesis. PDE 
regulation is similar to that in vascular smooth muscle, with the addition of PDE2, which increases 
cAMP hydrolysis when stimulated by cGMP, but may also hydrolyze cGMP. Agonists and small 
molecule inhibitors would be similar for those shown in the upper panel. Chronic stimulation by 
pressure over-load lowers PDE3 but increases PDE5 activity to alter the balance of cAMP/cGMP 
regulation. Adapted from reference [11]. 
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2.1  Structure of phosphodiesterases 
All PDEs are chimeric proteins comprising a catalytic domain (C domain) and a regulatory 
domain (R domain) (figure 3). R domains of mammalian PDEs (PDE 2, 5, 6, 10, and 11) 
contain either one or two predicted homologous GAF domains (cGMP binding PDEs, 
Anabaena adenylyl cyclases, and Escherichia coli (Fh1A) modules) of ~ 120 amino acids (aa) 
[13, 14]. The PDE superfamily is the only group of mammalian proteins known to have an 
abundance of GAFs; all isoforms of five PDE families (2, 5, 6, 10, and 11) contain two GAFs 
(a and b) arranged in tandem, and in PDEs 2, 5, and 6, at least one GAF forms an allosteric 
site for cGMP binding (figure 3). The GAF domain thus provides an allosteric binding site for 
cGMP which results in increased catalytic activity of the enzyme [14, 15]. 
Figure 3. Domain organization of 11 PDE gene families. All PDEs share significant homology in their 
catalytic domain but differ greatly in their N-terminal parts, which contain different types of regulatory 
domains. UCR domain is an upstream conserved region found only in PDE4. GAF domains were 
originally defined in PDE2, PDE5, and PDE6 and later shown in PDE10 and PDE11. PAS domain 
(Per, ARNT, and Sim proteins) was found only in PDE8. Adapted from reference [16]. 
Two structural components of cAMP and cGMP, i.e., the cyclic phosphodiester ring and the 
purine moiety, provide for the specificity with which these compounds interact with PDEs. 
Some PDEs are highly specific for cAMP (PDE4, PDE7, PDE8), others are highly specific for 
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cGMP (PDE5, PDE6, PDE9), and some have mixed specificity (PDE1, PDE2, PDE3, PDE10) 
[3, 13]. 
PDEs contain three functional domains, including a conserved catalytic core, a regulatory N-
terminus and a C-terminus. Regulatory N-terminal domains of these enzymes that vary widely 
among the PDE classes contain a calmodulin binding domain in PDE1, cyclic GMP binding 
sites in PDE2, 5, 6, 10 and 11, phosphorylation sites for various protein kinases in PDE1 - 5, 
and a transducin binding domain in PDE6 [3]. Due to the need to develop selective PDE 
inhibitors as therapeutic drugs, the structures of the catalytic domains of PDEs, which contain 
the active pocket that accommodates inhibitors, have been elucidated. The crystal structure of 
the catalytic domain of PDE5A has shown that catalytic domains of PDEs have three helical 
subdomains (figure 4, left): an N-terminal cyclin-fold region (which adopts the cyclin-fold 
topology), a linker region (10 aa residues) and a C-terminal helical bundle. The active site of 
PDE5 is located at the centre of the C-terminal helical bundle domain. The substrate pocket is 
approximately 10 Å deep, with a narrow opening and a wide inner space, giving a total 
volume of about 330 Å3 (figure 4, right). It is composed of four subsites: a metal-binding site 
(M site), core pocket (Q pocket), hydrophobic pocket (H pocket) and lid region (L region). 
The M site contains both a zinc ion and a second metal (presumably magnesium) ion which 
are assumed to play a role in stabilization of the structure and activation of hydroxide to 
mediate catalysis (figure 4, right) [3, 17].  
In the crystal structure of PDE5A in complex with sildenafil (a known PDE5 specific 
inhibitor), the Q pocket accommodates the pyrazolopyrimidinone group of sildenafil. This Q 
pocket provides the key hydrogen bonding of the conserved glutamine residue with substrates 
or inhibitors of PDEs, and the hydrophobic interactions, which come from the residues on 
both sides of the pyrazolopyrimidinone group, forming a ‘clamp’ like structure. The 
ethoxyphenyl group of sildenafil fits into the hydrophobic H pocket. The variation of 
hydrophobic residues in the H pocket among PDEs can give PDE inhibitors the selectivity to 
corresponding PDEs. The L region of PDE5A, composed of residues Tyr 664, Met 816, Ala 
823 and Gly 819, surrounds the methylpiperazine group of sildenafil. The conformational 
change between closed and open forms of this region seems to be involved in inhibitor 
binding [3, 17].  
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Figure 4. Left: Overview of the PDE5 complex structures. Stereo ribbon diagram of the human PDE5 
structure. The catalytic domain of the PDE5 molecule can be divided into three subdomains: an N-
terminal cyclin-fold domain (residues 537–678, yellow), a linker helical domain (residues 679–725, 
blue) and a C-terminal helical bundle domain (residues 726–860, violet). The bound sildenafil and 
tadalafil molecules are overlapped and shown as stick models (red and green, respectively). Two 
metal ions are represented as green spheres. Right: Surface representation of the active site of 
PDE5A occupied by sildenafil. The active site can be divided into four subsites: a metal-binding site (M 
site), core pocket (Q pocket), hydrophobic pocket (H pocket) and lid region (L region). Adapted from 
reference [3]. 
2.2. Tissue expression and distribution of PDE5 
First purified from rat lung, phosphodiesterase 5 (PDE5) has now been identified in many 
species and in a wide variety of tissues. So far, three PDE5 isoforms, PDE5A1, PDE5A2 and 
PDE5A3 have been identified in humans and dogs [18]. While PDE5A1 and PDE5A2 are 
found in nearly all tissues, with PDE5A2 being more widespread, the distribution of PDE5A3 
is limited to smooth muscle (tables 1 and 2). There are no known differences in cGMP 
catalytic activity among these isoforms [19]. 
Tissue and cellular expression of PDE5 has been examined by Northern blot analysis, in situ 
hybridization (ISH), and real time-polymerase chain reaction (RT-PCR) for mRNA 
expression and by Western blot analysis, immunohistochemistry (IHC), enzymatic assay, and 
inhibitor binding for protein expression [19-21]. Lakics et al reported that PDE5 mRNA is 
most abundantly expressed in the lung, bladder, stomach, pancreas and intestine [21]. 
However, the expression of PDE5 in the lungs was the highest both relative to other PDEs 
present in the lungs and to PDE5 expression in other tissues.  
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Most authors agree on the abundant expression of the enzyme in the lungs with two notable 
exceptions by Loughney et al [22] and by Yanaka et al [23] who reported the absence of lung 
PDE5 activity. This of course contradicts with the fact that PDE5 was first identified and 
purified from lung and was first cloned from lung as well [24, 25]. 
 
Table 1. Distribution of PDE5 in selected tissues. Adapted from references [19, 20]. 
 Detection method  
 mRNA Proteins PDE5 isoforms 
Tissue PCR Northern ISH IHC Western Activity A1 A2 A3 
Brain + +   +  + + - 
Cerebellum + + + + + +    
Retina +         
Lung + +/- +  + + + + - 
Heart + +/-  + +/- +/- + + + 
Liver + -   -  + + - 
Stomach + +   + +    
Pancreas + +  +      
Spleen +         
SI + +   + +    
Colon + +   + +    
Kidney + +  +   + + - 
Bladder + +   + + + + + 
Prostate + +   +  + + + 
Urethra +   + +  + + + 
Penis + + + + + + + + + 
Ovary +    +     
Uterus + +   +  + + + 
SkM + +   -  + + - 
Platelet     + +    
+: detected; -: negative; PCR: Polymerase chain reaction; ISH: in situ hybridization; IHC:  
immunonhistochemistry; Activity: cGMP catalysis; SI: small intestine; SkM: Skeletal muscle  
immunonhistochemistry; Activity: cGMP catalysis; SI: small intestine; SkM: Skeletal muscle 
Chapter I 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most authors agree that PDE5 is expressed in vascular smooth muscle cells, platelets, lungs, 
penis and Purkinje fibers of the cerebellum [19, 21, 25]. However, each of the detection 
techniques used for identification of PDE5 or its mRNA has its advantages and disadvantages 
and because certain experimental variables (e.g., animal species, cultured cells vs tissues, with 
or without detergents, etc.) do exist, it is inevitable that disagreements between studies do 
occur. In particular, since vascular smooth muscle contains an abundance of PDE5, its 
possible inclusion in tissue preparations should always be considered for having a positive 
Table 2. Cellular distribution of PDE5 isoforms. Adapted from reference [19]. 
Cell lines/strains PDE5 isoforms A1 A2 A3 
T47-D (breast cancer) - + - 
Ishikawa (uterine cancer) - + - 
   - 
HT1080 (fibrosarcoma) - +  
COS-7 (fibroblasts) - + - 
    
Aorta SM - + + 
Bladder SM - + + 
Urethra SM - + + 
Penis SM - + + 
    
Penis endothelia - + - 
Aorta endothelia - + - 
    
CEM (leukemia) - + - 
Jurkat (leukemia) - + - 
K562 (leukemia) - + - 
Molt-4 (leukemia) - + - 
SM: smooth muscle    
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result that is generated by RT-PCR, Northern blot, or Western blot analyses. On the other 
hand, while contamination of the tissue of interest by smooth muscles is not an issue with 
immunohistochemical detection of PDE5, the presence of nonspecific immunological 
activities in most anti-PDE5 antibodies can be problematic [19, 21]. Selected cellular and 
tissue distribution of PDE5 with the assay method used for detection is given in tables 1 and 
2.  
2.3. Physiological role of PDE5 
The physiological role of PDE5 ranges from its classic player as a regulator of smooth muscle 
cells (SMCs) to a new emerging role as a regulator of apoptosis. Much of the information 
available on the role of cGMP comes from studies on smooth muscle, in which one of the 
earliest clearly defined effects of cGMP on cell function was described [10, 16, 20]. PDE5 has 
been shown to participate in many physiological and pathological processes. Particularly, with 
the convenience of using PDE5-selective inhibitors to discriminate PDE5 from other cGMP-
hydrolyzing enzymes, many new possible regulatory roles have been uncovered in recent 
years. In addition to the classic role of regulation of smooth muscle tone and the emerging 
role of regulation of apoptosis that will be discussed in more detail below, some of the 
interesting roles are (1) regulation of neuronal excitability and synaptic plasticity in Purkinje 
cells [26], (2) activation and inhibition of platelet aggregation [27], (3) regulation of 
antidepressant-sensitive serotonin transporter [28], (4) control of ion and fluid secretion in 
intestinal cells [29], (5) regulation of memory formation [30], and (7) handling of sodium 
secretion in renal cells [31].  
The best characterized physiological role of PDE5 is the termination of the cGMP-signaling 
pathway in smooth muscle, be it vascular, cavernous, or intestinal [10, 16, 20]. The cGMP 
signaling pathway in corpus cavernous smooth muscle is briefly discussed below (figure 2). 
Sexual stimulation triggers the release of nitric oxide (NO) from nerve endings. NO diffuses 
into cavernous smooth muscle cells and activates guanylyl cyclase, which then catalyzes the 
conversion of GTP to cGMP. Elevated levels of cGMP activate protein kinase G (PKG), 
which then phosphorylates gap junctions, potassium (K) channels, and calcium (Ca) channels. 
Phosphorylation of the K and Ca channels leads to increase of potassium efflux and reduction 
of calcium influx, respectively. When the cytoplasmic calcium concentration falls below a 
certain level (~500 nM), calcium dissociates from calmodulin, which in turn dissociates from 
the myosin light-chain kinase, thus inactivating it. With its kinase being inactivated and its 
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phosphates being removed by phosphatase, the myosin light chain thus becomes 
dephosphorylated. Dephosphorylated myosin light chain inhibits the binding of the myosin 
head to actin, resulting in smooth muscle relaxation. Relaxed cavernous smooth muscle 
allows the entry of blood into the cavernous spaces, thus expanding the penis. To return the 
penis to the flaccid state, cGMP is principally degraded by PDE5 – despite of the co-presence 
of several other cGMP-hydrolyzing PDEs [16, 20]. 
It is currently accepted that cGMP inhibits platelet activation via reduction in intracellular 
Ca2+ [27]. This concept is supported by the finding that pre-incubation of cGMP analogs with 
platelets inhibits platelet activation. Consistent with this concept, NO donors that inhibit 
platelet activation enhance intracellular cGMP. However, Li et al [27] showed that the cGMP-
stimulated platelet responses are biphasic, consisting of an initial transient stimulatory 
response that promotes platelet aggregation and a subsequent inhibitory response that limits 
the size of thrombi. This might be a reason for experimental use of PDE5 inhibitors in stroke 
rat model as increased cGMP concentrations shorten the time for initiation of the inhibitory 
phase and consequently resulting in smaller thrombi [33]. Thus, cGMP exerts a time and 
concentration dependent biphasic effect on platelet activation. Besides, other PDEs (such as 
PDE2 and PDE3) may come into interplay [27, 33].  
PDE5 expression in the brain is limited; however, expression of PDE5 mRNA and protein has 
been reported for cerebellar Purkinje cells and there is a considerable literature indicating that 
the cerebellum has a significant role in cognitive processing [30, 34, 35]. In addition, there is 
a small body of preclinical literature that suggests that PDE5 inhibitors could affect cognitive 
function [30, 35, 36]. Prickaerts et al [36] reported that several PDE5 inhibitors facilitate 
memory consolidation in rodent novel object recognition tasks. The mechanism for these 
precognitive effects remains to be determined. An increase in cGMP concentrations in 
Purkinje cells, which are the principal output neurons of the cerebellum, could therefore 
conceivably account for the effects of PDE5 inhibitors in the rodent cognition assays. There 
are also scattered cells in hippocampus and cortex that express PDE5 mRNA as visualized by 
in situ hybridization [37]. In humans, a PDE5 inhibitor enhanced auditory evoked potentials 
during a selective attention and verbal recognition memory task [38].  This could be indicative 
of the capacity of PDE5 inhibitors to focus attention. Zhu et al in another manuscript reported 
the role of cGMP-targeted PDE5 in limiting the regulation of antidepressant-sensitive 5-HT 
transport in RBL-2H3 cells (cell line that supports G-protein coupled receptor stimulation of 
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the serotonin transporter through a PKG linked pathway) [39]. Therefore, it is probable that 
the cGMP-PDE5 pathway is involved in early memory consolidation in at least rodents and 
inhibition of PDE5 improves brain function such as memory consolidation and plasticity [30, 
34-37]. Nonetheless, it remains to be determined whether the distribution of PDE5 in human 
brain is similar to that in rodents.  
An emerging and intriguing role for PDE5 is the regulation of apoptosis in both cancer and 
normal cells. It appears that PDE5 plays both a pro-apoptotic and anti-apoptotic role in 
different tissues. Fukuo et al reported that NO released from vascular smooth muscle cells 
(VSMCs) of rats may induce apoptosis in VSMCs themselves. It also induces up-regulation of 
Fas receptor (apoptosis stimulating factor, an important cell surface receptor protein of the 
TNF receptor family known also as CD95, that induces apoptosis on binding Fas ligand) via a 
cGMP-independent mechanism [40]. Hence, in VSMCs PDE5 could play an anti-apoptotic 
role. Taimor et al also reported that NO induces apoptosis in a cGMP dependent manner in 
isolated adult cardiomyocytes of rats where PDE5 could play an anti-apoptotic role [41]. 
However, De Meester et al reported that NO played an anti-apoptotic role in porcine aortic 
endothelial cells [42]. 
When breast cancer cells were treated with exisulind (an oxidative metabolite of sulindac that 
will be discussed under section 3, the PDE5 inhibitors), growth inhibition and apoptotic death 
were observed [43]. Similar observations have now been made in cancer cells of the prostate 
[44], bladder [45], colon [46-48], and lung [49]. In colon cancer cells, exisulind induced 
apoptosis was found to involve the inhibition of PDE2 and PDE5 and activation of PKG [47]. 
Induction of apoptosis through PDE5 inhibition has also been observed in normal cells, albeit 
requiring concomitant activation of the cGMP-signaling pathway. First, in human pulmonary 
artery smooth muscle cells, stimulation of soluble guanylyl cyclase (by BAY41-2272) and 
inhibition of PDE5 (by sildenafil) not only reduced DNA synthesis and cell proliferation but 
also increased apoptosis [50]. Second, in pulmonary arterial endothelial cells, stimulation of 
particulate guanylyl cyclase (by atrial natriuretic peptide, ANP) and inhibition of PDE5 (by 
zaprinast) also reduced cell growth and induced apoptosis. In pulmonary microvascular 
endothelial cells, which do not express PDE5, ANP alone was able to induce apoptosis, thus 
further illustrating the importance of the suppressive role of PDE5 on apoptosis [51].  
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2.4. Pathophysiological role of PDE5 
Phosphodiesterase 5 has been implicated in a number of diseases including pulmonary arterial 
hypertension, cardiac hypertrophy and ventricular remodeling, myocardial ischemia, 
atherosclerosis, and others [10, 52]. The main focus of this dissertation is on the 
pathophysiological role of PDE5 in the pulmonary vasculature and heart. Hence, the role of 
PDE5 in these organs will be discussed in some detail while its role in other diseases will be 
mentioned as a passing remark. 
The billion dollar income generating drug Viagra® (sildenafil) is used in the treatment of 
sexual dysfunction where it inhibits PDE5 in corpus cavernosum [19, 34, 53]. To date, we 
have not come across any publication that claims up-regulation of PDE5 in erectile 
dysfunction (ED). The use of PDE5 inhibition in ED is to retard enzymatic hydrolysis of 
cGMP in the corpus cavernosum as the enzyme is relatively abundantly expressed in the 
penis. To a certain extent the use of PDE5 inhibition to treat pulmonary arterial hypertension 
is also based on abundant expression of the enzyme in the lungs [25] though a recent 
publication reported that PDE5 was up-regulated in lambs with pulmonary hypertension, 
induced by an aortopulmonary vascular graft (shunt) [54]. Pulmonary arterial hypertension 
(PAH) is a debilitating chronic disease of the small pulmonary arteries characterized by 
vascular narrowing leading to a progressive increase in pulmonary vascular resistance 
[55].   The consequence of this increased right ventricle afterload is a failure of the afterload-
intolerant right ventricle. Vasoconstriction, remodeling of the pulmonary vessel wall and 
thrombosis contribute to the increased pulmonary vascular resistance in PAH. There are a 
number of factors involved at both the molecular and cellular level [56]. 
At the cellular level, smooth muscle cells, fibroblasts, inflammatory cells and platelets play an 
important role in disease progression of PAH. Stimuli such as hypoxia, shear stress, 
inflammation, or response to drugs or toxins may lead to disorganized endothelial cell 
proliferation which ultimately leads to narrowing of the arteries [57]. On the other hand 
inflammatory mechanisms appear to play a significant role in some types of pulmonary 
hypertension including monocrotaline induced PAH in rats and PAH of various origins in 
humans [57, 58].  
At the molecular level, prostacyclin (prostaglandin I2, an important endogenous pulmonary 
vasodilator), vasoactive intestinal peptide (VIP, a neuropeptide primarily functioning as a 
neurotransmitter with potent systemic and pulmonary vasodilator effects), endothelin (ET-1, a 
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potent pulmonary vasoconstrictor) and NO appear to play an important role in PAH. 
Pulmonary vasoconstriction is believed to be an early component of the pulmonary 
hypertensive process. Excessive vasoconstriction has been related to abnormal function of 
endothelial dysfunction. Endothelial dysfunction leads to chronically impaired production of 
vasodilators such as NO and prostacyclin along with prolonged over-expression of 
vasoconstrictors such as endothelin (ET-1). Besides, the abundant expression of PDE5 in the 
pulmonary vasculature further aggravates the vasoconstriction by degrading the already 
impaired production of cGMP (figure 5) [56].  
 
Figure 5. Consequences of pulmonary artery endothelial cell dysfunction on pulmonary artery smooth 
muscle cell tone and proliferation. Dysfunctional pulmonary artery endothelial cells (blue) have a 
decreased production of prostacyclin and nitric oxide, with an increased production of endothelin-1-
promoting vasoconstriction and proliferation of pulmonary artery smooth muscle cells (red). ET = 
endothelin; ETA = endothelin receptor A; ETB = endothelin receptor B. (Adapted from reference [56]. 
Physiological hypertrophy is a normal part of the growth response of cells, including 
cardiomyocytes, which are terminally differentiated and cannot undergo hyperplastic growth. 
This form of hypertrophy is described as both concentric (characterized by addition of 
sarcomeres in parallel, leading to increased width of the myocyte) and eccentric 
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(characterized by the addition of sarcomeres in series, leading to increased length). Concentric 
cardiac hypertrophy can also develop as a response to stressors, in most cases an excess load 
placed on the heart, for example, with uncorrected hypertension or valvular disease, or post- 
myocardial infarction (MI) when the remote non-infarcted myocardium hypertrophies. 
Hypertrophy is initially believed to be adaptive, normalizing systolic wall stress, though this 
concept has been challenged recently and it is not clear that hypertrophy is really necessary to 
maintain systolic function in the face of moderately elevated afterloads. Eccentric 
hypertrophy most often results from volume overloads such as those seen with valvular 
insufficiency [59, 60]. Though there are a number of factors that cause cardiac hypertrophy, 
here the discussion is limited to the role of PDE5 in cardiac hypertrophy.  
Despite early evidence of myocardial PDE5 gene expression, protein synthesis and enzyme 
activity in cardiomyocytes are rather low compared with lung tissue, and have been 
traditionally thought to be physiologically insignificant [52]. The action of NO in the vascular 
smooth muscle cells is via cGMP mediation which is mainly terminated by PDE5; however, 
NO regulation of the cardiovascular system involves both cGMP-dependent and independent 
mechanisms (figure 2). The former directly interacts with the family of catabolic PDEs that 
control cGMP levels and thus distal effects such as protein kinase G stimulation where the 
latter involves the cross-talk between cAMP and cGMP downstream. Growing evidence 
supports an important role of several PDEs, including PDE1, PDE2, PDE3 and PDE5, in the 
regulation of cGMP in cardiac myocytes (figure 2) [5, 11].   
Although the role of PDE5 in the myocardiocytes in healthy condition is considered minimal 
or negligible, several authors have reported its deleterious effect in different cases of cardiac 
hypertrophy. Nagendran et al reported a marked up-regulation of PDE5 in hypertrophied right 
ventricles sampled from nine patients with right ventricle hypertrophy [61]. In addition, 
Pokreisz et al reported a 5-fold up-regulation of PDE5 in the left ventricles of patients with 
dilated and ischemic cardiomyopathy [62]. This group also showed that transgenic mice with 
cardiomyocyte specific PDE5 over-expression (PDE5 TG) responded poorly after myocardial 
infarction induced by coronary artery ligation. Vandenwijngaert et al from the same 
laboratory reported up-regulation of PDE5 in patients with severe aortic stenosis and in mice 
subjected to high pressure overload by transverse aortic constriction (TAC) [63]. The findings 
of Pokreisz were further strengthened by the report from Shan et al who reported a 4-fold up-
regulation of PDE5 in 20 patients with ischemic cardiomyopathy or idiopathic dilated 
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cardiomyopathy [64]. Lu et al also reported a 4.5-fold increase in expression of PDE5 in 
patients with end stage congestive heart failure (CHF) [65]. Despite the low expression of 
PDE5 in the myocardium during healthy condition, many experts in the field showed its 
important but deleterious effect in cardiac remodelling. 
Inconsistent changes in the expression of sGC have been reported in different animal models 
of hypercholesterolemia and atherosclerosis [66]. However, sGC activity appears 
dysfunctional as endothelium-dependent and independent vasodilations are markedly 
inhibited [66]. While PKG expression remains unchanged, its activity as assessed by 
phosphorylated- Vasodilator-Stimulated Phosphoprotein (VASP) is strongly reduced [67].  
3. Phosphodiesterase 5 inhibitors 
For many years, nonselective PDE5 inhibitors such as caffeine (1,3,7-trimethylxanthine), 
theophylline (1,3-dimethylxanthine) and 3-isobutyl-1-methylxanthine (IBMX) have been used 
to investigate the physiological effects of cyclic nucleotides [1, 34]. But in the early 1990s a 
drug which was being investigated by Pfizer for its role as an anti-hypertensive and anti-
angina medication was serendipitously found to have an erectile side effect in a Phase I 
angina trial. This compound, sildenafil, was the first PDE5-selective competitive inhibitor 
approved by FDA for treatment of male erectile dysfunction (MED). Later in 2005, sildenafil 
was approved for treatment of PAH [34]. 
Thanks to this discovery, thousands of compounds have been synthesized and screened 
against PDE5. Due to the wide variety of structures reported for PDE5 inhibitors, rigid 
classification of the currently available compounds becomes difficult. Here, a limited number 
of selected PDE5 inhibitors which are deemed to have some relevance with this dissertation 
are discussed based on a loose classification system.  
Currently, there are a number of PDE5 inhibitors that are available on the market for 
treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil, udenafil, avanafil and 
mirodenafil. Except for tadalafil and avanafil, all approved PDE5 inhibitors share a similar 
core structure (figure 6) [68]. Zaprinast was among the earliest reported PDE5 inhibitors that 
did not make it to the clinic but served as a precursor for many subsequent PDE5 inhibitor 
discoveries.  
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Figure 6. Structures of selected PDE5 inhibitors. 
The pyrazolopyrimidinone (14, 33, 35, udenafil) derivatives were among the first PDE5 
specific inhibitors reported and approved. The representative molecule in this group is 14 
which was the first approved PDE5 inhibitor for the treatment of MED [34, 53]. 33 and 35 
were among the most potent compounds patented by Pfizer/Pharmacia & Upjohn based on 
IC50 values (table 3) [68-70]. Other PDE5 inhibitors patented by the same company belong to 
the pyridopyrazine derivatives (RPP07, RPP011B and RPP012) [71, 72]. These compounds 
attract special attention as, unlike other PDE5 inhibitors, they are claimed to readily cross the 
blood-brain barrier [32, 72, 73]. RPP07  (PF-5) was investigated by Mannit et al for its effect 
on improving functional recovery after stroke in a rat model and it was tested in healthy 
human volunteers and proved to be well tolerated with a mean apparent elimination half-life 
of 17 - 25 h after oral dosing [72-74,76]. No further development has been reported, however 
rat studies indicate significant CNS exposure. Hence RPP07 may have potential as a brain 
penetrant tool allowing clinical evaluation of the role of PDE5 in the CNS. 
The imidazotriazine group, to which vardenafil, 7, and 8 belong was the second class of PDE5 
inhibitors to be approved for the treatment of ED [74-76].  The other group that contains an 
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approved PDE5 inhibitor is that of the β-carbolines to which tadalafil belongs [77]. The 
quinoline PDE5 inhibitors (e.g., 19 and 22) are among a series of potent and selective 
inhibitors described in a patent filed by Bristol-Myers Squibb in 2001 [78, 79]. The IC50 value 
reported for 19 (50 pM) is among the highest PDE5 inhibitory activity reported so far and also 
in our in vitro PDE5 inhibitory assay it was found to have the highest inhibitory activity. 
There has not been any follow up report on this compound from the same group but a recent 
article reported the potential use of a close derivative of 19 for the treatment of Alzheimer’s 
disease [80]. 
Table 3.  In vitro PDE inhibitory activity (IC50) for selected PDE5 inhibitors. 
Compounds Class Reported PDE inhibitory activity Ref. 
  PDE5a PDE6-foldb PDE11-foldc  
Sildenafil (14) pyrazolopyrimidine 3.6 8 NA 74 
Tadalafil β-carboline 5 1000 NA 77 
Vardenafil imidazotriazine 0.7 11 NA 74 
7 imidazotriazine 0.6 NA NA 74 
19 quinoline 0.6 110 NA 79 
22 quinoline 0.05 7800 NA 79 
33 pyrazolopyrimidine 0.89 91 99 70 
35 pyrazolopyrimidine 0.007 170 47 70 
10 pyridopyrazine 3.28 51 2460 72 
14 pyridopyrazine 0.2 158 2460 72 
18 pyridopyrazine 0.22 198 4920 72 
aPDE5 IC50 (nM); bPDE6 selectivity defined as (PDE6 IC50)/(PDE5 IC50); cPDE11 selectivity defined as 
(PDE11 IC50)/(PDE5 IC50); Ref: References; NA: No data available. 
Exisulind is a metabolite derived from the irreversible oxidation of the nonsteroidal anti-
inflammatory drug (NSAID) sulindac to sulindac sulfone and, unlike its precursor which is an 
inhibitor of cyclooxygenase, it is able to inhibit the cGMP degrading enzymes PDE2 and 
PDE5 [43-47, 68, 81]. Exisulind as PDE5 inhibitor is being investigated for its apoptosis-
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inducing property in the treatment of colon cancer, non small-cell lung cancer and prostate 
cancer [43-47, 81]. 
3.1. Potential application of PDE5 inhibitors 
PDE5 inhibitors were originally investigated as drugs for the treatment of cardiovascular 
diseases, but their success is attributable to their potency in the treatment of erectile 
dysfunction. Sildenafil (Viagra®) was the first PDE5 inhibitor drug marketed and, at present, 
all the commercially available PDE5 inhibitors have been registered for erectile dysfunction 
and some are also approved for the treatment of pulmonary arterial hypertension (sildenafil 
and tadalafil). In Europe and North-America, sildenafil, vardenafil and tadalafil are approved 
for marketing whereas udenafil and mirodenafil are approved in South Korea for human use 
[68]. In the treatment of erectile dysfunction, PDE5 inhibitors work in synergy with 
endogenous NO and exert their effect by increasing the level of cGMP in corpus cavernosum 
smooth muscle. Without the concomitant production of NO in the penis PDE5 inhibitors are 
not effective [82]. cGMP functions and the potential therapeutic use of PDE5 inhibitors are 
outlined in figure 7.  
Figure 7. cGMP functions and possible therapeutic use of PDE5 inhibitors. PDE5 inhibitors block the 
degradation of cGMP (bottom panel) leading to an increase of the level of cGMP that can exert its 
action on several target organs. On the right side, both the approved and possible (question mark) 
therapeutic applications of PDE5 inhibitors in humans. Adapted from reference [34]. 
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Sildenafil was approved for the treatment of severe pulmonary hypertension in 2005 and 
tadalafil is the other PDE5 inhibitor approved for PAH. The principle for the use of PDE5 
inhibitors in the treatment of PAH is the same vasodilatory effect in the pulmonary 
vasculature [83]. More recently, investigations in the paediatric population suggest that PDE5 
inhibitors could also be useful for treatment of neonatal pulmonary hypertension [84]. 
PDE5 inhibitors were shown to be able to prevent the development of cardiac hypertrophy 
and, more important, they were able to reverse existing cardiac hypertrophy [85]. Sildenafil 
was reported to suppress myocyte hypertrophy and improve in vivo heart function in mice 
exposed to chronic pressure overload induced by transverse aortic constriction (TAC) [87]. 
The same study showed that sildenafil reversed pre-established hypertrophy induced by 
pressure load while restoring chamber function to normal. Another group also showed the 
effectiveness of sildenafil in decreasing cardiac hypertrophic response to isoproterenol in rats. 
Vardenafil was also shown to reduce myocardial infarct size following ischemia/reperfusion 
injury in rabbits [88]. Szabo et al described the protective nature of vardenafil against 
myocardial and endothelial injuries after cardiopulmonary bypass with hypothermic cardiac 
arrest [89]. In a 1-year prospective study in heart failure patients, sildenafil was shown to 
improve left ventricular diastolic function, cardiac geometry, and clinical status [90]. All these 
findings strongly suggest the potential role of PDE5 inhibitors for treatment of cardiac 
hypertrophy. 
Raynaud’s phenomenon is a vasospastic disorder in which there is a constriction of digital 
arteries and precapillary arterioles, and it can be a primary (where the cause is unknown) or a 
secondary phenomenon (the cause is secondary to another primary disease, most commonly 
connective tissue disorders such as systemic lupus erythematosus). Two studies reported the 
benefit of the use of PDE5 inhibitors in Raynaud’s phenomenon [91, 92]. The use of PDE5 
inhibitors with secondary Raynaud’s phenomenon was associated with an improved 
microcirculation due to vascular dilation and with a symptomatic improvement; an improved 
blood flow was observed also in patients with primary Raynaud’s phenomenon but few data 
are available till now [91]. 
McPherson and co-workers first described in 1999 the potential use of PDE5 inhibitors for 
treatment of cystic fibrosis, a severe autosomal pathology with dramatic consequences at 
pulmonary level due to the secretion of abnormally viscous mucus [93]. Preclinical studies 
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demonstrated that PDE5 inhibitors are able to correct the functional abnormalities resulting 
from mutation in the cystic fibrosis transmembrane regulator protein [94]. 
cGMP regulation plays a crucial role in a variety of processes and signal transduction in the 
CNS and, consequently, PDE5 inhibitors have been investigated for the treatment of central 
nervous system (CNS) disorders [35, 95]. In different experiments it has been demonstrated 
that PDE5 inhibitors produce an improvement of memory in different animal models such as 
object recognition and avoidance learning [30, 36, 96]. Some PDE5 inhibitors were shown to 
have an effect on functional improvement in rats after stroke [32, 73]. They were also shown 
as neurorestorative agent for the treatment of stroke, as demonstrated by studies in rat models 
of stroke by measuring neurogenesis, synaptogenesis and angiogenesis [31, 97]. 
Many other applications have also been proposed for PDE5 inhibitors such as treatment of 
idiopathic achalasia, a disease characterized by a reduced ability to move food down the 
oesophagus [98]; treatment of altitude-induced hypoxaemia [99]; the cure of lower urinary 
tract symptoms in men with benign prostatic hyperplasia [100]; to enhance the 
neurohypophysial excitability and the release of oxytocin [101].  
Despite the apparent role of phosphodiesterases in a multitude of diseases, there has not been 
much interest from molecular imaging professionals to develop probes labeled with short 
lived radionuclides that could be employed in imaging of PDE related pathophysiological 
processes with positron emission tomography. However, in recent years there has been a 
revival in interest to develop such probes for in vivo imaging of PDEs [102]. In this regard a 
notable success is the development of a carbon-11 labeled rolipram ([11C]rolipram) used for 
quantification of PDE4 in brain [103]. Another success was the development of fluorine-18 
labeled tracer for in vivo visualization of PDE10 in the brain [104]. A potential PET 
radioligand to visualize PDE1 was reported in a patent application [105]. Despite the 
commercial availability of several PDE5 inhibitors and the successful application in various 
diseases, there has been only one report on a PET radioligand for in vivo visualization of 
PDE5 [106]. A compound named [11C]RAL-01 (a close derivative of tadalafil, figure 8) was 
evaluated in pigs and showed a rapid uptake in liver and extensive elimination in bile. There 
was also considerable (self)-displaceable binding in the myocardium whereas retention in 
lungs was relatively low. The absence of retention in lungs was unexpected in view of the 
high levels of expression of PDE5 in lung tissue, and further it was not unequivocally 
demonstrated that the displaceable binding was PDE5 specific. The tracer readily entered the 
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brain and showed a relatively homogeneous distribution; however, its specificity for PDE5 in 
the brain is questionable as the enzyme is expressed in a restricted manner (the cerebellum). 
Figure 8. Structure of [11C]RAL-01 
4. Molecular imaging 
Molecular imaging is a rapidly emerging multidisciplinary field that studies the visual 
representation, localization and quantification of biological processes at the cellular and 
subcellular levels within intact living organisms. Imaging of molecular changes enables 
understanding of fundamental biochemical and physiological processes and, thereby, offers 
insights for disease characterization and detection. Furthermore, molecular imaging has an 
important relevance for patient care, as it allows early diagnosis of disease and a personalized 
approach for treatment follow-up. The field of molecular imaging covers imaging modalities 
such as positron emission tomography (PET), single photon emission computed tomography 
(SPECT), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, 
ultrasound imaging and photoacoustic tomography [102, 107]. Here, the discussion is limited 
to PET and PET related radiopharmaceutical because in this dissertation only radionuclides 
used in PET imaging are evaluated.  
PET is an exciting field of molecular imaging that uniquely explores the biochemical process 
at the cellular (subcellular) level. It is a non-invasive molecular imaging technique used in 
nuclear medicine. Radioactive molecules that decay by positron emission are used as PET is 
based on the detection of two coincident gamma rays emitted during annihilation of 
positroniums, formed by collision of positrons with electrons. Nevertheless, the development 
of PET-radiopharmaceuticals requires a multidisciplinary approach including organic 
synthesis of the standard non-radioactive reference compound and precursors, effective 
incorporation of radionuclides into the precursor (radiochemistry), isolation of the desired 
radiolabeled molecule (purification), radiochemical and chemical purity determination 
(quality control), confirmation of radiolabeled molecule identity, and formulation of the 
Chapter I 
26 
 
radiolabeled molecule in such a way that it is appropriate for administration to experimental 
animals or humans (sterile, pyrogen free, pH value, osmolarity, toxicity and physical state of 
the sample). The basics from production of radionuclides to radiopharmaceutical formulation 
will be discussed in brief in the subsequent paragraphs.  
4.1. PET Radiopharmaceutical: development and requirements [108-113] 
The initial step towards developing radiolabeled molecules begins with organic synthesis of 
precursors suitable for incorporating radionuclides. Radionuclides (radioactive nuclides or 
radioisotopes are unstable atoms due to the unsuitable composition of neutrons and protons, 
or excess energy, and therefore decay by emission of radiations such as α particles, β- particles, β+ 
particles, electron capture, and isomeric transition.  The stability of a nuclide is governed by 
the structural arrangement and binding energy of the nucleons in the nucleus. One criterion of 
stability is the neutron-to-proton ratio (N/Z) of the stable nuclides; the radionuclides decay to 
achieve the N/Z of the nearest possible stable nuclide. Radioactive decay by particle emission 
or electron capture changes the atomic number of the radionuclide, whereas decay by g-ray 
emission does not. 
α decay occurs in heavy nuclei such as 235U, 239Pu, etc. In the decay process two protons and 
two neutrons, i.e. nucleus of helium molecule are emitted. α particles are emitted with discrete 
energy and have a very short range in matter, e.g., about 0.03 mm in human tissues. 
β- decay occurs in radionuclides that are neutron rich. In the decay process, a neutron in the 
nucleus is converted to a proton along with the emission of a β- particle and an anti-neutrino  
( ν ).  β- decay is usually represented as ݊	 → ݌ ൅ βି ൅ 	 ν .	Examples are 131I and 90Y.  
Positron decay:  β+ occurs when a radionuclide is proton rich; it decays by the emission of a 
positron  β+ along with a neutrino ν. In essence, a proton in the nucleus is converted to a neutron 
in the process. β+ decay is usually represented as (݌	 → ݊ ൅ βା ൅ 	ν) and some examples of 
positron-emitting nuclides are: 11C, 13N, 15O, 19F, 66Ga, 68Ga, 82Rb and 124I. Since a neutron is 
one electron mass heavier than a proton, the right hand side of decay representation is two 
electron mass more than the left-hand side, i.e., 2 X 0.511 MeV = 1.022 MeV more on the 
right side. For conservation of energy, therefore, the radionuclide must have transition energy 
of at least 1.022 MeV to decay by β+ emission. The energy beyond 1.022 MeV is shared as 
kinetic energy by the  β+ particle and the neutrino. PET is based on the principle of coincidence 
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detection of the two 511 keV photons arising from positron emitters, which will be discussed 
in certain detail later.  
Electron capture (EC) occurs when a radionuclide is proton rich, but has energy less than 
1.022 MeV, then it decays by electron capture. In the process, an electron from the nearest 
shell, i.e., K-shell, is captured by a proton in the nucleus to produce a neutron. EC decay is 
usually represented as (݌		 ൅ eି 	→ ݊ ൅ ν) and some examples radionuclides that decay by EC 
are: 11C (1.9 %), 19F (3 %), 68Ga (11 %), and 124I (23 %).  
Isomeric transition: when a nucleus has excess energy above the ground state, it can exist in 
excited (energy) states, which are called the isomeric states. The lifetimes of these states 
normally are very short (10-15 to 10-12 s); however, in some cases, the lifetime can be longer in 
minutes to years. When an isomeric state has a longer lifetime, it is called a metastable state 
and is represented by “m” as superscript after the mass number (e.g. 99mTc). In isomeric 
decay, γ-ray is emitted as radionuclides decay to ground state. Having an energy state of 140 
keV above 99Tc and decaying with a half-life of 6 h, 99mTc is an isomer of 99Tc. Isomeric 
transition for 99mTc is represented as (99mTc → 99Tc + γ). 
Internal conversion is a radioactive decay process where an excited nucleus interacts 
electromagnetically with an electron in one of the lower atomic orbitals, causing the electron 
to be emitted (ejected) from the atom. Thus, in an internal conversion process, a high-energy 
electron is emitted from the radioactive atom, but not from a nucleon in the nucleus. The 
electron emitted is called an Auger electron.  
The most commonly used PET radionuclides including 11C and 18F with a half life of 20.4 
min and 109.7 min, respectively are cyclotron produced (table 5). This necessitates the 
presence of on-site cyclotron for production of radionuclides because the desired short-lived 
radionuclides need to be incorporated into the desired molecule, purified, formulated for 
administration and analyzed for (radio)chemical purity and identity within a brief time frame 
(< three half-lives) to ensure there is enough tracer left to administer to the subject undergoing 
the PET-scan. 
In a cyclotron, charged particles such as hydride ion (H-), deuterons, α particle from the ion 
source (S) are accelerated in circular paths in dees under vacuum by means of an 
electromagnetic field (figure 9). The charged particles move along the circular paths under a 
magnetic field with gradually increasing energy, the larger the radius of the particle trajectory, 
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the higher the energy of the particle. The negative charge in hydride ion is stripped of its 
electron by a carbon foil (D) placed perpendicular along its path and directed via the window 
(W) to the target where it interacts with the molecules which then can cause nuclear reactions 
in nuclei. 
 
Figure 9. A schematic illustration of a cross-section of a cyclotron: V, alternating voltage; S, ion 
source; A and B, dees under vacuum; D, carbon foil stripper; W, window. 
The type of radionuclide produced during the nuclear reaction depends on the molecules kept 
in the target. Here, the production of fluorine-18 and carbon-11 is discussed. 
Fluorine-18 (t1/2 = 110 minutes) is commonly produced by the 18O(p,n)18F reaction on water 
target enriched with oxygen-18 (H218O) using 11 to 18MeV protons in medical cyclotrons. 
This produces nucleophilic fluorine-18 ([18F]F-). For F-18 production, an enrichment of > 95 
% is used, because 16O can also undergo a nuclear reaction (16O(p,α)13N) in the cyclotron. The 
18F- is present as [18F]HF in the target water, and can easily be extracted from it by ion 
exchange cartridges. [18F]F- is passed through a carbonated anion exchange cartridge to get 
rid of the bulk of the H218O. The [18F]F- can be eluted from the cartridge by 
carbonate/cryptand mixture (usually K2CO3/4,7,13,16,21,24-Hexaoxa-1,10-
diazabicyclo[8.8.8]-hexacosane). However, any remaining water should be removed as 
solvated fluoride is a poor nucleophile (this can be achieved by azeotropic distillation with 
acetonitrile). [18F]F- can be converted to different synthons (such as 1-bromo-2-
[18F]fluoroethane by reaction with 2-bromoethyl trifluoromethane-sulfonate at 120 oC which 
can be further converted to the more reactive 2-[18F]fluoroethyl trifluoromethane-sulfonate by 
passing through a silver triflate column at 225 oC). Other methods to produce radioactive 
fluorine are given in table 4. 
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Table 4. Nuclear reactions for 18F-production. 
20Ne(d,α)18F 
20Ne(p,2pn)18F 
16O(3He,p)18F 
16O(α ,pn)18F 
18O(p ,n)18F 
20Ne(3He,αn)18Ne, 8Ne (t1/2 1.67 s) decays to 18F 
6Li(n , α)3H, the 3H reacts in a following nuclear reaction 16O(3H ,n)18F 
 
The most convenient method for producing carbon-11 in a cyclotron is by the 14N(p,α)11C 
nuclear reaction. With O2 (0.1-0.5 %) present, [11C]CO or [11C]CO2 is produced in-target 
from the nuclear reaction of protons from the accelerator with 14N2, while by adding H2 (5-10 
%) to the target gas [11C]CH4 is produced. [11C]CO2 or [11C]CH4 is recovered by initially 
trapping in a column trap inserted into liquid nitrogen filled cup (Deware) and later removing 
it by flushing with helium or heating the trap. Several reactive molecules have been prepared 
by simple on-line or one-pot procedures from [11C]CO2 or [11C]CH4. Some of the most 
important of those secondary precursors are shown in figure 10. The most common 
production method for other commonly used PET tracers are given in table 5. 
 
Figure 10. The most important 11C precursors used in the synthesis of 11C-labeled compounds 
produced from either [11C]CO2 or [11C]CH4.  
[11C]CO2 [11C]CH4 [11C]CCl4[11C]CO
[11C]HCN[Carbonyl-11C]RCOOMX
[11C]CH3OH [11C]CH3I
[Carbonyl-11C]RCOCl [11C]RCOCl2
[11C]RCH2OH[
11C]RCH2X
[11C]CH2O [11C]CH3OTf
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Table 5. Frequently used PET-radionuclides, their nuclear reactions for production, decay nuclides 
and some physical characteristics. Adapted from van Veghel [108]. 
Radionuclide Reaction  t1/2  Daughter Emax  (keV) Rmax  
11C 14N(p,α)11C 20.4 min 11B 961 3.9 
18F 18O(p,n)18F 109.8 min 18O 634 2.3 
13N 16O(p,α)13N 9.97 min 13C 1198 5.1 
15O 15N(d,n)15O 2.04 min 15N 1732 8.0 
124I 124Te(p,n)124I 4.17 d 124Te 2138 10.2 
68Ga 68Ge generator 67.6 min 68Zn 1899 8.9 
64Cu 64Ni(p,n)64Cu 12.7 h 61Ni 653 2.4 
89Zr 89Y(p,n)89Zr 78.4 h 89Y 897 3.6 
p: proton; n: neutron; d:deuteron; α: helium nucleus (2p+2n); Reaction: nuclear reaction for production of 
radioisotopes;t1/2: physical half-life; Daughter: daughter product/nuclide of the decay; Emax: maximum energy 
of the β; Rmax: maximum range of β+in H2O (mm) 
Once, a radioisotope is produced in the target and transferred to a reactive synthon the next 
step is radiolabeling where priority is given for effective incorporation of the positron 
emitting radionuclide in the desired precursor molecule. Due to the high energies of the 
gamma rays emitted upon decay of the radioisotopes, traditional bench-top chemistry is not an 
option and radiolabeling reactions are performed in synthesis modules housed in lead shielded 
“hot cells” (figure 11) to avoid high radiation doses. 
The most commonly used methods employed in the preparation of labeled compounds for 
clinical use are: Isotope exchange reactions.In isotope exchange reactions, one or more atoms 
in a molecule are replaced by isotopes of the same element having different mass numbers. 
Examples are 125I-triiodothyronine (T3) and 125I-thyroxine (T4).  
Introduction of a foreign label: in this type of labeling, a radionuclide is incorporated into a 
molecule that has a known biological role, primarily by the formation of covalent or 
coordinate covalent bonds. The tagging radionuclide is foreign to the molecule and does not 
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label it by the exchange of one of its isotopes. Examples are 18F-fluorodeoxyglucose 
([18F]FDG) 99mTc-labeled albumin, 51Cr-labeled red blood cells, and many iodinated proteins 
and enzymes. 
Labeling with bifunctional chelating agents: in this approach, a bifunctional chelating agent is 
conjugated to a macromolecule (e.g., protein, antibody) on one side and to a metal ion (e.g. 
Tc) by chelation on the other side. An example is 68Ga-octreotide (68Ga-Dotatoc).  
Biosynthesis: In biosynthesis, a living organism is grown in a culture medium containing the 
radioactive tracer, the tracer is incorporated into metabolites produced by the metabolic 
processes of the organism, and the metabolites are then chemically separated. For example, 
vitamin B12 is labeled with 60Co or 57Co by adding the tracer to a culture medium in which the 
organism Streptomyces griseus is grown. Other examples of biosynthesis include 14C-labeled 
carbohydrates, proteins, and fats.  
Recoil labeling: in a nuclear reaction, when particles are emitted from a nucleus, recoil atoms 
or ions are produced that can form a bond with other molecules present in the target material. 
Several tritiated compounds can be prepared in the reactor by the 6Li(n,α)3H reaction. The 
compound to be labeled is mixed with a lithium salt and irradiated in the reactor.  
 
Figure 11. Picture of lead shielded “hot cells” and a radiolabeling synthesis module. (Courtesy van 
Veghel [114]). 
Excitation labeling: Excitation labeling entails the utilization of radioactive and highly 
reactive daughter ions produced in a nuclear decay process. During β decay or electron 
capture, energetic charged ions are produced that are capable of labeling various compounds 
of interest. For example, Krypton-77 decays to 77Br and, if the compound to be labeled is 
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exposed to 77Kr, then energetic 77Br ions label the compound to form the brominated 
compound. Similarly, various proteins have been iodinated with 123I by exposing them to 
123Xe, which decays to 123I. The yield is considerably low with this method. 
In most cases the radiolabeling of molecules with the two most used PET radionuclides (11C 
and 18F) is introducing the nuclides to readymade precursors by nucleophilic substitution or a 
leaving group substitution such as triflates, mesylates and tosylates. The longer half-life of 18F 
allows more complicated and time-consuming chemistry and provides the opportunity to 
transport 18F-labeled tracers to PET-facilities that are not equipped with a cyclotron. 
Moreover, multiple subjects can be scanned using the same batch of 18F-labeled tracer and the 
low maximal positron energy of fluorine-18 (634 keV) results in high resolution PET-images. 
The latter is an advantage over gallium-68 (68Ga) and iodine-124 (124I), as their emitted high 
energy positrons (table 5) may cause significant loss of spatial resolution when small 
structures are to be visualised using high resolution microPET-cameras [115-117]. The more 
complex cyclotron production of 124I, as well as copper-64 (64Cu) and zirconium-89 (89Zr), 
(solid targets vs. gas or liquid targets for 11C and 18F), limits their use. The radioisotopes 13N 
and 15O are, due to their very short half-lives, only available in the chemical forms in which 
they are produced in the cyclotron target (e.g. 13N-NH3) or require instant high yield reactions 
(e.g. 15O-H2O) [116]. The emergence of 68Ga in nuclear medicine can be explained by its 
broad availability at a reasonable cost-price via a 68Ge/68Ga generator and thus the non-
requirement of an on-site cyclotron [115]. 
Radiopharmaceuticals targeting specific entities such as receptors or enzymes are often 
referred to as “tracers” because they are used in a very small (trace) amounts (in micro- to 
nanograms). To be useful for PET-imaging, the tracer should show high binding affinity (Kd), 
preferably in the subnanomolar to low nanomolar range, and selectivity for its target. Still, it 
is often difficult to estimate the required affinity of a tracer, in the perspective of high quality 
images, since the expression level of a protein usually varies among different tissues and may 
be up- or down-regulated in pathophysiological conditions [116]. 
4.2. Positron emission tomography (PET) 
Principle of PET 
PET is an exciting field of molecular imaging that uniquely explores the biochemical process 
at the cellular (subcellular) level. It is a non-invasive molecular imaging technique used in 
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nuclear medicine and is based on the detection of two coincident gamma rays emitted during 
annihilation of positroniums, formed by collision of positrons with electrons.  
PET-radionuclides, characterised by an excess of protons (or lower proton to neurton ratio 
than their stable isotope), are unstable and decay by conversion of a proton into a neutron and 
subsequent emission of a positron and neutrino (a chargeless and an almost massless particle). 
The positron (β+), which is the positively charged anti-particle of an electron (β-), travels a 
short distance (0-10 mm, depending on its characteristic kinetic energy and density of the 
tissue in which the emission occurs) and combines with an electron in the surrounding tissue 
to form a positronium that immediately annihilates. Upon annihilation, two gamma rays of 
each 511 keV are emitted simultaneously in opposite directions (180°) which are detected in a 
PET camera as a coincident event. This coincident event is used to localize the origin of 
annihilation with a PET camera and computer algorithm. A PET-camera typically consists of 
multiple rings of scintillation detectors composed of inorganic crystals, such as sodium iodide 
doped with thallium [NaI(Tl)] (though they are no longer used in PET cameras and their use 
is restricted in gamma cameras for planar or SPECT imaging), bismuth germanate (BGO), 
luthetium oxyorthosilicate doped with cerium (LSO), yttrium oxyorthosilicate doped with 
cerium (YSO), gadolinium oxyorthosilicate doped with cerium (GSO) and barium fluoride 
(BaF2) with each detector connected in a coincidence circuit with a detector located on the 
opposite side of the ring [109]. The physical properties of the common PET scintillator 
detectors are given in table 5. 
The simultaneous detection of a pair of 511-keV gamma rays by two opposite detectors 
within the PET-camera indicates that an annihilation event took place somewhere along the 
imaginary line between those two detectors (figure 12). Only the gamma rays detected within 
a brief time frame (10-20 ns) are registered and by combining the data from millions of 
annihilation events a three-dimensional image can be reconstructed using mathematical 
techniques. In this way, it is possible to visualise the distribution of radioactivity in the body 
over time and quantify the radioactivity bound to the target [109, 110]. 
In diagnostic nuclear medicine, PET is considered a very sensitive technique, allowing the 
detection of picomolar concentrations and thus subpharmacological amounts of 
radiopharmaceuticals. State-of-the-art clinical PET scanners typically have a spatial resolution 
of 4-6 mm, however, new systems developed for brain imaging show increased spatial 
resolution up to 2.5 mm. Small animal microPET scanners achieve a spatial resolution of 1-2 
Chapter I 
34 
 
mm. The ability to perform translational research starting from preclinical animal models 
directly to clinical settings is one of the most unique and powerful features of PET [110, 115]. 
The technique is applied to gain information on functional state and metabolic activity of 
organs and tissues through specific binding of radiopharmaceuticals to their target proteins 
(e.g. receptors, transporters or enzymes), which is a major advantage compared to anatomic 
imaging techniques such as X-ray computed tomography (CT) that can only provide 
information on structural changes. Molecular processes such as receptor density and 
occupancy, transporter and enzyme activity, and gene expression, among many others, can be 
visualised in vivo. This permits to study the role of certain proteins in selected pathologies, to 
detect diseases before morphological signs appear and to measure therapy response in an early 
stage. In addition, PET is a powerful tool to study the pharmacodynamic and pharmacokinetic 
properties (e.g. dose-occupancy relationship and brain uptake) of new therapeutics and, 
thereby, facilitates drug development. 
Table 6. The physical properties of the common PET scintillator detectors. Adapted from reference [109]. 
Property NaI(Tl) BGO LSO YSO GSO BaF2 
Effective Z 50 74 66 34 59 52 
Density (g/cm3) 3.7 7.1 7.4 4.5 6.7 4.9 
Scintillation decay time (ns) 230 300 40 70 60 0.6 
Photon yield per keV 38 6 29 46 10 2 
Relative light output 100 15 75 118 25 5 
Linear attenuation coefficient, µ/cm 0.32 0.96 0.87 0.39 0.70 0.44 
Energy resolution (% at 511 keV) 6.6 20 10 12.5 8.5 11.4 
NaI(Tl): sodium iodide doped with thallium; BGO: bismuth germanate; LSO: luthetium oxyorthosilicate doped with 
cerium; YSO: yttrium oxyorthosilicate doped with cerium; GSO: gadolinium oxyorthosilicate doped with cerium; 
BaF2: barium fluoride; keV: kiloelectron volt; ns: nanosecond; effective Z: the effective atomic number 
The latest innovation in the field of nuclear medicine is the development of clinical PET/MR-
scanners, housing the two modalities in a single imaging system that assures accurate 
anatomical designation of PET-images. The combination of other imaging modalities is 
intensively being explored and technical advancements in the field of multimodal imaging 
will definitely provide unique opportunities in the future.  
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Figure 12. Schematic representation of the principle behind PET showing the positron decay and 
annihilation which produces two gamma rays of 511 keV. The two gamma rays are detected as 
coincident by two opposite detectors and are processed to generate 3D images. (Courtesy of van 
Veghel [108]). 
5. Objectives and overview of the thesis 
Despite the success enjoyed by the application of several PDE5 inhibitors in the treatment of 
different diseases, there has not been a successful PET radioligand targeting PDE5 except in 
one publication which evaluated a carbon-11 labeled tracer ([11C]RAL-01) though specificity 
of the tracer for PDE5 was not established [102, 106]. Therefore, development of PDE5 
specific PET radioligands would allow to quantify and evaluate changes in PDE5 expression, 
select patients that would benefit from PDE5 inhibitor treatment early during disease 
progression and assess PDE5 occupancy and optimize dose regimens in patients treated with 
PDE5 inhibitors. 
The main purpose of this research work was the development of PET probe(s) labeled with 
carbon-11 or fluorine-18 and the biological evaluation in order to select the optimal 
radioligand with high affinity and specificity for the PDE5 enzyme, ultimately enabling in 
vivo visualization/evaluation of PDE5. A successful PET radioligand(s) with high affinity and 
specificity for PDE5 would enable to quantify changes in PDE5 expression as a function of 
disease progression and could, furthermore, be used in clinical studies to quantify the 
occupancy of PDE5 in heart failure and PAH patients undergoing treatment with PDE5 
inhibitors which could be exploited to determine the optimal dose of PDE5 inhibitors that are 
used in those patients. 
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During the course of the research, the general stages of new tracer development have been 
followed more or less: target selection (phosphodiesterase 5 expression in PAH and cardiac 
hypertrophy); lead selection and optimization (organic synthesis of selected PDE5 inhibitors 
reported in the literature); radiolabeling (carbon-11 and fluorine-18 production and labeling of 
precursors); purification (mainly HPLC based); formulation (pH adjustment, sterile filtration, 
ethanol concentration adjustment); quality control (mainly HPLC based and in some cases 
high resolution mass spectrometry); in vitro tests (mainly autoradiography); and ex vivo/in 
vivo evaluation of tracers in laboratory animals (plasma/brain radiometabolite analysis, 
biodistribution studies, microPET imaging, toxicity study [112]. 
Chapter II discusses the most time consuming aspect of radiochemistry in any new tracer 
development: synthesis of the labeling precursor and non-radioactive standard reference 
compounds that were used to authenticate the radiolabeled tracers. Non-radioactive standard 
compound or reference compound is essentially the same as the labeled compound except a 
stable isotope is used in place of the radioactive isotope and behaves identically to the labeled 
variant in every way and is used as surrogate to establish in vitro binding data, analytical as 
well as purification procedures by means of HPLC or other purification methods. Besides, the 
preliminary biological evaluation of the six tracers out of the total nine tracers that have been 
evaluated during the course of the last four years is discussed. A detailed description of the 
organic synthesis of precursors and reference compounds, characterization, HPLC analysis 
data, in vitro affinity assay results and biological evaluation data are given in the supporting 
document for Chapter II.  
Chapter III is a continuation of the results described in Chapter II on the vardenafil 
derivatives. In this chapter, based on the conclusion of Chapter II, further biological 
evaluation of [11C]7 is reported. Biodistribution studies in transgenic mice with 
cardiomyocyte specific PDE5 over-expression (PDE5 TG), blocking studies in PDE5 TG 
mice as well as microPET imaging in PDE5 TG mice and in rats with monocrotalin induced 
PAH model, plasma radiometabolite analysis in mice and pigs, and large animal studies are 
reported. In this chapter, the high affinity and specific binding of [11C]7 to PDE5 is 
established.  
In Chapter IV, a separate class of PDE5 inhibitors with the ability to cross the BBB is 
discussed. The organic synthesis, radiolabeling, preliminary biological evaluation 
(biodistribution in NMRI mice and PDE5 TG mice), in vitro autoradiography, microPET 
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imaging in PDE5 TG mice and rats are reported for two 11C and 18F labeled pyridopyrazine 
derivatives.  
Chapter V describes a toxicity study (microdosing approach) of compound 7 
(NMVardenafil) in rats. This was performed to move towards first- in-human applications.  
A general discussion on the results of the experiments undertaken with future perspectives 
and limitations of the current study/work are discussed in Chapter VI.  
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Abstract 
Introduction: The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 
5 (PDE5) is considered to play an important role in various etiologies such as pulmonary 
arterial hypertension (PAH) and chronic heart failure. This PDE5 modulation represents an 
important prognostic and/or therapeutic target; however, there is currently no method to non-
invasively evaluate the PDE5 expression levels in vivo. 
Methods: Radiolabeling was achieved by N-alkylation of the corresponding precursors with 
[11C]methyl trifluoromethanesulfonate ([11C]CH3OTf) or 2-[18F]fluoroethyl trifluoromethane-
sulfonate   ([18F]FEtOTf). Biodistribution of radiolabeled tracers was studied in NMRI mice 
and their specific binding to PDE5 was investigated by comparing their lung retention as the 
enzyme is abundantly expressed in this organ.  
Results: The overall radiochemical yields ranged between 18 and 60 % for labeled 
radiotracers with radiochemical purity of > 99 %. The highest retention in the lungs at 30 min 
post injection was observed for vardenafil derivatives [11C]-7 and [18F]-11 and the retention of 
the ethoxyethyl pyrazolopyrimidine derivative [11C]-37 was moderate. The other investigated 
compounds [11C]-8, [11C]-14, [11C]-21 and [11C]-33 showed lower retention in lungs in 
agreement with their lower in vitro affinity for PDE5.  
Conclusion: Among the different radiolabeled PDE5 inhibitors evaluated in this study, the 
vardenafil derivatives [11C]-7 and [18F]-11 are found to be promising tracers for in vivo 
visualization of PDE5. 
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1. Introduction 
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are 
ubiquitous second messengers responsible for transducing effects of various extracellular 
mediators including hormones, light and neurotransmitters [1-3].  
The hydrolysis of cyclic nucleotides to their respective linear forms is catalyzed by a 
superfamily of enzymes known as phosphodiesterases (PDEs). The human genome contains 
21 distinct PDE genes that encode 11 PDE protein families (PDE1 through PDE11). Some 
PDEs specifically hydrolyze cAMP or cGMP while others have mixed specificity. cAMP-
specific PDEs include PDE4, 7 and 8 and cGMP-specific PDEs are PDE5, 6 and 9, 
whereas PDE1, 2, 3, 10 and 11 metabolize both cyclic nucleotides [1]. 
PDE5 is expressed in vascular smooth muscles, lungs, platelets, corpus cavernosum, and 
Purkinje fibers in the cerebellum [4]. It plays an important role in the regulation of vascular 
smooth muscle tone in the pulmonary vasculature, platelet aggregation, neuronal excitability 
and synaptic plasticity in Purkinje cells, handling of sodium secretion in renal cells and 
apoptosis [2, 4]. Moreover, PDE5 is considered to play an important role in disease 
progression such as pulmonary arterial hypertension (PAH), ischemic and dilated 
cardiomyopathy [2, 5-9]. As such, three PDE5 inhibitors (sildenafil, vardenafil and tadalafil) 
have been approved by FDA for the treatment of male erectile dysfunction and PAH and 
several others are in clinical evaluation for use in PAH [10-13]. A number of authors also 
advocate the use of PDE5 inhibitors to ameliorate cardiac hypertrophic response in chronic 
heart failure as the enzyme is up-regulated up to 5-fold in patients with ischemic and dilated 
cardiomyopathy [14-19].  
Despite the involvement of PDE5 in several ailments and the success of PDE5 inhibitors in 
clinical practice, there is currently no method to non-invasively evaluate PDE5 expression 
levels in vivo. With regard to PAH, development of carbon-11 and/or fluorine-18 labeled 
PDE5 specific probes would enable the quantification of PDE5 availability and occupancy by 
PDE inhibitors in the pulmonary vasculature and consequently pave the path for 
determination of optimal doses regimens of PDE5 inhibitors used in the treatment of PAH.  In 
addition, developing a positron emission tomography (PET) probe provides an insight into the 
extent and severity of PDE5 up-regulation in chronic cardiomyopathy and can potentially 
predict adverse remodeling and progression towards heart failure.  
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In recent years there have been several attempts to develop radioligands targeting PDEs with 
some success [20]. Only one article discusses the attempt to develop a PDE5 radioligand. In 
this article Jacobsen et al described the development of a PET radioligand [11C]RAL-01 for in 
vivo visualization of PDE5 though PDE5-specific binding could not be demonstrated for the 
tracer [21]. Here, we discuss the synthesis, radiolabeling and preliminary biological 
evaluation of different PDE5 inhibitors in mice as a potential radioligands for in vivo 
visualization of PDE5 expression. 
2. Results and discussion 
2.1. Organic synthesis 
Four different families of PDE5 inhibitors were prepared, namely derivatives of vardenafil, 
sildenafil, 4-benzylaminoquinoline, and ethoxyethylpyrazolopyrimidine derivatives (figures 1, 
2, 3, and 4). Precursors 5, 6, 13, 20, 32, and 35 were prepared for labeling with carbon-11 
and/or fluorine-18 to provide [11C]-7, [11C]-8, [18F]-11 and [11C]-14, [11C]-21, [11C]-33, [11C]-
37 (figure 5).  
Compounds 7, 8 and 11 are close analogues of vardenafil, in which the ethyl substituent on 
the piperazine ring was replaced by a methyl group and 2-fluoroethyl group in 7 and 11, 
respectively and the N-ethylpiperazine is replaced with N,1-dimethylpiperidin-4-amine in 8 
[22]. Precursors 5, 6, and the authentic references 7, 8 and 11 were prepared according to 
figure 1 starting from commercially available 1 based on procedures described in literature 
[23-26].  
Sildenafil (14) is the first FDA approved PDE5 inhibitor for the treatment of male erectile 
dysfunction and pulmonary arterial hypertension [22, 27]. Precursor 13 for radiolabeling was 
prepared according to figure 2 starting from commercially available 12 [26]. Sildenafil (14) 
that was used for authentication was obtained from a commercial source.  
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Figure 1. Synthesis of vardenafil derivatives (7, 8 and 11).Reaction conditions: (a) HSO3Cl, 0 oC→RT, 
16 h; (b) N-Boc-Piperazine, CH2Cl2, 4-DMAP, RT, 16 h; (c) t-Butyl-4-(methylamino)piperidine-1-
carboxylate, CH2Cl2, 4-DMAP, RT, 5 h; (d) CH2Cl2, TFA, 0 oC→RT, 16 h; (e) 1-Methylpiperazine, 4-
DMAP, CH2Cl2, RT, 16 h; (f) N,1-Dimethylpiperidine-4-amine, 4-DMAP, DIEA, RT, 16 h; (g) 1) FEtBr, 
DIEA, CH3CN, 50 oC, 16 h, then reflux, 6.5 h; 2) CH2Cl2, TFA, 0 oC→Rt, RT, 2 h; (h) 4-DMAP, RT, 16 
h.  
Figure 2. Synthesis of precursor (13) of sildenafil (14). Reaction conditions: (a) Piperazine, THF, RT, 
2.5 h. 
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Figure 3. Synthesis of precursors and reference of 4-benzylaminoquinoline derivative. Reaction 
conditions: (a) Diethyl ethoxymethylenemalonate, PhCH3, reflux, 6 h; (b) Diphenylether, reflux, 2 h; (c) 
POCl3, reflux, 48 h; (d) n-Propanol, 3-Chloro-4-methoxybenzyl amine, DIEA, reflux, 2 h; (e) 1 N 
NaOH/MeOH, RT, 4 h; (f) CH2Cl2, MeOH, 4-DMAP, RT, 1 h, then to 0 oC, DCC, 16 h. 4-BAQ (4-
aminobenzyl quinoline). 
Figure 4. Synthesis of precursors and reference of ethoxyethyl pyrazolopyrimidine derivatives. 
Reaction conditions: (a) 1) EtOH, 1 M t-BuOK (in THF), 75 oC, 30 min, 2) 4 oC, N2H4, 75 oC, 1 h; (b) 
THF, MeOH, 1 M LiOH, reflux, 3 h; (c) H2SO4 (fuming), HNO3 (fuming), 0 oC → 50 oC, 30 min, 60 oC, 
16 h; (d) SOCl2, N2, reflux, 3 h, THF, 0 oC, NH3, 1 h; (e) THF, Triphenylphosphine, 0 oC, 2-EtOEtOH, 
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di-tert-Butyl azodicarboxylate, 3.5 h, 0 oC, 6 M HCl, 40 oC, 1 h; (f) EtOH, Pd(OH)2/C, 
ammoniumformate, 40 min, reflux, 2 h; (g) Carbonyldiimidazol, CH3CN, 75 oC, 1 h, RT, 2 h, 0 oC, H2O; 
(h) Phenylphosphonic dichloride, N2, 135 oC, 48 h, 0 oC, 3 h, H2O, THF, 1 M HCl, pH 1; (i) 0 oC, THF, 
2-Amino-4-picoline, 1 M Lithium bis(trimethylsilyl)azanide (in THF), 5 oC, 30 min, 10 % citric acid, 5 oC, 
1 h; (j) Piperazine, 2-PrOH, 175 oC, 45 min; (k) 1-Methylpiperazine and the rest same as (j); (l) tert-
Butylpiperidin-4-yl carbamate and the rest same as (j); (m) CH2Cl2, 0 oC, N2, TFA, 1 h, RT, 1 h; (n) tert-
Butyl methylpiperidin-4-ylcarbamate and the rest same as (j); (o) same as (m).   
4-Benzylaminoquinoline derivative (22) was first reported in 2003 by Bi et al as a selective 
PDE5 inhibitor with the highest inhibitory activity for PDE5 among its predecessors [11, 12, 
28]. 19 along with 22 were among a series of PDE5 inhibitors reported by the same group. A 
series of compounds (19, 20, 21, and 22) were prepared according to figure 3 based on 
literature reports [28-30]. Synthesis attempts to demethylate 22 to provide the phenolic 
precursor for radiolabeling were not successful. Therefore, 21 which is a methyl ester 
analogue of 19 was selected for biological evaluation.   
Figure 5. Radiosynthesis of PDE5 radioligands. 
Compound 35, an ethoxyethyl pyrazolopyrimidine derivative reported by Tollefson et al. [31] 
has the highest PDE5 inhibitory activity (IC50 = 7 pM) among the PDE5 inhibitors reported 
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thus far [11, 12]. We have synthesized two of the derivatives in this group (33 and 37) along 
with the precursors 32 and 35 for carbon-11 radiolabeling according to the literature methods 
(figure 5) [31-36]. A methyl group was introduced on a primary amine of the 4-
(aminomethyl)piperidine moiety of 35 in order to get 37 which resulted in a slightly different 
compound than the one reported by Tollefson and 37 was used in subsequent biological 
evaluation.  
A detailed description of the synthesis of all compounds, 1H-NMR and HRMS data for 
precursors and reference compounds are provided in the supporting information. 
2.2. In vitro PDE5 inhibitory activity assay 
In vitro PDEs inhibitory activity (IC50) was experimentally determined for the different series 
of compounds. Their PDEs inhibitory activity for selected families (PDE5, PDE6 and PDE11) 
is given in table 1 (IC50 values for all PDE families are given in supporting information).  
Vardenafil and its close derivative (7) were reported to have an IC50 value of 0.7 nM and 0.6 
nM in vitro PDE5 inhibitory activities, respectively [22] and this value was in line with our in 
vitro PDE5 inhibitory assay for 7 (0.8 nM). The other two vardenafil derivatives (8 and 11) 
also showed PDE5 inhibitory activity in sub nanomolar to lower nanomalar range (1.1 nM 
and 0.7 nM, respectively). 
Table 1. IC50 (µM) values of PDE5 inhibitors for selected PDE families 
Compounds  hPDE5A3 hPDE6AB hPDE11A4 
7  0.0008 0.0031 0.8137 
8  0.0011 0.0031 0.9918 
11  0.0007 0.0023 0.6979 
14  0.0173 0.1175 7.3393 
21  0.0081 0.0830 7.7678 
33  0.1636 0.3513 3.2574 
35  0.0032 0.0008 0.0076 
37  0.0032 0.0008 0.0095 
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The ethoxyethyl pyrazolopyrimidine derivatives (33 and 35) were reported to have an IC50 
value of 0.89 nM and 0.007 nM for PDE5, respectively [31]. 37 was selected for biological 
evaluation as the parent compound 35 was not suitable for radiolabeling other than at the 
primary amino site. A methyl group was introduced on a primary amine of the 4-
(aminomethyl)piperidine moiety of 35 which resulted in a slightly different compound than 
the one reported by Tollefson.  The IC50 value determined for these two compounds (35 and 
37) in our assay gave identical results (3.2 nM) for both compounds (table 1). But the in vitro 
PDE5 inhibitory activity for 33 was 163 nM; which is a significant deviation from the 
literature reported value of 0.89 nM.  
Other groups of PDE5 inhibitors sildenafil (14) and 4-benzylaminoquinoline derivative (21) 
were found to have an in vitro PDE5 inhibitory activity much higher than the other PDE5 
inhibitors with the exception of 14 and 33. 4-Benzylaminoquinoline derivative (22) was first 
reported in 2003 by Bi et al. as a selective PDE5 inhibitor with the highest inhibitory activity 
for PDE5 among its predecessors based on its IC50 value (50 pM) [28]. In our in vitro assay, 
22 was found to have the highest inhibitory activity (0.3 nM) and selectivity for PDE5 among 
the PDE5 inhibitors evaluated in this study although this value was 16-fold higher than that 
reported by Bi et al. Its ethylester (19) derivative was reported to have an IC50 value 
equivalent to that of vardenafil (0.7 nM) [22, 28]. For 21, a methylester analogue of 19, the in 
vitro PDE5 inhibitory activity was found to be 8 nM. This is the third highest IC50 value 
among the PDE5 inhibitors evaluated in this study. 
Most of the PDE5 inhibitors evaluated in this study showed a significant in vitro PDE5 
inhibitor activity in the nanomolar range.  However, the experimentally determined values for 
the PDE5 inhibitors showed a difference from literature reported values except for 7. This 
may be due to differences in the assay method.  
2.3. Radiosynthesis 
Radiolabeling was achieved by the one-step N-alkylation in anhydrous DMF of the amine 
precursors (5, 6, 13, 32 and 35), or esterification of 20 with [11C]methyl 
trifluoromethanesulfonate ([11C]CH3OTf) with the use of base (NaOH or DIEA). N-alkylation 
of 5 with 2-[18F]fluoroethyl trifluoromethanesulfonate (2-[18F]FEtOTf , figure 5) gave the 18F-
analog [18F]-11. The reaction mixtures were kept at room temperature (RT) for 2 min. All 
radiotracers were purified by HPLC. The overall radiosynthesis, including alkylation (either 
with [11C]CH3OTf or [18F]FEtOTf), HPLC purification, sterile filtration and radiotracer 
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formulation was completed in 50 to 60 min from end of bombardment for carbon-11 labeling 
and 60 to 90 min for fluorine-18 labeling. 
The incorporation yield (non-decay corrected radiochemical yield, RCY based on HPLC 
recovered activity) of alkylation with [11C]CH3OTf  or [18F]FEtOTf ranged from 18 to 60 % 
for the different compounds, and the radiochemical purity after HPLC purification was greater 
than 99 % for all compounds. The identity of the labeled compounds was confirmed using 
analytical HPLC by co-injection of the corresponding authentic reference analogues (7, 8, 11, 
14, 21, 33 and 37). The specific activities of the different radiotracers ranged from 60 
GBq/µmol to 209 GBq/µmol (table 2) at the end of formulation of radiotracers for animal 
administration. Representative radiochromatograms of RP-HPLC purification and identity 
confirmation with co-injection of tracer solution and non radioactive standard reference 
compound is given for [11C]7 in supporting information. 
2.4. Biodistribution Studies 
As the first step in the evaluation of the suitability of carbon-11 or fluorine-18 labeled tracers 
for in vivo visualization of PDE5, our focus was on the retention of the tracers in the lungs of 
healthy mice. Abundant expression of PDE5 in the lungs among different species had been 
established by several authors [4, 10, 37, 38]. Hence, it was expected that a suitable tracer 
would show high uptake and retention in the lungs. This uptake should also be blocked by 
pre-treatment with a competitive inhibitor of the enzyme if tracer binding is PDE5 specific.  
Comparison of the different radiotracers was made based on the percentage of injected dose 
(% ID) and standard uptake value (SUV) in different organs and tissues. For each tracer the % 
ID and SUV (obtained by normalizing the % ID for animal’s body weight and the weight of 
organ of interest) are given in tables 3 and 4. Particular emphasis was given to the tracer 
distribution in the lungs at 30 min post injection (pi).  
Results obtained from the preliminary biological evaluation of the several radiotracers are 
given in tables 3 and 4. When comparing the lung retention at 30 min pi, [11C]-7 and [18F]-11 
showed the highest retention followed by a moderate observed retention for [11C]-8 and [11C]-
37. The lung retention of [11C]-14, [11C]-21 and [11C]-33 was low. The tracer concentration in 
the lung at 30 min pi of [11C]-7 (8.0±1.9 SUV) and [18F]-11 (8.9±0.8 SUV) were the highest 
among all organs (supporting information) with lung-to-blood SUV ratios of 11.2 and 7.9, 
respectively. This is in agreement with literature findings that PDE5 is abundantly expressed 
Chapter II  
50 
 
in the lungs. The in vitro low PDE5 inhibitory activity of 14 (sildenafil) in our assay was also 
reflected in the in vivo lower uptake and retention of [11C]-14 in the lungs of NMRI at 30 min 
pi compared to [11C]-7 uptake (tables 3 and 4).  
Table 2. Results of radiochemistry, logD and PSA values of PDE5 tracers 
Radioligand RCY (%) 
Specific activity 
(GBq/µmol) logD at pH7.4 PSA (Å2) 
[11C]-7 29 (n=6) 77 0.73 112.9 
[11C]-8 60 (n=1) 209 0.41 112.9 
[18F]-11 25 (n=3) 60 0.94 112.9 
[11C]-14 50 (n=3) 145 1.33 113.4 
[11C]-21 56 (n=4) 155 5.21 84.3 
[11C]-33 33 (n=2) 57 3.37 80.6 
[11C]-37 18 (n=2) 61 0.88 89.8 
logD at pH 7.4 generated with MarvinSketch 5.5.0.1 software (ChemAxon Ltd), PSA (polar surface area) is 
software generated  (Molinspiration Cheminformatics 2011); GBq (gigabecquerel) 
The biodistribution study of [11C]-21 in NMRI mice at four time points (tables 3, 4 and 
supporting information) is in agreement with the moderate in vitro inhibitory activity for 
PDE5 with relatively low lung uptake followed by rapid wash-out. The lung uptake of [11C]-
21 at all studied time points (supporting information) was the lowest compared to that of all 
other tracers evaluated in this study. Plasma radiometabolite analysis of [11C]-21 at 30 min pi 
showed that at least 58 % of the activity was still in the form of intact tracer (supporting 
document). This rules out fast metabolism as the culprit for the observed absence of retention 
of [11C]-21 in the lungs.  
Together with [11C]-14 and [11C]-21, [11C]-33 was among those which showed the lowest 
uptake and retention at 30 min pi.  [11C]-33 also showed a significant wash-out from the lungs 
from 5.1±1.0 % ID at 2 min to 1.7±0.3 % ID at 30 min pi (table 3 and supporting 
information). Radiotracers [11C]-14, [11C]-21 and [11C]-33 showed the lowest in vitro PDE5 
inhibitory activity and this corresponds also with their low in vivo retention in the lungs 
(figure 6). Interestingly, retention of [11C]-37 in the lungs at 30 min pi was high and 
comparable to that of [11C]-7 (table 3). Comparison of % ID (4.4±1.2 and 5.9±1.1 for [11C]-37 
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and [11C]-7, respectively) and SUVs (6.6±1.5 and 8.0±1.9 for [11C]-37 and [11C]-7, 
respectively) in the lungs of NMRI mice showed no significant difference in the retention of 
the two tracers (p = 0.1 and 0.3 for % ID and SUV, respectively). The specificity of [11C]-37 
for PDE5 was subsequently tested with a pre-blocking study (table 5) using the PDE5 specific 
inhibitor tadalafil [39]. 
Table 3. Biodistribution of the various radiolabeled PDE5 inhibitors in NMRI mice at 30 min post 
injection (n = 4, SD = standard deviation) 
aPercentage of Injected Dose (% ID±SD) 
Organs [11C]-7 [11C]-8 [18F]-11 [11C]-14 [11C]-21  [11C]-33  [11C]-37 
kidneys 2.5±0.4 5.6±1.0 3.0±0.6 8.7±6.3 2.2±0.3 4.9±0.4 11.6±1.01 
Liver 16.5±2.1 23.2±3.9 8.7±0.4 18.0±1.6 14.2±1.1 20.3±2.9 30.0±0.9 
Lungs 5.9±1.0 3.2±0.4 6.4±1.6 1.0±0.1 0.7±0.1 1.7±0.3 4.4±1.2 
Heart 0.3±0.0 0.1±0.0 0.5±0.1 0.3±0.0 0.4±0.1 0.4±0.1 0.6±0.0 
Intestines 32.3±6.1 39.5±3.2 20.7±3.1 25.5±1.7 31.1±3.1 18.0±1.9 16.7±1.2 
Blood 3.3±0.3 1.6±0.2 8.5±0.5 3.7±0.5 2.8±0.1 1.8±0.3 2.8±0.5 
Penis 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.0±0.0 0.1±0.0 0.0±0.0 
Data are expressed as mean±SD; apercentage of injected dose calculated as CPM in organ * 100%/total CPM 
recovered  
All of the studied compounds showed accumulation in the intestine over a time period and 
were cleared from plasma mainly via the hepatobiliary pathway (supporting information). 
However, [11C]-8 showed a higher percentage of activity in the kidneys and urine/bladder (% 
ID, 5.6±1.0 and 5.2±1.3 respectively, table 3 and supporting information) and this might be 
attributed to a polar radiometabolite. Though [11C]-14 and [11C]-37 showed high percentage 
of activity in the kidney at 30 min pi (8.7±6.3 and 11.6±1.0 % ID, respectively), these was not 
accompanied by excretion in the urine (2.3±0.3 and 0.8±0.3 % ID, respectively). This might 
be due to reabsorption and/or retention of the tracers after glomerular filtration.  
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Table 4. Standard uptake values of the various radiolabeled PDE5 inhibitors at 30 min post injection 
in NMRI mice (n = 4, SD = standard deviation) 
aStandard Uptake Value (SUV±SD) 
Organs [11C]-7 [11C]-8 [18F]-11 [11C]-14 [11C]-21  [11C]-33  [11C]-37 
Kidneys 1.3±0.1 3.7±0.6 1.8±0.3 5.0±3.6 1.3±0.1 3.3±0.8 7.4±1.3 
Liver 3.5±0.4 4.8±0.9 2.0±0.1 3.5±0.3 3.5±0.3 4.4±0.9 6.4±0.3 
Lungs 8.0±1.9 3.8±1.2 8.9±0.8 1.5±0.2 1.0±0.2 2.7±0.4 6.6±1.5 
Heart 0.7±0.1 0.3±0.1 1.2±0.1 0.7±0.1 1.1±0.3 0.9±0.1 1.1±0.2 
Intestines 3.5±0.6 4.8±0.3 2.2±0.2 3.0±0.2 1.3±0.8 2.5±0.2 2.0±0.2 
Blood 0.7±0.3 0.2±0.0 1.2±0.1 0.5±0.1 0.4±0.0 0.3±0.0 0.2±0.0 
Muscle 0.4±0.1 0.3±0.0 0.7±0.1 0.5±0.0 0.6±0.0 0.4±0.1 0.5±0.1 
Penis 0.7±0.1 0.5±0.1 1.3±0.1 1.0±0.2 0.5±0.1 0.6±0.1 0.3±0.0 
L/Bb 11.2±2.3 16.9±5.1 7.4±0.9 2.9±0.5 2.5±0.4 10.9±2.2 31.8±3.8 
H/Bc 0.9±0.2 1.4±0.1 1.0±0.1 1.4±0.3 2.9±0.8 3.4±0.21 5.2±0.8 
Data are expressed as mean±SD; aSUV calculated as (CPM in organ * Weight of mouse)*100% /(total CPM 
recovered * organ weight); bL/B: Lung to Blood ratio; cH/B: Heart to Blood ratio 
 
 
Figure 6. Lung retention of the different radiolabeled tracers in relation to their in vitro PDE5 activity. 
pIC50, SUV (standard uptake value). 
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Myocardial uptake of any of the evaluated tracers was very limited as expected due to the low 
expression level of PDE5 in normal conditions in mouse myocardium. None of the 
radiolabeled compounds showed significant brain uptake as expected from the calculated low 
logD and high PSA value. 
One of the main clinical applications of PDE5 inhibitors is in the treatment of male erectile 
dysfunction where PDE5 inhibitors inhibit cGMP degradation and maintain penile 
tumescence. Despite this fact, the maximum observed activity at 30 min pi in the penis was 
0.2±0.0 % ID for [18F]-11. However intriguing this might seem, the general consensus is that 
PDE5 is abundantly expressed in the lungs and not in the penis [4, 10, 37, 38] and moreover, 
there might be a difference in expression level of PDE5 in the penis of humans and mice. As 
it was not our interest of research we didn't as well pursue this issue any further.    
2.5. Blocking study in NMRI mice 
Owing to the appealing property (a high lung retention) of [11C]-7 and [11C]-37, a pre-
blocking study was performed in order to confirm the specificity of [11C]-7 and [11C]-37 
binding to PDE5 in the lung. Pre-blocking was conducted in mice with tadalafil, a structurally 
unrelated PDE5 inhibitor [39].  The results (table 5 and supporting information) show that 
lung uptake of [11C]-7 was significantly reduced (> 86 % reduction in % ID and SUV) in 
tadalafil pre-treated groups (p < 0.001) whereas other organs including the heart showed no 
significant difference in retention compared to the control group. This indicates that binding 
of [11C]-7 in the lungs is PDE5 specific.  
Pre-treatment of mice with tadalafil in [11C]-37 injected group resulted in an almost 46 % 
reduction of retention (both % ID and SUV) of [11C]-37 in the lungs from 6.6±1.5 to 3.6±0.9 
SUV (table 5). Though the reduction was found to be statistically significant (p = 0.03), the 
residual activity in the lungs was much higher than for [11C]-7. The lower reduction observed 
after PDE5 blocking of this tracer might be attributed to higher in vivo affinity of [11C]-37  for 
PDE5 or off-target binding of the tracer. The former reasoning is supported by the higher 
lung/blood SUV ratio of [11C]-37 vs [11C]-7 (32 vs 11, table 4) but is in contrast to the 
experimentally determined IC50 value (3.2 nM vs 0.7 nM, respectively). The fact that the 
residual activity after pre-treatment remained high might be the contributing factor for the 
observed high retention in the lungs of mice despite the moderate in vitro PDE5 inhibitory 
activity (figure 6). Additional experiments will be required to determine the exact cause for 
the inability to fully block lung retention of [11C]-37. 
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Table 5. Comparison of pre-blocking effect on the uptake of [11C]-7 and [11C]-37 at 30 min 
post injection in control and tadalafil pre-treated (10 mg/kg, sc, 60 min prior to tracer 
injection) NMRI mice (n = 4, SD = standard deviation) 
aStandard uptake values (SUV±SD) 
[11C]-7 [11C]-37 
Organ Control Tadalafil treated Control Tadalafil treated 
Kidneys 1.3±0.1 1.7±0.3 7.4±1.3 6.2±0.9 
Liver 3.5±0.4 4.8±0.4 6.4±0.3 6.4±0.9 
Lungs 8.0±2.0 1.0±0.2 6.6±1.5 3.6±0.9 
Heart 0.7±0.1 0.7±0.1 1.1±0.2 1.3±0.1 
Intestines 3.5±0.6 4.6±0.3 2.0±0.2 2.2±0.3 
Blood 0.7±0.3 0.4±0.2 0.2±0.0 0.3±0.0 
Muscle 0.4±0.1 0.5±0.1 0.5±0.1 0.9±0.9 
Penis 0.7±0.1 0.7±0.17 0.3±0.0 0.6±0.6 
Data are expressed as mean±SD; aSUV calculated as (CPM in organ * Weight of mouse)*100% 
/(total CPM recovered * organ weight) 
3. Conclusion 
We have been able to successfully prepare and radiolabel different derivatives of PDE5 
inhibitors reported in literature. Although initial biological evaluation of ethoxyethyl 
pyrazolopyrimidin derivative [11C]-37 showed favorable properties, further investigation is 
required to confirm its specificity for PDE5. Initial biological evaluation of [11C]-14 and 
[11C]-20 revealed that these tracers have low affinity for PDE5 and do not possess the 
property required of a PET tracer for in vivo visualization of PDE5. Of all the radiotracers that 
have been evaluated in this study, the vardenafil derivatives [11C]-7 and [18F]-11 are the 
tracers with the most favorable properties for in vivo visualization of phosphodiesterase type 
5. The vardenafil derivatives were selected for further biological evaluation in clinically 
relevant animal models and the results are presented in Chapter III. 
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4. Experimental section 
4.1.Chemistry 
All final compounds (precursors and references) were characterized by LC-MS and 1H-NMR. 
A detailed description of the synthesis of all compounds with their 1H-NMR and HRMS data 
for precursors and references is provided in the supporting information 
4.2. In vitro affinity test 
Compounds 7, 8, 11, 14, 21, and 37 were dissolved in DMSO to a concentration of 5 mM, and 
33 to a concentration of 2 mM. All compounds were profiled on the PDE assay platform, 
comprising members of each of the 11 described PDE families.  
PDE1B1 and PDE11A4 were expressed in human embryonic kidney (HEK) cells from full-
length human recombinant clones. Human recombinant phosphodiesterases 2A, 4D3, 5A3, 
7A1, 9A1, 10A2 were expressed in Sf9 cells, using a recombinant baculovirus construct 
containing the full length sequence with a 6xHis sequence following the start Met to allow 
metal affinity purification of the recombinant protein. Cells were harvested and the 
phosphodiesterase protein was purified by metal chelate chromatography on Ni-sepharose 
6FF (GE Health Care).  PDE6AB, PDE3B and PDE8A were purchased as partially purified 
Sf9 cell lysates (Scottish Biomedical, UK). All enzymes were diluted in 50 mM Tris pH 7.8, 
1.7 mM EGTA, 8.3 mM MgCl2, except for PDE9A that was diluted in 50 mM Tris pH 7.8, 5 
mM MnCl2 and PDE1B was diluted in 50 mM Tris pH 7.8, 1.7 mM EGTA, 8.3 mM MgCl2 
complemented with 624 U/mL calmodulin and 800 µM CaCl2. The affinity of the compounds 
for the PDEs is measured by a scintillation proximity assay (SPA).  
PDE Yttrium Silicate SPA beads allow PDE activity to be measured by direct binding of the 
primary phosphate groups of non-cyclic AMP or GMP to the beads via a complex iron 
chelation mechanism. The amount of bound tritiated product ([3H]-AMP or [3H]-GMP) is 
measured by liquid scintillation counting in a TopCountTM (Perkin Elmer)).  
The compounds were dissolved and diluted in DMSO in polystyrene plates to a concentration 
of 100-fold of the final concentration in the assay. Human recombinant PDE5A3 enzyme 
solution (10 µl) was added to 20 µl of incubation buffer (50 mM Tris pH 7.8, 8.3 mM MgCl2, 
1.7 mM EGTA), 10 µl substrate solution consisting of a mixture of non-tritiated and tritiated 
substrate (1 µM cGMP, 0.01 µCi 3H-cGMP), and 0.4 µl compound in DMSO in a 384-well 
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plate, and incubated for 30 min at room temperature. After incubation, the reaction was 
stopped with 20 µl of stop solution, consisting of PDE SPA beads (17.8 mg beads/mL in 200 
mM zinc chloride). To measure the blank value, the enzyme was omitted from the reaction 
mixture. After sedimentation of the beads for 30 min, the radioactivity was measured in a 
PerkinElmer TopCount scintillation counter and results were expressed as counts per minute 
(cpm). The same assay principle was applied for the measurement of the inhibition of other 
members of the PDE family, with appropriate modifications of enzyme concentration, 
incubation buffer, substrate solution, incubation time and stop solution. Each experiment was 
performed in duplicates. 
Data were calculated as the percentage of inhibition of total activity measured in the absence 
of test compound (% control). A best-fit curve is fitted by a minimum sum of squares method 
to the plot of % control versus compound concentration, from which an IC50 value (inhibitory 
concentration causing 50 % inhibition of hydrolysis) is obtained. 
4.3 Radiosynthesis 
Carbon-11 was produced in a Cyclone 18/9 cyclotron (IBA, Louvain-la-Neuve, Belgium) via 
an [14N(p,α)11C] nuclear reaction. A mixture of N2 (95 %) with H2 (5 %) was irradiated with 
18-MeV protons for 30 min to get [11C]CH4 ([11C]CH4). [11C]CH4 was transferred to a home-
built synthesis module to convert it to [11C]CH3I which was then converted to the more 
reactive [11C]methyl triflate ([11C]CH3OTf) by passing through a silver triflate column (150 x 
3 mm) heated at 180 oC.  
[11C]CH3OTf was streamed with helium through a solution of 250 - 500 μg precursors in 
DMF at room temperature. The reaction mixture was diluted with buffer and then injected 
onto HPLC (XBridge™ C18, 5μm, 4.6 x 150 mm; Waters) for purification. Radiotracers were 
eluted with a mixture of buffer and ethanol (EtOH) at a flow rate of 1 mL/min. The peak 
corresponding roughly to retention time of reference compound was collected and analyzed 
by RP-HPLC for purity and identity for biological evaluation. For all evaluation of tracers in 
animals, the ethanol concentration was diluted with normal saline to a maximum of 10 % and 
then sterile filtered through a 0.22 μm membrane filter (Millipore Millex GV 13 mm). 
Chemical and radiochemical purity of tracers were assayed with HPLC (XTerra™ C18, 5 μm, 
4.6 mm x 100 mm) eluted with buffer and acetonitrile (ACN) at a flow rate of 1 mL/min, UV 
detection at 254 nm. 
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[18F]Fluoride (18F-) was produced in a Cyclone 18/9 cyclotron (IBA) via an [18O(p,n)18F] 
nuclear reaction by bombarding oxygen-18 enriched water (H218O) with 18 MeV protons. 
[18F]F- was then passed through a preconditioned, (by successive washing with 10 mL of 0.5 
M K2CO3 solution and 10 mL of de-ionized water), anion exchange cartridge (SepPak Light 
Accell plus QMA, Waters) to get rid of the bulk of the H218O. The [18F]F- was then eluted 
with 24 mM K2CO3/98 mM Kryptofix 2.2.2® (4,7,13,16,21,24-Hexaoxa-1,10-
diazabicyclo[8.8.8]-hexacosane) in 750 µl of a mixture of acetonitrile:water (95:5 v/v) into a 
reaction vial. Any remaining water was removed by azeotropic distillation with acetonitrile. 
[18F]F- was converted to 1-bromo-2-[18F]fluoroethane by reaction with 2-bromoethyltriflate at 
120 oC. The reaction product was passed through a silver triflate column heated at 225 oC to 
convert it to the more reactive 2-[18F]fluoroethyl trifluoromethanesulfonate.     
With a stream of helium the 2-[18F]fluoroethyl trifluoromethanesulfonate  was bubbled 
through a solution of 250 - 500 μg precursor in 250 µl DMF at room temperature. The 
purification, formulation, sterile filtration, and quality control were done in similar conditions 
as above for carbon-11 labeled tracers. 
4.4. Biological evaluation 
4.4.1. Biodistribution Studies 
For biodistribution study adult NMRI mice, weighing 25 to 40 g were used. Animals were 
housed in individually ventilated cages in a thermo regulated (22°C), humidity-controlled 
facility under a 12 h/12 h light/dark cycle, with free access to food and water. All animal 
experiments were conducted according to the Belgian code of practice for the care and use of 
animals, after approval from the Animal Ethics Committee, KU Leuven (Ethische Commissie 
Dier Proeven, KU Leuven, License number: LA1210237). 
Biodistribution studies of carbon-11 or fluorine-18 labeled tracers were performed in healthy 
NMRI mice at 2, 10, 30, and 60 min post injection (n = 4/time point). Mice were 
anesthetized with 2.5% isoflurane in oxygen at a flow rate of 1 L/min and 5 to 7 MBq of the 
tracer under study was injected via tail vein and sacrificed by decapitation at the specified 
time points. Blood and major organs were collected in tarred tubes and weighed. The 
radioactivity in blood and organs was counted using an automated γ-counter and expressed as 
a percentage of injected dose (% ID) and standardized uptake value (SUV). For the 
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calculation of total radioactivity in blood, blood mass was assumed to be 7 % of the body 
weight. 
4.4.2. Blocking study 
In order to assess the affinity and specificity of [11C]-7 and [11C]-37 for PDE5, a blocking 
study was performed. In brief, NMRI mice were subcutaneously injected with tadalafil (a 
structurally unrelated PDE5 inhibitor, TCR, Canada) 10 mg/kg, subcutaneous (sc), 60 minutes 
prior to tracer administration. Tadalafil solution for injection was prepared in such a way that 
the final concentration was 1 mg/mL in 10 % dimethylsulfoxide in 40 % (2-hydroxypropyl)-
β-cyclodextrin solution and sterile filtered via a 0.22 μm membrane filter (Millipore, Ireland).  
Biodistribution was then performed as mentioned above and results were expressed as % ID 
and SUV.  
All animal experiments were conducted according to the Belgian code of practice for the care 
and use of animals, after approval from the Animal Ethics Committee, KU Leuven (Ethische 
Commissie Dier Proeven, KU Leuven, License number: LA1210237). 
4.4.3. Statistics 
All calculated results are expressed as mean ± standard deviation (SD). For comparison the 
Student’s t-test was used and p < 0.05 was considered statistically significant.   
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Chapter II - Supporting information 
Chemistry 
All final compounds (precursors and references) were characterized by, LC-MS and 1H-NMR. 
Chemical and radiochemical purity was determined by RP-HPLC and representative 
chromatograms for compounds 5 and 7 are given in figures 1 and 2. 
1H-NMR spectra were recorded on a 400 MHz spectrometer (Bruker AVANCE) and either, 
deuterated chloroform (CDCl3) or deuterated methanol (MeOD) or deuterated dimethyl 
sufoxide (DMSO-d6) was used as a solvent as indicated. Chemical shifts are reported in parts 
per million relative to tetramethylsilane (δ = 0). Coupling constants are reported in hertz (Hz). 
Splitting patterns are defined as follow: s (singlet), br s (broad singlet), d (doublet), q 
(quartet), dd (double doublet), t (triplet), dt (double triplet), or m (multiplet). 
High-performance liquid chromatography (HPLC) analysis was performed on a LaChrom 
Elite HPLC system (Hitachi) connected to an ultraviolet spectrometer set at 254 nm. For the 
analysis of radiolabeled compounds, the HPLC eluate (after passage through the UV detector) 
was led over a 7.62-cm (3-in.) NaI(Tl) scintillation detector connected to a single-channel 
analyzer (GABI box; Raytest, Straubenhard, Germany). Quantification of radioactivity 
measurements in biodistribution studies was performed using an automated -counter 
equipped with a 7.62-cm (3-in.) NaI(Tl) well crystal coupled to a multichannel analyzer (1480 
Wizard; Wallac, Turku, Finland). The results were corrected for background radiation and 
decay during counting. 
All solvents and chemicals were obtained from commercial sources (Acros Organics, Aldrich 
or Fluka unless specified otherwise) and used as such without further purification. Purity of 
all final compounds (precursors and references) was ≥ 95 % and was determined by HPLC.  
Vardenafil derivatives 
The synthesis of the precursors for radiolabeling and reference compounds were carried out 
based on procedures described in literature [23-26].  
4-Ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)benzen-1-
sulfonyl chloride (2)  
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2-(2-Ethoxyphenyl)-5-methyl-7-propylimidazo[1,5-f][1,2,4]triazin-4(3H)-one (1, 1.0 g, 3.20 
mmol, Toronto Research Chemicals Inc,) was added slowly to a solution of chlorosulfonic 
acid (2.12 mL, 10 eq) at 0 oC. The reaction mixture was allowed to warm to room temperature 
(RT), stirred overnight and then poured into ice water (50 mL). After 5 min a white 
precipitate was formed and stirring was continued for 1 h at RT. The precipitate was filtered 
off, washed with water and dried under vacuum (0.64 g, first fraction). Further, the filtrate 
was extracted with CH2Cl2 (3 x 10 mL) and dried over MgSO4, evaporation of the solvent 
gave an additional amount of 2 as colorless foam (0.26 g, second fraction). Yield (combined): 
(900 mg, 68%) 
1H NMR (MeOD, 400 MHz): δ 1.07 (t, 3H, J 7.4, CH3), 1.46 (t, 3H, J 7.0, CH3), 1.87-1.98 
(m, 2H, CH2), 2.76 (s, 3H, CH3), 3.22 (t, 2H, J 7.5, CH2), 3.31 (q, 2H, J 7.0, CH2), 7.54 (s, 
1H, Ar), 8.30-8.32 (m, 2H, Ar). MS: (M+H)+ m/z = 411.1. 
4-Ethoxy-N-methyl-3-{5-methyl-4-oxo-7-propyl-3H,4H-imidazo[4,3-f][1,2,4]triazin-2-yl}-N-
(Boc-piperidin-4-yl)benzene-1-sulfonamide (3) 
To a solution of 2 (160 mg, 0.39 mmol) in CH2Cl2 (5 mL) at 0 oC were added 1-Boc-4-
(methylamino)piperidine (APOLLO Scientific) (0.25 mL, 1.17 mmol, 3 eq) and a catalytic 
amount of 4-DMAP and the reaction mixture was stirred for 5 h at room temperature. The 
mixture was diluted with CH2Cl2, washed with a saturated solution of ammonium chloride 
and dried over MgSO4. The solvent was evaporated under reduced pressure and the crude 
residue was purified on a silica gel column with CH2Cl2 as eluent to obtain 3 as colorless oil 
(170 mg, 74 %). 
1H NMR (DMSO-d6, 400 MHz): δ 7.94 (s, 2H), 7.35 (d, 1H), 4.22 (q, 2H), 3.90 (m, 1H), 3.35 
(m, 4H), 2.83 (t, 2H), 2.66 (s, 3H), 2.51 (s, 3H), 1.75 (hex, 2H), 1.44-1.48 (m, 4H), 1.37 (s, 
9H), 1.34 (t, 3H), 0.93 (t, 3H). MS: (M+H)+  m/z = 589.1 
2-[2-Ethoxy-5-(N-Boc-piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-4a,7-dihydro-3H-
imidazo[5,1-f][1,2,4]triazin-2-yl)-4-one (4)  
A solution of 2 (640 mg, 1.56 mmol) in dichloromethane (10 mL) was added drop-wise to a 
solution of N-boc-piperazine (872 mg, 4.68 mmol, 3 eq) in dichloromethane (2 mL) at RT 
followed by the addition of a catalytic amount of 4-DMAP. After stirring overnight, a 
saturated solution of NH4Cl (20 mL) was added, the organic phase was separated, dried over 
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MgSO4 and concentrated under reduced pressure. The resulting white residue was 
recrystallised from diethyl ether to yield 4 (594 mg, 68 %).  
1H NMR (DMSO-d6, 400 MHz): δ 7.88 (s, 2H), 7.4 (d, 1H), 4.3 (q, 2H), 3.42 (m, 2H), 2.80-
2.95 (m, 8H), 2.49 (s, 3H), 1.74 (m, 2H), 1.36 (s, 9H), 1.32-1.37 (t, 3H), 0.93 (t, 3H). MS: 
(M+H)+  m/z = 561.0  
2-[2-Ethoxy-5-(piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-4a,7-dihydro-3H-
imidazo[5,1-f][1,2,4]triazin-2-yl)-4-one (5)  
A solution of 4 (482 mg, 0.86 mmol) in a mixture of TFA (1 mL) and CH2Cl2 (2 mL) at 0 oC 
was stirred for 2 h at RT. The solvents were removed at reduced pressure and the residue was 
co-evaporated twice with heptane (2 x 5 mL) to obtained colourless oil, which was then 
recrystallized from methanol/diethylether mixture to yield 5 as a TFA salt. Yield (395 mg, 
80% yield as a TFA salt). 
1H NMR (MeOD, 400 MHz): 0.93 (t, 3H, J 7.36, CH3), 1.33 (t, 3H, J 6.9, CH3), 1.73 (q, 2H, J 
7.44, CH2), 2.48 (s, 3H, CH3), 2.76-2.86 (m, 8H, CH2), 4.21 (q, 2H, J 6.84, CH2), 7.39 (d, 1H, 
J 8.6, Ar), 7.83-7.88 (m, 2H, Ar). HRMS-ESI: calcd for C21H29N6O4S+ 461.1971, found 
461.1978. 
4-Ethoxy-N-methyl-3-{5-methyl-4-oxo-7-propyl-3H,4H-imidazo[4,3-f][1,2,4]triazin-2-yl}-N-
piperidin-4-yl)benzene-1-sulfonamide (6)  
To a solution of 3 (100 mg, 0.17 mmol) in CH2Cl2 at 0 oC was added TFA (1 mL) in CH2Cl2 
(4 mL). After overnight stirring at RT, the reaction mixture was evaporated under reduced 
pressure and the residue was co-evaporated three times with heptane (3 x 10 mL). The 
obtained oil was dried overnight under vacuum at 60 oC, triturated with diethyl ether and 
stirred overnight at RT. The solvent was carefully removed under reduced pressure and the 
oily residue dried under vacuum at 60 oC for 72 h yielding a white solid (50 mg, 0.1 mmol, 25 
%). 
1H NMR (DMSO-d6, 400 MHz): δ 0.72 (t, 3H, J 7.4, CH3), 1.12 (t, 3H, J 6.9, CH3), 1.23-1.29 
(m, 2H, CH2), 1.51-1.63 (m, 4H, 2CH2), 2.32 (s, 3H, CH3), 2.47 (s, 3H, CH3), 2.66-2.83 (m, 
4H, 2CH2), 3.03-3.09 (m, 2H, CH2), 3.84-3.91 (m, 1H, CH), 4.00 (q, 2H, J 6.8, CH2), 7.14 (d, 
1H, J 8.6, Ar), 7.74-7.78 (m, 2H, Ar), 11.75 (br s, 1H, NH). HRMS-ESI: calcd for 
C24H35N6O4S+ 503.2440, found 503.2442 
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2-[2-Ethoxy-5-(N-methylpiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-4a,7-dihydro-3H-
imidazo[5,1-f][1,2,4]triazin-2-yl)-4-one (7)  
The procedure was the same as for preparing 4, except N-methylpiperazine (53.3 mg, 0.13 
mmol) was used instead of N-Boc-piperazine. The title compound was obtained as a white 
powder (46 mg, 0.1 mmol, 74 %). 
1H NMR (CDCl3, 400 MHz): δ 8.44 (d, 1H), 7.88 (dd, 1H), 7.17 (d, 1H), 4.33 (q, 2H), 3.08 
(m, 4H), 3.00 (t, 2H), 2.63 (s, 3H), 2.51 (m, 4H), 2.29 (s, 3H), 1.88 (hex, 2H), 1.59 (t, 3H), 
1.04 (t, 3H). HRMS-ESI: calcd for C22H31N6O4S+ 475.2127, found 475.2132. 
4-Ethoxy-N-methyl-3-{5-methyl-4-oxo-7-propyl-3H,4H-imidazo[4,3-f][1,2,4]triazin-2-yl}-N-
(1-methylpiperidin-4-yl)benzene-1-sulfonamide (8)  
To a solution of 2 (160 mg, 0.4 mmol) in 5 mL CH2Cl2 at 0 oC, a tip of spatula of 4-DMAP 
and N,1-dimethylpiperidin-4-amine (150 mg, 1.17 mmol, APPLO Scientific) were added. The 
reaction mixture was stirred overnight at room temperature. The mixture was diluted with 
CH2Cl2, washed with saturated ammonium chloride solution and dried over MgSO4. The 
residue was passed through a silica gel column with 2 % to 7.5 % MeOH/CH2Cl2 as the eluent 
to obtain the title compound as colorless oil which turned to solid upon storage (50 mg, 0.1 
mmol, 25 %). 
1H NMR (400 MHz, CDCl3): δ 1.02 (t, 3H, J 7.4, CH3), 1.58 (t, 2H, J 7.0, CH3), 1.70-2.05 
(m, 8H, 2CH2), 2.24 (s, 3H, CH3), 2.62 (s, 3H, CH3), 2.78 (s, 3H, CH3), 2.82-2.87 (m, 2H, 
CH2), 2.98 (t, 2H, J 7.4, CH2), 3.78-3.86 (m, 1H, CH), 4.32 (q, 2H, J 7.0, CH2), 7.11 (d, 1H, J 
8.8, Ar), 7.92 (d, 1H, J 6.4, Ar), 8.49 (s, 1H, Ar). 
HRMS-ESI: calcd for C24H35N6O4S+ 503.2440, found 503.2442. 
4-(2-Fluoroethyl)-piperazine bis TFA salt (10) 
A mixture of 1-boc-piperazine (1.02 g, 5.47 mmol), 1-bromo-2-fluorethane (4.17 g, 32 mmol) 
and DIEA (41.36 mg, 55.41 mL, 32 mmol) in CH3CN (10 mL) was heated at 50 oC overnight 
and then refluxed for 6.5 h. The reaction mixture was cooled to RT and the solvent removed 
at reduced pressure. The residue was treated with 1 M NaOH (6.24 mL), extracted with 
EtOAc (2 x 20 mL) and dried over MgSO4. Purification was done by silicagel 
chromatography using a gradient mixture of 0 to 10 % MeOH in CH2Cl2 to afford colorless 
oil (9) (1.11 g, 87.4 %). An aliquot of 9 (1 g, 4.31 mmol) was dissolved in CH2Cl2 (10 mL) 
was treated drop wise at 0 oC with TFA (5 mL) and stirred at RT for 2 h. The solvent was 
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removed with under reduced pressure and the residue co-evaporated twice with heptane (2 x 
10 mL). To the resultant oil was carefully added diethyl ether with vigorous stirring. A white 
precipitate was obtained which was filtered under a stream of nitrogen and dried under 
vacuum (742 mg, 70 % as bis TFA salt). For the next reaction TFA salt of 1-(2-
fluoroethyl)piperazine was partitioned between CH2Cl2 and saturated Na2CO3 solution. The 
organic layer was separated and the aqueous layer was washed with CH2Cl2. The combined 
organic layers were dried over MgSO4, filtered and the filtrate was concentrated under 
reduced pressure. A white precipitate was obtained which was filtered off under a steady 
stream of N2 and further dried under vacuum 
1H NMR (DMSO-d6, 400 MHz): δ 4.73 (dt, 2H, J 4.6 & 47.4, CHaHb), 3.23-3.35 (m, 10H, 
CH2). MS: (M+H)+  m/z = 133.0 
2-[2-Ethoxy-5-(N-2-fluoroethylpiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-4a,7-
dihydro-3H-imidazo[5,1-f][1,2,4]triazin-2-yl)-4-one (11) 
The procedure was the same as for preparing 4 except 1-(2-fluoroethyl)piperazine bis TFA 
(10, 578 mg, 2.35 mmol) and equivalent amount of DEIA was used instead of N-boc-
piperazine to afford the title compound as white crystals (310 mg, 0.6 mmol, 43 %). 
1H NMR (CDCl3, 400 MHz): δ 1.01 (t, 3H, J 7.3), 1.58 (t, 3H, J 6.9), 1.81-1.90 (m, 2H), 2.62 
(s, 3H), 2.98 (t, 2H, J 8.1), 4.31 (q, 2H, J 6.9), 4.42 (t, 2H, J 4.7), 4.54 (t, 2H, J 4.7), 7.20 (d, 
1H, J 8.0), 7.85 (d, 1H, J 8.0), 8.51 (s, 1H), 9.69 (br s, 1H). HRMS-ESI: calcd for 
C24H32N6O4S+ 507.2190, found 507.2190. 
Sildenafil precursor 
The sildenafil precursor for radiolabeling was prepared following the procedure described in 
literature [26,26].  
2-[2-Ethoxy-5-(piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-4a,7-dihydro-3H-
imidazo[5,1-f][1,2,4]triazin-2-yl)-4-one (13) 
of 4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-
yl)benzene-1-sulfonyl chloride (12, A solution of (181 mg, 0.44 mmol, Toronto Research 
Chemicals Inc) in THF (15 mL) was treated with piperazine (189.7 mg. 2.2 mmol) in THF 
(4.4 mL). The mixture was stirred at room temperature for 2.5 h, solvent was removed at 
reduced pressure, and the residue was washed with cold water (18 mL). The resulting 
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precipitates were filtered under suction, washed with ice-cold water, drained to dryness (68. 3 
mg, 0.15 mmol, 34 %).  
1H NMR (CDCl3, 400 MHz): δ 1.02 (t, 3H, J 7.3), 1.65 (t, 3H, J 7.0), 1.82-1.90 (m, 2H), 2.91-
2.96 (m, 6H), 3.03-3.06 (m, 4H), 4.28 (s, 3H), 4.38 (q, 2H), 7.15 (d, 1H, J 8.8r), 7.83 (dd, 1H, 
J 2.4 & 8.8r), 8.83 (d, 1H, J 2.4), 10.80 (br s, 1H). HRMS-ESI: calcd for C21H29N6O4S+ 
461.1971, found 461.1962 
4-Benzylaminoquinoline derivatives 
The precursor and reference compounds were prepared following procedures described by Bi 
et al [28,29] and Neise et al [30]. 
2-[(4-Cyano-2-ethylphenylamino)methylene]malonic acid diethyl ester (16)  
To a solution of 4-amino-3-ethylbenzonitrile (15, 14.62 g, 100 mmol, Amfinecom Inc, 
Illinois, USA) in toluene (120 mL, Fisher Scientific, UK) was added diethyl 2-
(ethoxymethylene)malonate (25 mL, 110 mmol, 1.1 eq) and the reaction mixture  was 
refluxed for 6 h.  470 mL of heptane was poured into the reaction mixture, upon which a 
white precipitate was formed. This was filtered off under reduced pressure, and washed 
several times with heptane and dried under vacuum overnight (22.4 g, 70.8 mmol, 70.8 %) 
1H NMR (CDCl3, 400 MHz): δ 1.26-1.38 (m, 9H, CH3), 2.70 (q, 2H, J 7.5, CH2), 4.24 (q, 2H, 
J 7.0, CH2), 4.30 (q, 2H, J 7.0, CH2), 7.26 (t, 1H, J 8.4, Ar), 7.48-7.56 (m, 2H, Ar), 8.49 (d, 
1H, J 13.0, Ar), 11.32 (br d, 1H, J 12.7, NH). MS: (M+H)+  m/z = 317 
6-Cyano-8-ethyl-4-hydroxyquinoline-3-carboxylic acid ethyl ester (17) 
Diphenyl ether (100 mL) was kept at vigorous reflux to which 16 (12 g, 37.9 mmol) was 
added in portions, over a course of one hour. The solution was further refluxed for an hour, 
cooled to RT and poured into heptane (200 mL). The resulting precipitate was filtered off and 
washed well with heptane to yield the title compound as a light brown solid (9.8 g, 36.3 
mmol, 96 %). 
MS: (M+H)+  m/z = 271.0 
4-Chloro-6-cyano-8-ethylquinoline-3-carboxylic acid ethyl ester (18)  
To 17 (9.5 g; 35.2 mmol) was carefully added phosphorous (V) oxychloride (POCl3, 45 mL) 
and the resulting mixture was refluxed for 48 h. The excess POCl3 was evaporated under 
reduced pressure and the residue was co-evaporated once with CH2Cl2 and twice with toluene. 
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The resulting brown solid was dissolved in CH2Cl2 and treated with NEt3 until aqueous 
washings of aliquots had pH > 10. The solution was then filtered through a short path of silica 
gel with 5 % ethylacetate/heptanes to give the title compound as an off-white solid (6.3 g, 
21.8 mmol, 62.1 %). 
MS: (M+H)+  m/z = 289.6 
4-(3-Chloro-4-methoxy-benzylamino)-6-cyano-8-ethyl-quinoline-3-carboxylic acid ethyl ester 
(19)  
To a solution of 18 (2.4 g, 8.3 mmol) in n-propanol (40 mL) was added 3-chloro-4-
methoxybenzyl amine hydrochloride (2 g, 11.7 mmol, 1.5 eq., ChemiCollect) and DIEA (8 
mL, 46 mmol, ≈ 6 eq.). The mixture was refluxed for 2 h under vigorous stirring and thenwas 
cooled and poured into water (100 mL). The resulting precipitate was filtered, washed with 
water (100 mL) and ethanol (2 x 10 mL) respectively. The solid was then co-evaporated with 
ethanol to get the title compound as a white solid (3 g, 7.1 mmol, 86.7 %). 
1H NMR (CDCl3, 400 MHz): δ 1.29-1.40 (m, 6H, 2CH3), 3.18 (q, 2H, J 7.4, CH2), 3.90 (s, 
3H, CH3), 4.34 (q, 2H, J 7.1, CH2), 4.83 (d, 2H, J 5.3, CH2), 6.94 (d, 1H, J 8.4, Ar), 7.22-7.25 
(m, 1H, Ar), 7.38 (s, 1H, Ar), 7.63 (s, 1H, Ar), 8.35 (s, 1H, Ar), 9.21 (s, 1H, Ar), 9.57 (br s, 
1H, NH). MS: (M+H)+  m/z = 424.7 
4-(3-Chloro-4-methoxybenzylamino)-6-cyano-8-ethylquinoline-3-carboxylic acid (20, 
precursor).  
A mixture of 19 (1 g, 2.4 mmol) and 12 mL each of THF, MeOH and 1M NaOH was stirred 
well. The solids gradually dissolved. After complete dissolution (3 h or more) THF and most 
of the MeOH was evaporated under reduced pressure to leave an aqueous slurry of a white 
solid. The slurry was acidified to pH 1.5 with HCl, stirred well for 1 h, and then filtered and 
washed well with water. Co-evaporation twice to dryness with absolute ethanol afforded the 
title compound as a white chalky solid (720 mg, 1.8 mmol, 77 % yield). 
1H NMR (CDCl3, 400 MHz): δ 1.20 (t, 3H, CH3), 3.06 (q, 2H, J 7.4, CH2), 3.81 (s, 3H, CH3), 
4.90 (s, 2H, CH2), 7.11 (d, 1H, J 8.4, Ar), 7.30 (d, 1H, J 8.3, Ar), 7.45 (s, 1H, Ar), 7.83 (s, 
1H, Ar), 8.61 (s, 1H, Ar), 8.93 (s, 1H, Ar). HRMS-ESI: calcd for C21H19 ClN3O3+ 396.1115, 
found 396.1114; HRMS-ESI: calcd for C21H17 ClN3O3- 394.0958, found 394.0946 
4-(3-Chloro-4-methoxy-benzylamino)-6-cyano-8-ethylquinoline-3-carboxylic acid methyl 
ester (21) [30] 
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A solution of  20 (100 mg, 0.24 mmol) and 4-DMAP (26 mg, 0.208 mmol) in a mixture of 1 
mL CH2Cl2 and 1 mL MeOH was stirred and cooled in an ice bath to 0 oC while 
dicyclohexylcarbodiimide (DCC, 60 mg, 0.29 mmol) was added over a period of 5 min. After 
additional 5 min of stirring at 0 oC the ice bath was removed and the reaction mixture was 
stirred overnight at RT. Precipitate of dicyclohexylurea was removed by filtration and the 
filtrate was washed with two 10 mL portion of 0.5 M HCl and two 10 mL portions of 
saturated NaHCO3. Additional precipitate of dicyclohexyl was removed by filtration of both 
layers. The organic solution was dried over MgSO4 and concentrated under reduced pressure. 
The residue was further purified by passing through silica gel with 5% ethylacetate/heptanes 
to afford 21 (65 mg, 0.16 mmol, 67 %).  
1H NMR (CDCl3, 400 MHz): δ 1.32 (t, 3H, J 7.5, CH3), 3.18 (q, 2H, J 7.4, CH2), 3.90 (s, 6H, 
2CH3), 4.83 (d, 2H, J 5.4, CH2), 6.94 (d, 1H, J 8.4, Ar), 7.23 (d, 1H, J 7.0, Ar), 7.37 (s, 1H, 
Ar), 7.64 (s, 1H, Ar), 8.35 (s, 1H, Ar), 9.18 (s, 1H, Ar), 9.56 (br s, 1H, NH). HRMS-ESI: 
calcd for C22H21ClN3O3+ 410.1271, found 410.1273 
Ethoxyethlypyrazolopyrimidine derivatives 
The various ehtoxyethylprazolopyrimidin derivatives including the two precursors for 
labeling and the references were prepared following procedures described in literature [31-
36]. 
3-Ethyl-1H-pyrazole-5-carboxylic acid ethyl ester (23)  
To a solution of 2-butanone (3.6 g, 50 mmol) in ethanol (250 mL) was added diethyl oxalate 
(8.8 g, 60.2 mmol) and t-BuOK (1 M solution in THF, 55 mL, 55 mmol, 1.1 eq.). The 
reaction mixture was heated at 75 °C for 0.5 h and cooled to 4 °C in an ice bath. A solution of 
hydrazine hydrochloride (6.9 g, 100.7 mmol,) in water (200 mL) was added drop wise and the 
resulting mixture was heated at 75 °C for 1 h. Solvent was removed under reduced pressure 
and residue partitioned between water and CH2Cl2. The organic layer was separated and dried 
over MgSO4, filtered and concentrated to provide the title compound as a white solid (5.6 g, 
44.1 mmol, 66%). 
1H NMR (400 MHz, CDCl3): δ 1.28 (t, 3H, J 7.6), 1.39 (t, 3H, J 7.1), 2.72(q, 2H, J 7.6), 4.38 
(q, 2H, J 7.1), 6.63 (s, 1H). MS: (M+H)+ m/z= 169.0 
3-Ethyl-1H-pyrazole-5-carboxylic acid (24)  
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To a solution of 23 (4.9 g, 38.6 mmol) in THF (270 mL) and methanol (60 mL) was added 1 
N LiOH (60 mL, 60 mmol) and the reaction mixture was refluxed for 3 h. The solvent was 
evaporated to yield a white solid that was taken up in water (60 mL) and washed with toluene 
(3 x 30 mL). The pH of the water layer was adjusted to 1 with 1 M HCl and extracted with 
EtOAc (3 x 30 mL). The organic layer was dried over MgSO4, filtered and concentrated. To 
the residue was added diethyl ether (100 mL) and this suspension was stirred for 1 hour. The 
white precipitate was filtered off and dried to provide the title compound (2.8 g, 25 mmol, 
64.8 %). 
1H NMR (400 MHz, DMSO-d6): δ 1.15 (t, 3H, J 7.6), 2.57 (q, 2H, J 7.6), 6.48 (s, 1H).  
MS: (M+H)+ m/z= 141.1. 
3-Ethyl-4-nitro-1H-pyrazole-5-carboxylic acid (25)  
A nitrating agent was prepared as follows: fuming sulphuric acid (4.6 mL) was added drop 
wise to stirred ice-cooled fuming nitric acid (4.16 mL). The ice bath was removed and the 
mixture was heated to 50 °C. To this mixture, 24 (3.9 g, 34.8 mmol) was added portion wise 
over a period 30 min, maintaining the reaction temperature below 60 °C. The resulting 
solution was heated overnight at 60 °C, cooled and poured into ice, providing a brown solid. 
This suspension was stirred at 0 °C for 1 h, filtered and dried in a vacuum oven at 50 °C. 
Yield 2.66 g (14.4 mmol, 41.4 %). 
1H NMR (400 MHz, DMSO-d6): δ 1.22 (t, J 9.0, 3H), 2.90 (q, J 7.5, 2H). 
3-Ethyl-4-nitro-1H-5-carboxamide (26)  
To a solution of 25 (8.3 g, 44.8 mmol) in (was added) thionyl chloride (40 mL) under N2 was 
(The reaction mixture was) refluxed for 3 h. Excess thionyl chloride was removed under 
reduced pressure vacuum. To remove residual traces of thionyl chloride, THF (2 x 20 mL) 
was added to the residue and evaporated at a reduced pressure. The acid chloride was 
suspended in THF (25 mL) and the mixture was cooled in an ice-bath. During 1 h gaseous 
ammonia was bubbled through the ice-cooled suspension. Water (25 mL) was added and the 
resulting mixture was evaporated under reduced pressure yielding a white solid. To this solid, 
water was added and after stirring for 1 h, the precipitate was filtered off and dried in vacuum 
oven. Yield 6.7 g (36.4 mmol, 81.3 %). 
1H NMR (400 MHz, DMSO-d6): δ 1.21 (t, 3H, J 7.6), 2.91 (q, 2H, J 7.6), 7.70 (s, 1H), 7.97 
(s, 1H). MS: (M+Na+) m/z= 206.3. 
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1-(2-Ethoxyethyl)-3-ethyl-4-nitro-1H-5-carboxamide (27)  
To a solution of 26 (6.7 g, 34.6 mmol) in THF (100 mL) was added triphenylphosphine (11.5 
g, 43.9 mmol, Janssen Pharmaceutica) and the reaction mixture was cooled to °C. 2-
Ethoxyethanol (4.27 mL, 44mmol, Alfa Aesar Chemicals) was added drop wise and then a 
solution of di-tert-butyl azodicarboxylate (10 g, 43.4 mmol) in THF (50 mL) was added over 
a period of 2.5 h. After an additional stirring for 1 h at 0 °C and 1 h at room temperature, the 
reaction mixture was again cooled to 0 °C, treated with 6 M HCl (18 mL), slowly warmed up 
to 40 °C and stirred for 1 h. Most of the solvent was removed under reduced pressure and the 
residue was partitioned between ethyl acetate and water. The water layer was washed once 
with ethyl acetate and the combined organic layers were washed with water and brine, dried 
over MgSO4, filtered and concentrated. The crude product was purified by chromatoghraphy 
on silica gel with 67 % EtOAc in heptane to give pure 27 (3.04 g, 34.4 %). 
MS: (M+Na+) m/z= 278.8. 
1-(2-Ethoxyethyl)-3-ethyl-4-amino-1H-5-carboxamide (28) 
To a solution of 27 (1.2 g, 4.5 mmol) in ethanol (22 mL), 10 % Pd(OH)2/C (200 mg) was 
added. Ammonium formate (1.4 g, 22 mmol) was added in 4 portions in a time span of 40 
min. The mixture was refluxed for 2 h, cooled, filtered and concentrated. The dark red liquid 
was purified by column chromatography on silica gel with EtOAc/hepatane mixture to 
provide 687 mg (3.1 mmol, 69 %) of the title compound. 
MS: (M+Na+) m/z= 248.7. 
1-(2-Ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione (29)  
A mixture of 28 (1.1 g, 4.3 mmol) and carbonyldiimidazole (1.1 g, 6.7 mmol, Janssen 
Pharmaceutica) in acetonitrile (5 mL) was heated at 75 °C during 1 h and stirred at room 
temperature for 2 h. The reaction mixture was cooled in an ice bath and water (50 mL) was 
added. The formed precipitate was filtered off, washed with water, dried in a vacuum oven at 
60 °C and used in the next step without further purification. Yield: 780 mg (3 mmol, 68 %). 
MS: (M-H+) m/z= 250.4. 
5-7-Dichloro-1-(2-Ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidine (30)  
To a mixture of 29 (1.0 g, 4.8 mmol) and phenylphosphonic dichloride (7.8 g, 40 mmol) was 
heated under N2 with stirring at 135 °C for 48 h. The reaction mixture was cooled, slowly 
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poured in an ice-water mixture and stirred for 3 h. The precipitate was filtered off, rinsed with 
water and suspended in a mixture of ethyl acetate (30 mL) and water (30 mL). The suspension 
was first acidified (pH 1-2) by addition of 1 M HCl and then neutralized by the addition of 10 
% NaHCO3 (pH 7). The organic layer was separated, washed with water and brine, dried over 
MgSO4, filtered and concentrated. The residue was purified by column chromatography on 
silica gel with 9% EtOAc in heptane to provide 797 mg (2.8 mmol, 65%) of the title 
compound as colourless oil. 
1H NMR (400 MHz, CDCl3): δ 1.05 (t, J 7.0, 3H), 1.40 (t, J 7.6, 3H), 3.02 (q, J 7.6, 2H), 3.42 
(q, J 7.2, 2H), 3.81 (t, J 5.9, 2H), 4.80 (t, J 5.9, 2H). MS: (M+H)+ m/z= 289.7. 
5-Chloro-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-
7amine (31).  
To an ice cold solution of 30 (757 mg, 2.6 mmol) in THF (7 mL) was added 2-amino-4-
picoline (563 mg, 5.22 mmol) and 1M lithium bis(trimethylsilyl)amide in THF (2 x 2.6 mL, 
5.2 mmol) at a temperature below 5 °C. The reaction mixture was stirred at 5 °C for 30 min, 
then the THF was evaporated under reduced pressure and the residue was neutralized by 
adding a solution of 10 % citric acid solution. The mixture was further stirred at 5 °C for 1 h, 
water was added and the resulting precipitate was filtered off, washed with water and dried in 
a vacuum oven at 50 °C yielding a yellow solid (816 mg, 2.3 mmol, 88.5 %). 
1H NMR (400 MHz, CDCl3): δ 1.16 (t, 3H, J 7.0, CH3), 1.37 (t, 3H, J 7.6, CH3), 2.4 (s, 3H, 
CH3), 2.96 (q, 2H, J 7.6, CH2), 3.62 (q, 2H, J 6.9, CH2), 3.90 (t, 2H, J 4.5, CH2 ), 4.70 (br s, 
2H, CH2), 6.83 (s, J 4.5, 1H, Ar), 8.17 (d, J 4.5, 1H, Ar), 8.31 (s, 1H, Ar). MS: (M+H)+ m/z= 
361.16. 
1-(2-Ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-5-(-piperazine-1-yl)-1H-pyrazolo[4,3-
d]pyrimidin-7-amine (32, precursor).  
A suspension of 31 (18 mg, 0.06 mmol) and piperazine (22 mg, 0.3 mmol) in 2-propanol (0.4 
mL) in a reaction vial was heated for 45 min on an oil bath at 175 °C. The reaction mixture 
was cooled, concentrated and purified by passing through silica gel with CH2Cl2/MeOH/(25 
%)NH4OH (190/9/1) as the eluant. The fractions with the pure product were combined and 
solvent removed under reduced pressure. The obtained oil was dissolved in diethyl ether (10 
mL) and treated with a solution of 4M HCl in methanol (0.5 mL). A yellow precipitate was 
formed, filtered off and dried in a vacuum oven. Yield: 12 mg (0.03 mmol, 48 %).  
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HRMS-ESI: calcd for C21H31N8O+ 411.2621, found 411.2624. 
1-(2-Ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-5-(4-methylpiperazine-1-yl)-1H-
pyrazolo[4,3-d]pyrimidin-7-amine (33, reference)  
The title compound was prepared following the procedure for the preparation of 32, but 
replacing piperazine by N-methylpiperazine. Final purification was done using HPLC. 
(XTerra Prep RP18, 5 µM, 7.8 x 150 mm; Gradient: Water/ACN: 95 → 5 % over 20 minutes) 
semi-prep, gradient elution H2O-ACN) 
Yield: 8 mg (0.02 mmol, 36 %).HRMS-ESI: calcd for C22H33N8O+ 425.2777, found 425.2770 
Tert-butyl(1-(7-(4-methylpyridin-2-ylamino)-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-
d]pyrimidin-5-yl)piperidin-4-yl)methylcarbamate (34)  
A suspension of compound 31 (18 mg, 0.05 mmol) and tert-butyl (piperidin-4-
yl)methylcarbamate (56 mg, 0.3 mmol, APOLLO Scientific) in 2-propanol in a reaction vial 
was heated at 175 °C for 45 min. After evaporation of the solvent under reduced pressure, the 
residue was purified by column chromatography on silica gel with gradient mixtures of 
ethylacetate and heptane as the eluant. Yield: 20 mg (0.04 mmol, 80 %) as yellow oil. 
1H NMR (400 MHz, CDCl3): δ 1.13 (t, J 7.0, 3H), 1.25 (br s, 2H), 1.32 (t, J 7.6, 3H), 1.39 (s, 
9H), 1.70 (d, J 11.7, 2H), 2.35 (s, 3H), 2.75-2.93 (m, 6H), 3.56 (q, J 7.0, 2H), 3.80 (t, J 4.6, 
2H), 4.58-4.62 (m, 4H), 6.92 (d, 1H), 8.09 (s, 1H), 8.19 (d, J 5.0, 1H), 9.6 (s, 1H) 
MS: (M+H)+ m/z= 538.4. 
5-(4-(Aminomethyl)piperidin-1-yl)-1-(2-ethoxyethyl)-3-eethyl-N-(4-methylpyridin-2-yl)-1H-
pyrazolo[4,3-d]pyrimidin-7-amine (35, precursor)  
Compound 34 (14 mg, 0.03 mmol) was suspended in CH2Cl2 (1 mL) and cooled to 0 °C under 
N2, TFA (0.5 mL) was added drop-wise and the solution was stirred for 1 h and further at RT 
for 1 h. The reaction mixture was concentrated under reduced pressure; the residue was 
dissolved in toluene (1 mL), then concentrated again under reduced pressure and dried in 
vacuum oven. Yield: 10 mg (0.2 mmol, 87.7 %).  
1H NMR (400 MHz, DMSO-d6): δ 1.08 (t, J 7.6, 3H), 1.20-1.36 (m, 7H), 1.84 (d, J 12.8, 2H), 
2.41 (s, 3H), 2.75-2.90 (m, 4H), 3.02-3.06 (m, 2H), 3.50-3.53 (m, 2H), 3.81 (t, J 4.8, 2H), 
4.50-4.75 (m, 4H), 7.05 (d, J 4.6, 1H), 7.91 (br s, 2H), 8.04 (s, 1H), 8.23 (d, J 5.5, 1H).  
HRMS-ESI: calcd for C23H35N8O+ 439.2934, found 439.2939. 
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Tert-butyl(1-(7-(4-methylpyridin-2-ylamino)-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-
d]pyrimidin-5-yl)piperidin-4-yl)methylmethylcarbamate (36)  
Following the procedure for the preparation of 34, but replacing tert-butyl (piperidin-4-
yl)methylcarbamate by tert-butyl (piperidin-4-yl) methylmethylcarbamate provided the crude 
title compound. Yield 16 mg (0.03 mmol, 58 %). 
1H NMR (400 MHz, CDCl3): δ 1.10-1.35 (m, 8H), 1.39 (s, 9H, boc), 1.61-1.67 (m, 2H), 1.90 
(br s, 1H, NH), 2.33 (s, 3H, Me), 2.75-2.90 (m, 8H), 3.09 (d, 2H, J 7.0), 3.56 (q, J 7.0, 2H), 
3.80 (t, J 4.5, 2H), 4.59-4.66 (m, 4H), 6.92 (d, 1H, J 5.0, Ar), 8.09 (s, 1H, Ar), 8.19 (d, 1H, J 
5.0, Ar), 9.65 (s, 1H, NH). MS: (M+H)+ m/z= 553.4. 
 
1-(2-Ethoxyethyl)-3-ethyl-5-(4-((methylamino)methyl)piperidin-1-yl)-N-(4-methylpyridin-2-
yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine (37, reference)  
Following the procedure for the preparation of compound 35, but starting from compound 36 
provided the crude title compound. Yield 8 mg (0.02 mmol, 90 %) 
1H NMR (400 MHz, CDCl3): δ 8.11 (d, 2H, J 5.2, Ar), 6.71 (d, 1H, J 4.8, Ar), 4.77 (d, 2H, J 
12.7, CH2), 4.59 (t, 2H, J 4.1, CH2), 3.86 (t, 2H, J 4.1, CH2), 3.58 (q, 2H, J 6.7, CH2), 2.83-
2.95 (m, 6H, 3CH2), 2.30 (s, 3H, CH3), 1.85-1.92 (m, 2H, CH2), 1.36-1.39 (m, 12H). MS:  
HRMS-ESI: calcd for C24H37N8O+ 453.3090, found 453.3097. 
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In vitro PDEs inhibitory activity assay 
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HPLC purification and quality control of labeled compounds 
Table 2. Purification and analysis of radiotracers 
Radioligand 
Mobile phase preparative 
HPLC (%,  buffer in EtOH)  
Rt 
(min) 
Mobile phase analytical HPLC 
(%, buffer in ACN)  
Rt 
(min) 
[11C]-7 67, 0.01 M Na2HPO4 pH 9 14.9 70, 0.01 M Na2HPO4  pH 9 10.1 
[11C]-8 67, 0.01 M Na2HPO4 pH 9 17.6 70, 0.01 M Na2HPO4  pH 9 9.8 
[18F]-11 67, 0.01 M Na2HPO4 pH 9 16.2 70, 0.01 M Na2HPO4  pH 9 12.8 
[11C]-14 65, 0.01 M Na2HPO4 pH 9 16 ** 65, 0.01 M Na2HPO4 pH 9 6.8 
[11C]-21 45, 0.01 M NaOAc pH 5.5 10.8 70, 0.01 M NaOAc pH 5.5 7.5 
[11C]-33 70, 0.05 M NaOAc pH 5.5 16 70, 0.05 M NaOAc pH 5.5 6.3 
[11C]-37 *70 , 0.01 M Na2HPO4 pH 9 22 70, 0.01 M Na2HPO4 pH 9  14.9 
Rt (retention time), ACN (acetonitrile),  
* ACN instead of EtOH 
** XTerra®, RP18 3.5 µm, 3 mm x100 mm 
 
 
Figure 1. Chromatogram of chemical purity determination of precursor (5)  
 UV1 integration 
Substance R/T Area %Area 
 min mAU*s % 
Reg #1 5,57 12925,81 96,83 
Reg #2 6,85 423,82 3,17 
Sum in ROI  13349,63  
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Figure 2. Chromatogra of chemical purity determination of reference (7).  
 UV1 Integeration 
Substance R/T Area %Area 
 min mAU*s % 
Reg #1 2,33 73,10 0,51 
Reg #2 3,07 4,73 0,03 
Reg #3 3,57 9,29 0,06 
Reg #4 5,08 37,07 0,26 
Reg #5 8,33 14259,10 99,14 
Sum in ROI  14383,30  
 
Figure 3. Radio-chromatograms of RP-HPLC purification of [11C]7.  
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Integration ChA 
Substance R/T Area %Area 
    
 min C/S*s % 
Reg #1 3.50 59273.8 53.46 
Reg #2 15.49 51596.2 46.54 
Sum in ROI  110870.0  
 
Figure 4. Radio-chromatograms of RP-HPLC of quality control (chemical and radiochemical purity control) of 
[11C]7  
Integration ChA 
Substance R/T Area %Area 
    
 min C/S*s % 
Reg #1 8.05 374051.6 100 
Integration UV1 
Substance R/T Area %Area 
 min mAU*s % 
Reg #1 4.50 0.97 3.16 
Reg #2 7.93 29.7 96.84 
Sum in ROI  30.67  
 
[11C]7 – Radio-signal 
peak 
7 – UV peak 
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Figure 5. Radio-chromatograms of RP-HPLC for identity confirmation by co-injection of standard non-
radioactive reference 7 with the isolated radioactive formulation of [11C]7. 
Integration ChA 
Substance R/T Area %Area 
    
 min C/S*s % 
Reg #1 10.97 36121.33 100 
Integration UV1 
Substance R/T Area %Area 
 min mAU*s % 
Reg #1 10.90 4764.359 100.00 
 
Specific activity determination 
The specific radioactivity of the tracer formulation defined as the radioactivity divided by the 
mass amount was determined by analytical HPLC (QC HPLC system). UV detection was 
done at the λmax of the authentic reference material. 
A UV calibration curve was constructed using three concentrations of the reference material 
(1, 5 and 10 µg/mL dissolved in the formulation vehicle). 20 µL of each concentration was 
injected onto HPLC in order to determine the UV absorption corresponding to the injected 
mass. The experiment was done in triplicate for each concentration.  A linear equation was 
derived from the mass (nmol) – UV response (area under the curve for absorption). 
[11C]7 – Radio-signal 
peak 
7 – UV peak 
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At the end of radiosynthesis, the concentration of the formulation was measured. An aliquot 
(20 µL) of the formulation was injected onto the QC HPLC system and the corresponding UV 
absorption was used to back calculate the mass of the compound (both labeled and unlabeled) 
in 20 µL formulation using the linear response of the calibration curve. The total mass of the 
compound in total volume of the formulation was determined. With the use of the molecular 
weight of the reference and the total amount of compound in the formulation, the mole weight 
was calculated which was subsequently used to calculate the specific activity of the 
radiotracer solution at the end of formulation. 
However, since there might be differences in response of UV detector either due to UV lamp 
life time (decreased energy) or the use of different HPLC system other than the one used for 
developing calibration curve, a onetime injection of a known amount (20 µL of a 1 µg/mL or 
20 µL of a 10 µg/mL) of reference solution (before QC analysis) was used in order to 
determine specific activity of subsequent radiolabeling formulation. 
 
Figure 6. Calibration curve developed for NMVardenafil. Each point is a triplicate. 
Example: [11C]NMVardenafil formulation was 621.6 MBq (16.8 mCi) in 7 mL sterile filtered 
solution at EOS. Injection of 20 µL of tracer formulation onto the analytical QC HPLC 
system gave absorption of 26.3 mAu*s (area under the curve, AUC). On that same day 
injection of 20 µL of 10 µg/mL solution of cold NMVardenafil gave absorption of 483.8 
mAu*s (AUC). The mass amount in the radioactive formulation was determined using 
following equation:  
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ݕ ൌ 		݉ݔ																																									݁ݍ	1 
 y is absorption (mAu*s), m is slope (mAu*s/nmol) and x is amount of compound both labeled 
and unlabeled (nmol) in the injected volume (20 µL)  
We get slop of 1148 mAu*s/nmol for 20 µL of a 10 µg/mL solution of reference compound 
(474.58 g/mol) and the origin (0,0). Using the slop and 26.3 mAu*s absorption (AUC) for the 
tracer formulation, the amount of labeled and unlabeled compound will be 22.91 pmol in 20 
µL of tracer solution. We get 8.0185 nmol as the total amount of labeled and unlabeled 
compound in 7 mL formulation. Specific activity is calculated as: radioactivity (GBq) / mass 
(µmol) 
ܵܣ ൌ 		ܣܿݐ݅ݒ݅ݐݕ/ܽ݉݋ݑ݊ݐ	݋݂	݈ܾ݈ܽ݁݁݀	ܽ݊݀	ݑ݈ܾ݊ܽ݁݀	ܿ݋݉݌݋ݑ݊݀																	݁ݍ	2 
For 621.6 MBq of [11C]NMVardenafil, the specific activity will be 77.5 GBq/µmol at end of 
formulation. 
Biological evaluations of labeled PDE5 inhibitors 
Biodistribution – [11C]-7 
Table 3. Biodistribution of [11C]-7 in NMRI mice at 2, 10, 30 and 60 min post injection (n = 4 
at each time point, SD = standard deviation) 
 percentage of injected Dose (% ID±SD) 
Organs 2min  10min  30min 60min  
bladder/urine  0.2±0.0 0.6±0.1 2.2±0.6 2.7±0.1 
kidneys 9.2±2.2 5.2±0.4 2.5±0.4 2.8±0.2 
liver 22.5±2.5 27.5±1.0 16.5±2.1 20.2±1.5 
spleen 0.7±0.1 0.9±0.3 0.4±0.1 0.7±0.2 
Pancreas 1.5±0.4 1.3±0.7 0.8±0.2 0.5±0.1 
lungs 8.1±0.8 5.8±0.8 5.9±1.0 5.1±0.3 
heart 0.9±0.2 0.4±0.1 0.3±0.0 0.4±0.1 
intestines 11.0±1.1 18.2±1.5 32.3±6.1 35.4±1.5 
stomach 1.6±0.1 2.5±0.6 5.5±2.7 3.5±0.9 
cerebrum 0.1±0.0 0.1±0.0 0.2±0.0 0.2±0.0 
cerebellum 0.0±0.0 0.0±0.0 0.1±0.1 0.1±0.0 
blood 6.2±0.2 5.3±0.4 3.3±0.3 3.3±0.3 
Penis   0.1±0.0  
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 100%/total CPM 
recovered 
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Table 4. Uptake values of [11C]-7 at 2, 10, 30 and 60 min post injection in NMRI 
mice (n = 4 at each time point, SD = standard deviation) 
standard uptake values (SUV±SD) 
2 min 10 min 30 min 60 min 
kidneys 5.7±1.2 3.4±0.4 1.3±0.1 1.6±0.1 
liver 4.9±0.7 5.6±0.2 3.5±0.4 4.1±0.3 
spleen 2.6±0.4 2.5±0.1 1.4±0.3 1.8±0.3 
Pancreas 1.8±0.5 2.1±0.2 1.1±0.2 1.1±0.2 
lungs 10.2±2.6 6.6±0.9 8.0±1.9 6.5±1.9 
heart 1.9±0.4 0.9±0.1 0.7±0.1 0.7±0.1 
intestines 1.3±0.1 2.1±0.2 3.5±0.6 4.0±0.4 
stomach 1.1±0.2 1.1±0.3 2.5±0.9 1.3±0.4 
Cerebrum 0.1±0.0 0.1±0.0 0.2±0.0 0.2±0.0 
cerebellum 0.1±0.0 0.0±0.0 0.2±0.0 0.2±0.1 
blood 1.2±0.3 0.7±0.3 0.7±0.3 0.3±0.1 
Muscle 0.8±0.3 0.3±0.1 0.4±0.1 0.3±0.0 
Penis 0.7±0.1 
Data are expressed as mean±SD; SUV calculated as (CPM in organ * Weigh of mouse)/(total CPM 
recovered * Weight of organ) 
Biodistribution – [11C]-8 
Table 5. Biodistribution of [11C]-8 in NMRI mice at 2 and 30 min post 
injection (n = 4 at each time point, SD = standard deviation) 
percentage of Injected Dose (% ID±SD) 
Standard uptake value 
(SUV±SD) 
organ 2 min 30 min 2 min 30 min 
bladder/urine 0.5±0.2 5.2±1.3  
kidneys 25.9±3.2 5.6±1.0 16.4±1.3 3.7±0.6 
liver 29.0±4.0 23.2±3.9 6.1±1.2 4.8±0.9 
spleen 1.16±0.1 0.3±0.1 3.5±0.2 1.0±0.3 
Pancreas 0.7±0.2 0.8±0.1 1.4±0.2 1.3±0.1 
lungs 4.5±1.1 3.2±0.4 4.4±0.7 3.8±1.2 
heart 0.8±0.1 0.1±0.0 1.9±0.2 0.3±0.1 
intestines 10.4±1.2 39.5±3.2 1.2±0.1 4.8±0.3 
stomach 1.1±0.1 2.5±0.5 0.6±0.1 1.5±0.4 
cerebrum 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
cerebellum 0.0±0.0 0.0±0.0 0.1±0.0 0.1±0.0 
blood 4.2±0.1 1.6±0.2 0.6±0.0 0.2±0.0 
muscle 0.4±0.1 0.3±0.0 
penis 0.0±0.0 0.1±0.0 0.3±0.0 0.5±0.1 
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 
100%/total CPM recovered; SUV calculated as (CPM in organ * Weigh of mouse)/(total CPM 
recovered * Weight of organ) 
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Biodistribution – [18F]-11 
Table 6. Biodistribution of [18F]-11 in NMRI mice at 2, 30 and 60 min post injection (n = 4 
at each time point, SD = standard deviation) 
percentage of Injected Dose (% ID±SD) Standard uptake value (SUV±SD) 
organ 2 min 30 min 60 min 2 min 30 min 60 min 
bladder/urine 0.1±0.1 3.0±0.6 5.3±0.2    
kidneys 13.0±1.5 3.0±0.6 2.0±0.1 7.3±0.8 1.8±0.3 1.2±0.0 
liver 17.4±4.3 8.7±0.4 6.5±0.8 4.0±1.2 2.0±0.1 1.5±0.1 
spleen 0.8±0.1 0.4±0.1 0.2±0.0 5.5±1.9 2.0±0.1 1.4±0.2 
Pancreas 1.0±0.2 0.5±0.1 0.4±0.1 2.0±0.1 0.9±0.1 0.8±0.1 
lungs 10.2±1.6 6.4±1.6 3.6±0.6 19.0±2.6 8.9±0.8 4.8±1.3 
heart 1.1±0.2 0.5±0.1 0.5±0.1 2.4±0.3 1.2±0.1 1.1±0.1 
intestines 11. 7±1.3 20.7±3.1 22.2±1.3 1.2±0.1 2.2±0.2 2.5±0.2 
stomach 2.0±0. 5 3.1±0.3 3.8±0.6 1.3±0.4 2.0±0.3 2.6±0.2 
cerebrum 0.1±0.1 0.7±0.1 0.8±0.2 0.2±0.1 0.9±0.1 1.1±0.1 
cerebellum 0.0±0.0 0.2±0.0 0.2±0.0 0.2±0.1 1.2±0.1 1.6±0.1 
blood 9.4±1.6 8.5±0.5 7.8±0.3 1.3±0.2 1.2±0.1 1.1±0.0 
muscle 0.8±0.3 0.7±0.1 0.7±0.0 
penis 0.0±0.0 0.1±0.0 0.2±0.0 0.5±0.1 1.3±0.1 1.5±0.1 
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 100%/total CPM 
recovered; SUV calculated as (CPM in organ * Weigh of mouse)/(total CPM recovered * Weight of organ) 
Biodistribution – [11C]-14 
Table 7. Biodistribution of [11C]-14 (sildenafil) in NMRI mice at 2 and 30 min post 
injection (n = 4 at each time point, SD = standard deviation) 
percentage of Injected Dose (% ID±SD) Standard uptake value (SUV±SD) 
organ 2 min 30 min 2 min 30 min 
bladder/urine 0.2±0.2 2.3±0.3  
kidneys 12.5±3.4 8.7±6.3 9.2±2.2 5.0±3.6 
liver 21.2±6.8 18.0±1.6 5.0±1.9 3.5±0.3 
spleen 0.2±0.3 0.0±0.0 1.0±1.7 0.0±0.0 
Pancreas 1.4±0.3 1.0±0.3 2.2±0.5 1.2±0.2 
lungs 4.8±0.9 1.0±0.1 9.5±1.2 1.5±0.2 
heart 1.3±0.1 0.3±0.0 3.2±0.2 0.7±0.1 
intestines 9.8±2.7 25.5±1.7 1.2±0.3 3.0±0.2 
stomach 1.4±0.5 5.8±1.1 0.7±0.3 3.4±1.4 
cerebrum 0.1±0.0 0.2±0.0 0.2±0.0 0.3±0.0 
cerebellum 0.0±0.0 0.1±0.0 0.2±0.0 0.3±0.1 
blood 8.2±0.8 3.7±0.5 1.2±0.1 0.5±0.1 
muscle 1.0±0.4 0.5±0.0 
penis 0.1±0.0 0.1±0.0 0.5±0.2 1.0±0.2 
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 
100%/total CPM recovered; SUV calculated as (CPM in organ * Weigh of mouse)/(total CPM 
recovered * Weight of organ) 
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Biodistribution – [11C]-21 
Table 8. Biodistribution of [11C]-21 in NMRI mice at 2, 10, 30 and 60 min post injection (n 
= 4 at each time point, SD = standard deviation)
  percentage of Injected Dose (% ID±SD)
Organs  2min   10min  30min 60min  
bladder/urine   0.1±0.0  0.2±0.1 1.2±0.2 2.1±1.4 
kidneys  7.3±0.9  2.7±0.2 2.2±0.3 1.6±0.3 
liver  51.6±3.8  40.7±3.7 14.2±1.1 20.4±2.6 
spleen  0.5±0.10  0.2±0.0 0.3±0.2 0.1±0.0 
Pancreas  0.7±0.1  0.9±0.4 0.6±0.2 0.3±0.1 
lungs  3.3±0.4  1.0±0.1 0.7±0.1 0.5±0.2 
heart  2.1±0.2  0.7±0.1 0.4±0.1 0.2±0.0 
intestines  5.6±0.3  12.6±2.8 31.1±3.1 42.6±4.7 
stomach  1.2±0.4  1.4±0.4 2.9±2.8 0.8±0.3 
cerebrum  0.3±0.0  0.4±0.0 0.3±0.0 0.2±0.0 
cerebellum  0.1±0.0  0.2±0.1 0.1±0.0 0.1±0.0 
blood  6.1±0.6  2.8±0.2 2.8±0.0 1.6±0.3 
penis 0.1±0.0 
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 100%/total CPM 
recovered 
 
Table 9. Uptake values of [11C]-21 at 2, 10, 30 and 60 min post injection in 
NMRI mice (n = 4 at each time point but at 30 min; n = 7, SD = standard 
deviation) 
standard uptake values (SUV±SD) 
2 min 10 min 30 min 60 min 
kidneys 4.7±0.6 1.5±0.1 1.3±0.1 0.9±0.1 
liver 11.7±1.9 7.5±1.1 3.5±0.3 4.0±0.6 
spleen 1.3±0.4 0.3±0.1 1.0±0.4 0.3±0.1 
pancreas 1.3±0.3 1.3±0.4 1.1±0.2 0.4±0.2 
lungs 6.1±1.3 1.5±0.1 1.0±0.2 0.7±0.2 
heart 5.4±0.9 1.5±0.1 1.1±0.3 0.5±0.0 
intestines 0.7±0.2 1.3±0.3 1.3±0.9 4.9±0.6 
stomach 0.6±0.2 0.5±0.2 2.6±1.0 0.4±0.1 
cerebrum 0.5±0.1 0.5±0.0 0.5±0.1 0.2±0.0 
cerebellum 0.5±0.1 0.6±0.1 0.5±0.0 0.2±0.1 
blood 1.1±0.4 0.4±0.1 0.4±0.0 0.2±0.1 
muscle 0.6±0.2 0.7±0.1 0.6±0.0 0.4±0.1 
penis 0.5±0.1 
Data are expressed as mean±SD; SUV calculated as (CPM in organ * Weigh of mouse)/(total 
CPM recovered * Weight of organ) 
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Plasma radiometabolite analysis – [11C]-21 
Table 10. Plasma radiometabolite analysis of [11 C]-21 
 Metabolite (%) Intact (%) 
2 min 4.6 95.4 
30 min 41.5 58.5 
 
Biodistribution – [11C]-33 
Table 11. Biodistribution of [11C]-33 in NMRI mice at 2 and 30 min post 
injection (n = 4 at each time point, SD = standard deviation) 
percentage of Injected Dose (% ID±SD) 
Standard uptake value 
(SUV±SD) 
organ 2 min 30 min 2 min 30 min 
bladder/urine 0.1±0.0 0.9±0.2  
kidneys 14.3±1.9 4.9±0.4 7.8±0.9 3.3±0.8 
liver 17.7±2.5 20.3±2.7 4.2±0.6 4.4±0.9 
spleen 0.9±0.2 0.6±0.2 3.1±0.1 2.7±0.6 
Pancreas 0.8±0.2 1.6±0.5 1.4±0.1 3.1±0.6 
lungs 5.1±1.0 1.7±0.3 7.2±0.5 2.7±0.4 
heart 1.2±0.4 0.4±0.1 2.5±0.5 0.9±0.1 
intestines 8.6±0.1 18.0±1.9 1.1±0.1 2.5±0.2 
stomach 1.1±0.1 4.0±0.6 0.9±0.1 3.8±0.8 
cerebrum 0.5±0.2 0.2±0.1 0.6±0.2 0.3±0.1 
cerebellum 0.2±0.0 0.1±0.0 0.7±0.2 0.3±0.1 
blood 3.2±0.4 1.8±0.3 0.5±0.0 0.3±0.0 
muscle 0.7±0.2 0.4±0.1 
penis 0.0±0.0 0.1±0.0 0.6±0.1 0.6±0.1 
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 
100%/total CPM recovered; SUV calculated as (CPM in organ * Weigh of mouse)/(total 
CPM recovered * Weight of organ) 
 
  
Evaluation of PET Radioligands for PDE5 
87 
 
Biodistribution – [11C]-37 
Table 12. Biodistribution of [11C]-37 in NMRI mice at 2, and 30 min post 
injection (n = 4 at each time point, SD = standard deviation) 
percentage of Injected Dose (% ID±SD) 
Standard uptake value 
(SUV±SD) 
organ 2 min 30 min 2 min 30 min 
bladder/urine 0.7±0.9 0.8±0.3  
kidneys 18.1±8.4 11.6±1.0 10.9±5.3 7.5±1.3 
liver 19.7±9.5 30.0±1.0 4.3±2.2 6.4±0.3 
spleen 1.0±0.5 1.5±0.9 3.9±1.8 2.8±0.7 
Pancreas 1.1±0.5 1.8±0.4 1.8±0.8 2.3±0.3 
lungs 4.5±1.7 4.4±1.2 7.6±3.2 6.6±1.5 
heart 1.4±0.5 0.7±0.2 3.5±1.4 1.1±0.2 
intestines 6.6±3.5 16.8±1.2 0.7±0.4 2.0±0.2 
stomach 1.1±0.7 2.±0.4 0.5±0.2 1.3±0.1 
cerebrum 0.1±0.1 0.0±0.0 0.2±0.1 0.1±0.0 
cerebellum 0.1±0.1 0.0±0.0 0.3±0.3 0.1±0.0 
blood 3.7±0.6 2.8±0.5 0.5±0.1 0.2±0.0 
muscle 0.2±0.1 0.1±0. 1.6±1.2 0.5±0.1 
penis 0.2±0.2 0.0±0.0 1.7±2.2 0.3±0.0 
Data are expressed as mean±SD; percentage of injected dose calculated as CPM in organ * 
100%/total CPM recovered; SUV calculated as (CPM in organ * Weigh of mouse)/(total CPM 
recovered * Weight of organ) 
Blocking study in NMRI mice 
Table 13. Comparison of pre-blocking effect on the uptake of [11C]-7 and [11C]-37 
at 30 min post injection in control and tadalafil pre-treated NMRI mice (n = 4, SD 
= standard deviation) 
% Injected dose (%ID±SD)* 
[11C]-7 [11C]-37 
organ Control Tadalafil treated Control Tadalafil treated 
Kidneys 2.5±0.4 3.5±0.5 11.6±1.0 12.5±1.4 
Liver 16.5±2.1 22.2±1.6 30.0±0.9 28.6±3.6 
Lungs 5.9±1.1 0.8±0.2 4.4±1.2 2.3±0.6 
Heart 0.3±0.0 0.3±0.0 0.6±0.0 0.4±0.0 
Intestines 32.2±6.1 33.9±1.9 16.7±1.2 16.6±2.0 
Blood 3.3±0.3 4.3±0.1 2.8±0.5 1.8±0.2 
Muscle 0.1±0.1 0.1±0.0 0.1±0. 0.1±0.1 
Penis 0.1±0.0 0.1±0.0 0.0±0.0 0.1±0.0 
Data are expressed as mean±SD; *percentage of injected dose calculated as CPM in organ * 
100%/total CPM recovered 
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Abstract  
Introduction: The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 
5 (PDE5) is considered to play an important role in a variety of diseases such as pulmonary 
arterial hypertension (PAH) and chronic heart failure. This PDE5 modulation represents an 
important prognostic and/or therapeutic target; however, there is currently no method 
available to non-invasively assess the spatial and temporal changes of PDE5 expression levels 
in vivo. Therefore, we aimed to develop a PDE5-specific PET imaging probes. 
Methods: [11C]NMVardenafil (a close analogue of vardenafil) was synthesized and evaluated 
in transgenic mice with cardiomyocyte-specific PDE5 over-expression (PDE5 TG), 
monocrotalin (MCT) treated rats and a pig. 
Results: [11C]NMVardenafil showed a selective and specific retention in the myocardium of 
PDE5 TG mice which could significantly be blocked by tadalafil, a structurally unrelated 
PDE5-specific inhibitor. Rats and pigs showed high tracer retention in the lungs, in agreement 
with the abundant and constitutive expression of the PDE5 enzyme in this organ.  
[11C]NMVardenafil retention in lungs of MCT treated rats was not significantly different 
compared to control rats. 
Conclusions: [11C]NMVardenafil showed selective, specific and high affinity binding to 
PDE5 in vivo. [11C]NMVardenafil has been selected as lead candidate for further clinical 
investigation in patients with pulmonary hypertension or patients with end-stage heart failure 
awaiting heart transplantation. 
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1. Introduction  
Phosphodiesterase inhibitors have been used for more than two thousand years since the 
advent of coffee in East Africa but only during the last 60 years these enzymes have been 
isolated and characterized (1). Phosphodiesterases (PDEs) are a superfamily of intracellular 
enzymes that catalyze the degradation of cyclic nucleotides (cyclic adenosine 
monophosphate/cAMP and cyclic guanosine monophosphate/cGMP). There are 11 families of 
PDEs (PDE1 through PDE11) of which some specifically catalyze the degradation of cAMP 
(PDE4, PDE7 and PDE8) while others are cGMP specific (PDE5, PDE6 and PDE9) and 
remaining families catalyze hydrolysis of both cAMP and cGMP with different affinities (2, 
3).  
Phosphodiesterase 5 (PDE5) is a cGMP-specific esterase that is expressed in vascular smooth 
muscle cells, lungs, platelets, corpus cavernosum and Purkinje fibers in the cerebellum (2, 3). 
PDE5 plays an important role in regulating vascular smooth muscle tone in pulmonary 
vasculature, platelet aggregation, handling of sodium secretion in renal cells, neuronal 
excitability, synaptic plasticity, neurogenesis and apoptosis (3, 4). In addition, PDE5 is 
implicated in a number of diseases including pulmonary arterial hypertension (PAH), 
atherosclerosis, and in ischemic and dilated cardiomyopathy.  There is increasing evidence 
that PDE5 plays a major role during disease progression of heart failure and cardiomyopathy 
even though PDE5 is not expressed to any significant level in the healthy myocardium (3, 5-
10). Recent studies reported significantly increased PDE5 expression in right and left 
ventricles of patients with pulmonary hypertension or an end-stage phase of ischemic and 
dilated cardiomyopathy (6-10). In mammalian experimental models, depletion of cGMP by 
excessive levels of PDE5 aggravated cardiac remodeling and suppressed cardiac contractile 
reserve after myocardial infarction or induced heart failure (7-10). In addition, preclinical and 
clinical data suggest that inhibition of PDE5 using vardenafil, a PDE5 inhibitor used for 
treating erectile dysfunction, reverses pathological remodeling and improves global cardiac 
function and quality of life (11-13). Therefore, [11C]NMVardenafil was evaluated in 
transgenic mice with up to 10-fold myocardiocyte-specific PDE5 over-expression (PDE5 TG) 
in order to assess its uptake and retention in myocardium (7, 10). 
Besides its role in cardiomyopathy, abundant expression of PDE5 in the lungs is a strong 
basis for using PDE5 inhibitors in PAH patients (14). Black and colleagues also reported 
elevated expression of PDE5 in pulmonary hypertensive lambs (15). PDE5 inhibitors in 
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general and vardenafil in particular have been shown to be beneficial in alleviating and 
reversing pulmonary arterial hypertension in rats (16-18).  
The development of a PDE5 specific PET radioligand can be of particular interest to assess 
and quantify spatial and temporal changes in PDE5 expression as a function of disease 
progression and to quantify PDE5 occupancy during pharmacologic treatment with PDE5 
inhibitors. Several radiolabeled tracers based on PDE5 inhibitors were successfully 
synthesized and investigated by our group for their suitability to non-invasively evaluate 
PDE5 expression (19). A carbon-11 labeled vardenafil derivative [11C]NMVardenafil (2-{2-
ethoxy-5-[4-(¹¹C)methylpiperazine-1-sulfonyl]phenyl}-5-methyl-7-propyl-3H,4H-imidazo[4,3-
f][1,2,4]triazin-4-one) showed a high PDE5-specific retention in the lungs of wild type mice 
with 87 % inhibitable PDE5 binding. This tracer showed considerable promise for PET 
studies of PDE5 binding in the cardiopulmonary system. In this study, we investigated 
[11C]NMVardenafil in PDE5 TG mice to assess its uptake and retention in the myocardium 
and in rats with monocrotaline (MCT) induced pulmonary hypertension (20). In addition, in 
vivo biodistribution studies of [11C]NMVardenafil in pigs were performed as translational 
proof-of-concept.  
 
Figure 1. Structures of [11C]NMVardenafil and vardenafil.   
2. Results and discussion 
2.1. Synthesis and radiolabelling 
Synthesis and radiolabeling of [11C]NMVardenafil have been reported previously (19). For all 
evaluation of tracer in animals, the ethanol concentration in the eluting solution of the 
radiotracer was diluted to < 10 % with normal saline and sterile filtered. Chemical and 
radiochemical purity of tracers were analyzed with HPLC and purity of more than 95 % was 
accepted (supporting information figures 1 and 2). 
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2.2. Biodistribution 
2.2.1. Wild type (C57Bl/6) mice 
[11C]NMVardenafil biodistribution was evaluated in transgenic mice with cardiomyocyte-
specific PDE5 over-expressing (N = 3) and wild type C57Bl/6 (Bl6) littermates (N = 3). 
Consistent with reports that PDE5 is abundantly expressed in lungs (14, 16) and in agreement 
with previous reports of the distribution of the tracer in another murine strain (19); the highest 
retention of [11C]NMVardenafil was observed in the lungs (8.1±0.7 % ID and 10.2±2.3 
SUVW) of wild type (WT) mice (figure 2 and supporting information).  
2.2.2. Transgenic mice with cardiomyocyte specific PDE5 over-expression (PDE5 TG) 
To assess specificity of [11C]NMVardenafil for PDE5, biodistribution studies in transgenic 
mice with cardiomyocyte-specific PDE5 over-expression (PDE5 TG) was studied at 30 min 
post injection (pi). The PDE5 TG mice are characterized by an up to 9-fold increase in PDE5 
protein expression and a 10-fold increase in sildenafil-inhibitable cGMP hydrolytic activity 
specifically in the cardiomyocytes compared to wild type littermates (7, 10). 
  
Figure 2. Biodistribution of [11C]NMVardenafil at 30 min post injection  in wild type (WT) mice, PDE5 
TG Transgenic mice with cardiomyocyte specific PDE5 over-expression mice (control,); PDE5 TG (NM 
pt): PDE5 TG mice pre-treated with NMVardenafil (10 mg/kg, SC, 60 min prior to tracer injection); 
PDE5 TG (tad pt): PDE5 TG mice pre-treated with tadalafil  (10 mg/kg, SC, 60 min prior to tracer 
injection); *(p < 0.05); ***(p < 0.001); SUVw: standardized uptake value based on weight. N = 3 for 
each group. 
At 30 min pi, the myocardial retention of [11C]NMVardenafil in PDE5 TG mice was more 
than 5-fold higher compared to wild type mice (from 1.1±0.0 to 6.1±1.1 % ID, p < 0.001) 
demonstrating selective binding to PDE5. The retention of [11C]NMVardenafil in the lungs of 
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PDE5 TG mice was reduced by more than 65 % (8.1±0.7 vs. 2.8±0.4 % ID) compared to wild 
type mice, probably due to a ‘‘stealing’’ effect of the available radiotracer in the plasma by 
the myocardium. 
2.2.3. Blocking study in PDE5 TG mice 
To challenge the PDE5 specific binding of [11C]NMVardenafil in PDE5 TG mice, a blocking 
study was performed by pre-treating PDE5 TG mice (N = 3) with tadalafil, a structurally 
unrelated competitive PDE5-specific inhibitor, (10 mg/kg) (21) or a self-blocking (N = 3) 
study with cold NMVardenafil (10 mg/kg) administered subcutaneously (sc), 60 min prior to 
tracer injection. [11C]NMVardenafil retention in the lungs (figure 2 and Supporting 
information-tables 1 and 2) was significantly blocked (more than 62 % reduction in % ID for 
both pre-treated groups, p < 0.01 and p <  0.001 in NMVardenafil and tadalafil pre-treated 
mice, respectively). Similarly, myocardial retention was reduced by more than 52 % after 
self-blocking (p < 0.05) and 58 % after tadalafil pre-treatment (p < 0.05) compared to non-
treated PDE5 TG mice. 
The difference in myocardial retention of [11C]NMVardenafil between the NMVardenafil and 
tadalafil pre-treated groups  was not statistically significant (p = 0.4). These results 
demonstrate that binding of [11C]NMVardenafil is PDE5-specific. Moreover, no significant 
difference in tracer retention in other organs was observed between non-treated mice and mice 
pre-treated with PDE5 inhibitor supporting our findings that the tracer binds selectively and 
specifically to PDE5 in lung and myocardial tissue. 
2.3. Plasma radiometabolite analysis of [11C]NMVardenafil  
2.3.1. Plasma of mice 
Mouse plasma (N = 3) was analyzed with reversed phase high pressure liquid 
chromatography (RP-HPLC) to quantify radiometabolites of [11C]NMVardenafil at 2 and 30 
min post tracer injection (table 1). At 2 min pi 81 % of the activity was present as intact 
radiotracer and this fraction was reduced to 37 % at 30 min pi. The main metabolite is most 
likely a result of demethylation of the piperazine [11C]methyl-group (figure 1) and it was not 
expected to contribute to the measured activity in lungs or myocardium (22). Radioactive 
metabolites detected were more polar than [11C]NMVardenafil as shown by the shorter 
retention time during RP-HPLC analysis (supporting information-figure 1). 
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2.3.2. Plasma of pig 
Plasma radiometabolites of [11C]NMVardenafil were also quantified in pig arterial plasma 
samples (N = 1) obtained at 2, 5, 10, 30 and 60 min pi (table 1). The fraction of activity 
recovered in the form of intact [11C]NMVardenafil ranged from 87 % at 2 min pi to 48 % at 
60 min pi. Similar to mice studies, all recovered radiometabolites were more polar than the 
intact tracer. 
Table 1. Plasma radiometabolite analysis of [11C]NMVardenafil in mice and pig plasma as a 
function of time post injection.  
  Mice plasma (N = 2)  Pig plasma (N = 1) 
 2 min   30 min   2 min  5 min   10 min  30 min  60 min 
Intact tracer (%)  81 - 82  31 – 44   87.3  94.6  74.6  59.5  48.4 
 
2.4. Small-animal PET study 
2.4.1. MicroPET imaging in PDE5 TG mice 
In vivo biodistribution of [11C]NMVardenafil was evaluated in PDE5 TG mice using dynamic 
microPET imaging. In addition to biodistribution studies, reversible and specific binding of 
[11C]NMVardenafil was assessed with chase and blocking experiments with tadalafil. Time-
activity curves (TACs) of the myocardium showed a significant uptake and retention in 
control PDE5 TG mice in agreement with biodistribution results (figure 3).  
In contrast to the findings in control PDE5 TG mice, there was no significant tracer retention 
and accumulation in tadalafil pre-treated mice. The tracer was quickly displaced after 
intravenous injection of tadalafil in the chase study (figures 3 and 4). These results 
demonstrate that in vivo binding of [11C]NMVardenafil to PDE5 is highly specific and 
reversible. 
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Figure 3. Time-activity curve of the myocardium in PDE5 TG mice after iv injection of 
[11C]NMVardenafil (7 MBq). Control (baseline scan); pre-treated: tadalafil 10 mg/kg, sc, 60 min prior to 
tracer injection; and chase: tadalafil 10 mg/kg, iv, 20 min after start of scan. 
 
Figure 4. Left: A summed image of dynamic microPET acquisition from 8 to 20 min after iv injection of 
[11C]NMVardenafil (7 MBq) in PDE5 TG mice. Right: A summed image of the same dynamic microPET 
acquisition from 40 to 50 min after the chase. Sagittal view (top right), transaxial (top left), and coronal 
view (bottom). 
2.4.2. MicroPET imaging of MCT induced pulmonary arterial hypertension rat model 
[11C]NMVardenafil was evaluated in a MCT induced pulmonary hypertension rat model to 
monitor changes in PDE5 expression level during disease progression. MCT is an 11-
membered macrocyclic pyrrolizidine alkaloid which is oxidized in the rat liver to the reactive 
metabolite monocrotaline pyrrole (MCTP). In rats, MCTP causes pulmonary vascular 
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syndrome characterized by proliferative pulmonary vasculitis, pulmonary hypertension and 
cor pulmonale (23, 24).  
The weight of rats was monitored throughout the experiment and served as a non-invasive 
indicator of disease progression (25). During the first week of isolation, all rats gained 
proportionally about 3.5 % in weight. In the experimental group (N = 3), two rats initially 
gained weight in the first week (5.1 % and 8.9 %, respectively), but lost weight in the sixth 
week (5.4 % and 21 %, respectively) and eventually died. The third MCT treated rat showed a 
similar pattern as the other MCT treated rat but started gaining weight from the fifth week on 
till the end of the experiment. In contrast to treated rats, all control rats gained weight till the 
end of the experiment. Therefore, loss of body weight was taken as indicators of a pre-
terminal disease stage (25). 
[11C]NMVardenafil-microPET scans of the MCT treated rats were acquired on a weekly basis 
for eight weeks and TACs for different lung regions are shown in figure 5.  
 
Figure 5. MicroPET follow up in MCT treated rats (75 mg/kg, ip). Time-activity curves for lung regions 
at subsequent imaging time points after injection of [11C]NMVardenafil (37 MBq). 
Rat lung TACs acquired at different time points post MCT treatment showed no significant 
difference compared to baseline scans or control group. It was concluded from this 
experiment that [11C]NMVardenafil PET could not detect significant changes in PDE5 
expression levels during the 6-weeks follow-up period after MCT treatment. There was no 
difference in uptake of the tracer between control and MCT pre-treated rats and there is still 
some controversy about this model and the uncertain correlation between this rat model and 
clinical features in PAH patients (20). 
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2.5. Pig PET study  
In addition to rodent experiments, in vivo biodistribution of [11C]NMVardenafil was also 
evaluated in a pig (N = 1). Similar to mice biodistribution results, a strong uptake and 
retention in the lungs was observed, whereas the myocardium was only faintly visible (figure 
6, bottom). There was a non-uniform uptake and retention of the tracer in the different lung 
regions. This might not be surprising taking into consideration the non-uniform distribution of 
PDE5 in the lungs (mainly distributed in the blood vessels). Whether the non-uniform 
retention of [11C]NMVardenafil was due to non-uniform PDE5 expression or related to 
heterogeneous perfusion and/or ventilation (figure 6) or a combination of these needs to be 
further investigated but, nevertheless, this observation is intriguing. Time-activity curves 
generated for the different regions of the lungs are given in figure 7. 
 
Figure 6. Transaxial (left), sagittal (middle), and coronal (right) fused PET-CT images of the lungs and 
myocardium in a pig model after intravenous administration of [11C]NMVardenafil (370 MBq). Top: 
Summed image between 6 and 12 s showing first-pass of the tracer with high activity in the right 
ventricle, pulmonary arteries and to a lesser extent in the dorsal part of the lungs. Middle: summed 
image between 30 and 36 s showing blood pool activity in the left ventricle and high tracer 
retention/perfusion in the lungs, mainly in the dorsal regions. Bottom: summed image between 720 
and 900 s showing high tracer retention in the lungs and slightly increased tracer uptake in the 
myocardial wall of the left ventricle. 
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The TACs obtained in different lung regions showed a high and significant tracer uptake and 
retention. The middle and dorsal regions of the lungs showed an initial higher uptake 
compared to the ventral areas (figure 6) whereas the latter regions showed an initial lower 
uptake but a steady accumulation was observed to finally reach similar levels of tracer 
retention (figure 7, TACs of left ventral/Lv and right ventral/Rv). With regard to perfusion 
and tracer delivery, the lung is quite different from other organs as it receives blood supply 
from the right ventricle with a much more concentrated tracer bolus after intravenous 
injection.  In addition lung perfusion is coupled to ventilation (26) and density of lung tissue 
varies according to local content of air during respiration. Anesthesia and mechanical 
ventilation may further influence local lung ventilation and perfusion making it extremely 
difficult to explain the heterogeneity of the observed [11C]NMVardenafil kinetics which may 
however be related to the putative role of PDE5 with regard to hypoxia related 
vasoconstriction (27). Further investigations are warranted to elucidate the underlying 
mechanisms of this heterogeneous tracer distribution. 
 
Figure 7. TACs reconstructed for lung regions after iv injection of [11C]NMVardenafil (370 MBq). Ld: 
Left dorsal (blue); Lv: Left ventral (green); Lm: Left middle (red); Rm: Right middle (light blue); Rv: 
Right ventral (orange); RL: Right dorsal (violet) 
3. Conclusion 
A carbon-11 radiolabeled vardenafil derivative ([11C]NMVardenafil) was synthesized and 
evaluated for its potential to non-invasively image PDE5 expression. Biodistribution and PET 
imaging studies in PDE5 TG mice and a pig model showed that the tracer binds specifically, 
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selectively and reversibly to PDE5 in the myocardium and lungs. A small animal PET study 
in MCT induced pulmonary hypertension model in rats could not show a significant 
difference in tracer uptake between control and experimental groups. In this study, we 
demonstrated that [11C]NMVardenafil has high affinity and specificity for PDE5 with 
promising properties for in vivo visualization of PDE5 and assessing receptor occupancy 
during treatment with PDE5 inhibitors. [11C]NMVardenafil has been selected as lead 
candidate for further clinical investigation in patients with pulmonary hypertension and end-
stage heart failure awaiting heart transplantation. Furthermore, this tracer may show 
considerable promise to study the role of PDE5 in hypoxia related vasoconstriction in vivo. 
4. Experimental section 
All animal experiments were conducted according to the Belgian code of practice for the care 
and use of animals, after approval from the Animal Ethics Committee, KU Leuven (Ethische 
Commissie Dier proeven, KU Leuven, License number: LA1210237). 
4.1. Radiosynthesis 
Synthesis and radiolabeling of [11C]NMVardenafil have been reported previously (19). For all 
evaluation of tracer in animals, the ethanol concentration in the eluting solution of the 
radiotracer was diluted to < 10 % with normal saline and sterile filtered. Chemical and 
radiochemical purity of tracer were analyzed with HPLC and purity of more than 95 % was 
accepted (19).  
4.2. Biodistribution in mice 
Adult wild type C57Bl/6 (Bl6) (KU Leuven Animalium) and PDE5 TG mice (graciously 
supplied by Cardiology Unit, KU Leuven) weighing 25 to 40 g were used for biodistribution 
studies. Animals were housed in individually ventilated cages in a thermo regulated (22°C), 
humidity-controlled facility under a 12 h/12 h light/dark cycle, with free access to food and 
water. Biodistribution studies of [11C]NMVardenafil were performed in wild type Bl6 and 
PDE5 TG mice at 30 min post injection (N = 3 per time point). Mice were anesthetized with 
2.5 % isoflurane in oxygen at a flow rate of 1 L/min and the radiotracer (5-7 MBq) was 
injected via tail vein. The mice were sacrificed by decapitation at 30 min pi and blood and 
major organs were collected and weighed. Radioactivity in blood and organs was counted 
using an automated γ-counter (Perkin Elmer Wizard 2480, Walthan, USA) and expressed as a  
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percentage of injected dose (% ID) and standardized uptake value based on weight (SUVW) 
where initially the concentration in organ was expressed as activity (KBq) per gram (g) and 
then adjusted for body weight and total injected dose. For calculating total radioactivity in 
blood and muscle, weight of blood and muscle was assumed to be 7 % and 40 % of body 
weight, respectively. 
4.3. Blocking study  
In order to assess the affinity and specificity of [11C]NMVardenafil for PDE5, a blocking 
study was performed in PDE5 TG mice (N = 3).  In brief, PDE5 TG mice were 
subcutaneously injected with tadalafil (a structurally unrelated PDE5 inhibitor, TCR, Canada) 
or cold NMVardenafil (self-blocking) 10 mg/kg, subcutaneous (sc), 60 min prior to tracer 
administration. Tadalafil or NMVardenafil solution for injection was prepared in such a way 
that the final concentration was 1 mg/mL in 10 % dimethylsulfoxide in 40 % (2-
hydroxypropyl)-β-cyclodextrin solution and sterile filtered through a 0.22 μm filter (Millex®-
GV, Millipore, Ireland).  Biodistribution study was then performed as described above and 
results were expressed as % ID and SUVW. 
4.4. Radiometabolites  
4.4.1. Plasma radiometabolites analysis in mice 
Radiometabolites of [11C]NMVardenafil in plasma of mice were quantified at 2 and 30 min pi 
(N =  2 per time point). Mice were anaesthetized with pentobarbital (60 mg/kg; ip) and 
injected with [11C]NMVardenafil (~7.4 MBq) via tail vein. Mice were decapitated at 
predetermined time points, blood was collected into lithium heparin PST tubes (BD 
Vacutainer; BD, Franklin Lakes, New Jersey) and stored on ice. After centrifugation (420 x g; 
10 min), plasma was separated and analyzed by HPLC on a Chromolith RP C18 column (3
mm×100 mm; Merck) eluted with gradient mixtures of CH3CN (A) and 0.05 M NaOAc pH 
5.5 (B) (0-4 min: isocratic 0 % A, 0.5 mL/min; 4-9 min: linear gradient 0 % A to 90 % A, 1
mL/min; 9-12 min: isocratic 90 % A, 1 mL/min; 12-15 min: linear gradient 90 % A to 0 % A, 
0.5 mL/min). The non-radioactive reference compound NMVardenafil was co-injected to 
determine the retention time of the intact parent tracer. The eluate from the UV detector was 
passed through a 3-in. NaI(Tl) scintillation detector, connected to a single channel analyzer. 
The eluate from the radiodetector was collected as 1-mL fractions (model 2110 fraction 
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collector, Bio-Rad, Hercules, CA). The radioactivity in each fraction was measured using an 
automated gamma counter. 
4.4.2. Plasma Radiometabolite Analysis in pigs 
After intravenous administration of 370 MBq of [11C]NMVardenafil  in an anesthetized pig 
blood was drawn at 2, 10, 30, 60 and 90 min. Blood was collected in lithium heparin-
containing tubes and stored on ice. Subsequently, the blood was centrifuged for 10 min at 
3155 x g and the supernatant (plasma) was drawn and spiked with 50 µg of the reference 
compound (NMVardenafil). The plasma was then analyzed with HPLC according to the 
procedure mentioned above.  
4.5. Small-Animal PET Studies 
All rodent imaging experiments were performed on a Focus 220 microPET scanner (Concorde 
Microsystems, Knoxville, USA). Male PDE5 TG mice were kept under gas anesthesia (2.5% 
isoflurane in O2 at a flow rate of 1 L/min) and 90 min dynamic scans were acquired in list 
mode. Acquisition data were separated into 24 time frames (frame x time: 4 x 15 s, 4 x 60 s, 
5 x 180 s, 8 x 300 s and 3 x 600 s min) and reconstructed with MAP. Time–activity curves 
(TAC) were generated for the heart for each individual scan, using PMOD software (version 
3.2; PMOD Technologies, Zurich, Switzerland). The radioactivity concentration in the heart 
region was expressed as standardized uptake value based on volume (SUVV) where the 
concentration in organ was expressed initially as activity (KBq) per volume of interest (mL) 
and then adjusted for body weight and total injected dose. 
4.5.1. MicroPET imaging in PDE5 TG mice 
Baseline imaging was performed in PDE5 TG mice and the same mice were used to 
determine specific binding of the tracer to PDE5 by blocking and chase experiments using the 
structurally unrelated PDE5-specific inhibitor tadalafil (21). Mice were intravenously injected 
with 5 to 7 MBq of [11C]NMVardenafil. For the blocking study, mice were pre-treated with 
10 mg/kg tadalafil, subcutaneously (sc), 60 min prior to tracer administration whereas for the 
chase experiment an intravenous (iv) injection of tadalafil 10 mg/kg was given 20 min after 
the start of PET acquisition. Tadalafil solution for injection was prepared in such a way that 
the final concentration was 1 mg/mL in 10 % dimethylsulfoxide in 40 % (2-hydroxypropyl)-
β-cyclodextrin solution and it was filtered through a 0.22 μm membrane filter.  
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4.5.2. MicroPET imaging of MCT induced pulmonary arterial hypertension rat model 
For microPET imaging, 6 Wistar rats (KU Leuven Animalium) less than 8 weeks old at the 
start of the experiment were used. All animals underwent a baseline microPET scan and were 
treated with monocrotaline (MCT) following a baseline scan. For this, 200 mg of MCT was 
dissolved in 3.3 mL of 1 M HCl and the solution was neutralized with 6.6 mL of 0.5 M NaOH 
in order to obtain a 20 mg/mL MCT solution (2 % MCT solution). MCT 75 mg/kg was 
injected intraperitoneally to induce PAH in three rats (6, 23, 25). Consecutive microPET 
scans of the MCT treated rats were performed on average on a weekly basis for several 
weeks. The weight of the rats was monitored throughout the experimental period. 
4.6. PET-Ct studies in pig 
Imaging experiments were performed on a PET scanner (Concorde Microsystems, HiRez 
Biograph 16, Siemens, Knoxville, USA). A 90-min ECG-gated PET scan was acquired in list 
mode. A low-dose CT scan was conducted for attenuation correction. A domestic pig (N = 1), 
weighing 40 kg was pre-anesthetized with an intramuscular injection of 8 mg/kg 
tiletamine/zolazepam (Zoletil 100®, Virbac) and 2.5 mg/kg xylazine hydrochloride (Xyl-M 
2%®, VMD). Continuation of anaesthesia was performed using a continuous infusion of 
propofol (10 mg/kg/h)(Diprivan 2%®, Astra Zeneca) and remifentanil (0.3 
μg/kg/min)(Ultiva®, GSK). After intubation, pig was ventilated with a 1:1 mixture of air and 
oxygen. Denudation of the carotid artery was performed and an 8 F sheet was introduced, 
after which pig was anticoagulated with an initial bolus of 10,000 IU unfractionated heparin 
(Heparine LEO®, Leo). Continuous ECG and invasive blood pressure monitoring was 
registered during the whole procedure. Regular blood gas analyses were performed in order to 
optimize the ventilatory settings.  
Statistics 
All calculated results are expressed as mean ± standard deviation (SD). For comparison the 
Student’s t-test was used and p < 0.05 was considered statistically significant.   
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Chapter III – Supporting Information 
Biodistribution study in Bl6 mice, PDE5 TG mice and PDE5 TG mice pre-
treated with PDE5 specific inhibitors 
Table 1. Biodstribution of [11C]NMVardenafil at 30 min post injection in wild type (Bl6) mice, PDE5 
TG mice and pre-treated PDE5 TG mice. N = 3 for each group. 
Control group (% ID±SD) PDE5 TG Pre-treated (% ID±SD) 
Bl6 mice PDE5 TG mice NMVardenafil pre-treated Tadalafil pre-treated
urine 0.1±0.1 1.1±0.9 1.6±0.1 1.4±1.2
kidneys 6.3±0.7 2.6±0.5 2.4±0.2 2.7±0.7
liver 17.7±3.7 16.0±3.4 18.6±0.8 16.8±2.0
spleen 0.7±0.2 0.5±0.1 0.4±0.1 0.4±0.1
pancreas 1.7±0.3 1.1±0.2 0.8±0.3 0.7±0.1
lungs 8.1±0.7 2.8±0.5 0.8±0.4 1.1±0.2
heart 1.1±0.1 6.1±1.1 2.9±0.4 2.5±0.5
intestines 11.5±1.7 30.7±4.9 32.3±1.9 30.0±2.7
stomach 1.9±0.6 2.4±0.3 1.9±0.4 3.3±0.4
cerebrum 0.1±0.0 0.3±0.0 0.3±0.0 0.3±0.0
cerebellum 0.0±0.0 0.1±0.0 0.1±0.0 0.1±0.0
blood 6.9±0.2 4.4±0.9 3.7±0.1 4.7±0.6
muscle 44.8±6.0 16.8±1.8 17.8±1.8 19.2±3.9
penis 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0
Pre-treatment: NMVardenafil or tadalafil, 10 mg/kg, sc, 60 min prior to tracer administration in both 
cases; % ID: percent injected dose; SD:standard deviation. 
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Table 2. Standardized uptake at 30 min pi in Bl6 and PDE5 TG mice and PDE5 TG mice pre-treated 
with NMVardenafil or tadalafil (average±SD, N = 3). 
Control group (SUVW±SD) PDE5 TG Pre-treated (SUVW±SD) 
Bl6 mice PDE5 TG mice NMVardenafil pre-treated tadalafil pre-treated
kidneys 5.1±0.7 2.0±0.4 1.8±0.2 1.8±0.3
liver 3.8±0.9 4.1±0.6 4.4±0.3 4.7±0.2
spleen 3.0±0.9 2.0±0.3 1.9±0.3 1.7±0.3
Pancreas 2.6±0.4 1.7±0.1 1.8±0.3 1.4±0.2
lungs 10.2±2.3 4.4±1.1 1.2±0.1 1.3±0.1
heart 2.3±0.1 12.8±2.5 6.5±1.6 6.3±1.4
intestines 1.5±0.2 3.8±0.6 3.8±0.1 4.3±0.4
stomach 1.3±0.4 2.4±0.2 1.2±0.3 2.5±0.8
Cerebrum 0.1±0.0 0.3±0.0 0.2±0.0 0.4±0.0
cerebellum 0.1±0.0 0.2±0.0 0.2±0.0 0.4±0.0
blood 0.4±0.3 0.2±0.1 0.1±0.1 0.1±0.0
Muscle 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Penis 0.6±0.2 0.8±0.2 0.6±0.0 0.8±0.1
Pre-treatment: NMVardenafil or tadalafil, 10 mg/kg, sc, 60 min prior tracer administration in both 
cases; SUVW: Standardized uptake based on weight. 
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Figure 1. Chemical purity determination of the precusor solution for radiolabeling of [11C]7.  
Column: XTerra C18 5 µm, 4.6 x100 mm 
Detection UV: 254 nm, Flow rate: 1 ml/min 
Mobile phase: Isocratic:  mixture of hydrogenmonophosphate buffer and ACN (70:30 v/v)  
Integration UV1 
Substance Retention time 
(min) 
Area (C/S*s) % Area 
Reg #1 1.48 254.54 1.98 
Reg #2 5.65 12575.57 98.02 
Sum in ROI  12830.11  
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Figure 2. Chemical purity determination of the reference compound 7 (NMVardenafil).  
QC of NMVardenafil formulation (250 µg/ml in DMSO) 
Injection volume: 20 µl 
Column   XTerra C18 5 µm, 4.6x100 mm 
Detection UV: 254 nm; Flow rate: 1 ml/min 
Mobile phase: Isocratic: A mixture of 0.01M Na2HPO4 (pH 9) and ACN (70:30 v/v)       
Integration UV1 
Substance Retention time 
(min) 
Area (C/S*s) % Area 
Reg #1 2.35 25.455 0.73 
Reg #2 5.12 7.932 0.23 
Reg #3 8.33 3464.756 99.05 
Sum in ROI  3498.144  
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Figure 3. Radio-chromatogram of mouse plasma analysis 2 min post [11C]NMVardenafil injection 
spiked with cold NMVardenafil.Mouse was injected with 7.5 MBq of [11C]NMVardenafil. Recovered 
activity after HPLC run was more than 84 % 
Integration ChA (Radiosignal) 
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(min) 
Area (C/S*s) % Area 
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Figure 4. Radio-chromatogram of mouse plasma analysis 30 min post [11C]NMVardenafil injection 
spiked with cold NMVardenafil Mouse was injected with 7.5 MBq of [11C]NMVardenafil. Recovered 
activity after HPLC run was more than 80 % 
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Abstract 
Introduction: The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 
5 (PDE5) plays an important role in various pathologies including pulmonary arterial 
hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or 
prognostic target; however, there is currently no method available to non-invasively assess 
PDE5 expression and occupancy levels in vivo. The purpose of this study was to evaluate 
pyridopyrazinone derivatives as PDE5 specific PET tracers. 
Methods: Radiolabeled tracers were prepared by N-alkylation of the amine precursor with 
[11C]methyl trifluoromethanesulfonate or [18F]F- substitution of a tosylate precursor to yield 
[11C]12 ([11C])RPP07B and [18F]17 ([18F]FRPP07), respectively. Biodistribution studies, 
autoradiography and in vivo small animal PET scanning were performed to determine the 
distribution and specificity of the tracers for PDE5.   
Results: Biodistribution studies of both tracers in control mice revealed the highest uptake in 
the lungs whereas very strong uptake was observed in the myocardium of transgenic mice 
with cardiomyocyte-specific PDE5 over-expression at 30 min post-injection. Binding 
specificity in vivo was demonstrated by a blocking study in which mice were pre-treated with 
a structurally unrelated PDE5 inhibitor (tadalafil). Dynamic microPET images in rats revealed 
that both tracers show relatively homogenous brain distribution; however in vitro 
autoradiography could not demonstrate specific binding to PDE5 in brain tissue. 
Conclusion: [11C]12 and [18F]17 were successfully synthesized and showed specific binding 
to PDE5. Both tracers are promising for in vivo visualization of PDE5, but microPET studies 
showed that [18F]17 appears to be superior with respect to its kinetics.  Both compounds are 
highly brain penetrant but retention in brain is a PDE5 independent process. 
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1. Introduction 
Phosphodiesterase type 5 (PDE5) is a member of the phosphodiesterase superfamily that 
specifically catalyzes and metabolically inactivates the second messenger cyclic guanosine 
monophosphate (cGMP). PDE5 is expressed in vascular smooth muscle cells, lungs, platelets, 
corpus cavernosum and Purkinje fibers in the cerebellum. PDE5 exerts potent effects on 
vascular tone in the corpus cavernosum and pulmonary vasculature and plays an important 
role in platelet aggregation, handling of sodium secretion in renal cells and apoptosis.1,2 PDE5 
is also implicated in a number of diseases including pulmonary arterial hypertension (PAH), 
ischemic and dilated cardiomyopathy.2,3-8 Expression of PDE5 in the human brain is still a 
subject of debate; nonetheless, there is a general consensus that PDE5 is expressed in the 
cerebellum (Purkinje cells) and in the hippocampal interneurons (in a scattered manner) of 
rodents. The cGMP-PDE5 signaling pathway in rodent brain is considered to play a role in 
early memory consolidation stages of object information, neuronal excitability, synaptic 
plasticity and neurogenesis.9,10  
Currently four PDE5 inhibitors (sildenafil, vardenafil, tadalafil and avanafil) have been 
approved for treating male erectile dysfunction and some of them are approved for PAH.11-13 
A number of authors also advocate the use of PDE5 inhibitors in cardiovascular diseases 
including heart failure and myocardial infarction since up-regulation of PDE5 in the 
myocardium has been observed in these conditions.4,5,14-19 In addition to aforementioned 
clinical indications, PDE5 inhibitors were also shown to improve early memory consolidation 
of object information in rodents and to improve functional recovery after stroke in rats.20,21 
However, it remains to be determined whether the distribution and physiological role of PDE5 
in the human brain is similar to that observed in rodents. Based on preclinical evidence, there 
might be a role for PDE5 inhibitors to improve functional recovery after stroke in patients but 
further investigation is needed.4,19,20  
Despite the involvement of PDE5 in several disorders and the success of PDE5 inhibitors in 
clinical practice, there is currently no method to non-invasively evaluate PDE5 expression and 
occupancy levels in vivo. Therefore, development of specific PDE5 PET radioligands would 
allow to quantify and evaluate changes in PDE5 expression, identify patients that would 
benefit from PDE5 inhibitors early during disease progression and assess PDE5 occupancy 
and optimize dose regimens in patients treated with PDE5 inhibitors.  
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In recent years, several attempts have been made to develop radioligands targeting PDEs with 
variable success.22 Jacobsen et al described the development of a PET radioligand, [11C]RAL-
01, for in vivo visualization of PDE5 though PDE5-specific binding could not be 
demonstrated.23 Our group also published a preliminary biological evaluation of a number of 
radiolabeled tracers targeting PDE5.24 In this article, [11C]-7 ([11C]NMVardenafil) was shown 
to be a selective and specific radiotracer with 87 % inhibitable PDE5 binding in the lungs of 
NMRI mice. However, none of the tracers were shown to have any significant retention in the 
brain.  
Here, we discuss the synthesis, radiolabeling and preliminary biological evaluation of 
derivatives of a novel PDE5 inhibitor, 3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-
methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one (PF-5), reported in 
literature, as potential radioligands for in vivo visualization of PDE5.25 
2.  Results and discussion 
2.1. Organic synthesis 
14 (RPP07) was first reported in 2010 by Hughes et al as a selective and brain penetrant 
PDE5 inhibitor.25 Compounds 10 and 18 were also among a series of PDE5 inhibitors 
reported by the same group and we developed two close derivatives of 14 as potential PET 
radioligands (scheme 1) for in vivo visualization of PDE5.   
Compounds 12 and 17 are close analogues of 14 in which the 2-hydroxyethyl substituent on 
the piperazine ring of 14 was replaced by methyl and 2-fluoroethyl in 12 and 17, respectively.  
Compounds 2 to 6 were prepared starting from commercially available 1 according to 
literature.25 Treatment of the dione (6) with thionyl chloride and DMF at reflux for 16 h 
yielded chloroimidate 7 (59 % yield).26 Reaction of 7 with tert-butyl piperazine-1-carboxylate 
or 2-(piperazin-1-yl)ethanol followed by standard Suzuki coupling with 6-methoxypyridin-3-
ylboronic acid resulted in 9 and 14, respectively with good overall yield (60 %). Standard 
deprotection of 9 with TFA and tosylation of 14 with tosyl chloride in the presence of 
triethylamine and trimethylammonium chloride27 furnished precursors 10 and 15 for 
radiolabeling with carbon-11 and fluorine-18, respectively. The standard non-radioactive 
references 12 (RPP07B) and 17 (FRPP07) were prepared by reacting the chloroimidate (7) 
with 1-methylpiperazine or 1-(2-fluoroethyl)piperazine followed by Suzuki coupling with 6-
methoxypyridin-3-ylboronic acid.  
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A detailed description of the synthesis of all compounds, 1H-NMR and HRMS data for 
intermediates, precursors and non-radioactive standard reference compounds is provided in 
supporting information. 
 
Scheme 1. Organic synthesis of pyridopyrazinone derivatives 10 and 15 (precursors) and 12 and 17 
(references). Reactions conditions: (a) 1,4-dioxane, (Boc)2O, 27 h, reflux; (b) TMEDA, n-BuLi, Et2O,-
60 → -10 ○C, 2 h; then N-fluorobenzenesulfonimide (NFSI), THF -60 → 0 ○C, 1 h, 58 %; (c) 2-
propoxyethanamine, EtOH, reflux, 22 h, 70 %; (d) 4 M HCl, 1,4-dioxane, room temp, 16 h, 87 %; (e) 
MeOC(O)C(O)Cl, i-Pr2NEt, CH2Cl2, 0 ○C  → room temp, 4 h; then PhMe, 105 ○C; (f) PhMe, SOCl2, 
DMF, 130 ○C, 59 % (for steps e and f); (g) tert-butyl piperazine-1-carboxylate, Et3N, THF, room temp, 
4 h, 83 %; (h) 6-methoxypyridin-3-ylboronic acid, (Ph3P)4Pd (0), Na2CO3, 1,4-dioxane-EtOH, reflux, 16 
h, 61 %; (i) TFA, CH2Cl2, 0 ○C → room temp, 16 h, 60 %; (j) same as (g) except 1-methylpiperazine, 
78 %; (k) same as (h), 65 %; (l) same as (g) except 1-(2-hydroxyethyl)piperazine, 71 %; (m) same as 
(h), 59 %; (n) (Et)3N, (Me)3N.HCl, CH2Cl2, 4-methylbenzene-1-sulfonyl chloride, 0 ○C → room temp, 16 
h, 38 %; (o) same as (g) except 1-(2-fluoroethyl)piperazine, 69 %; (p) same as (h), 50 %. 
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2.2. In vitro PDE5 inhibitory activity assay 
In vitro PDE5 inhibitory activity (IC50) was determined for 10, 12, 14 and 17. Their IC50 
values for selected families of phosphodiesterases (PDE5, PDE6 and PDE11) are given in 
table 1. IC50 values for all other PDE families are given in supporting information-table 1.  
The pyridopyrazinone derivatives (10, 14 and 18) were reported to have an IC50 of 3.28, 0.2, 
and 0.22 nM in vitro PDE5 inhibitory activities, respectively.25 In our assay 10, 12, 14 and 17 
were found to have a PDE5 inhibitory activity in the lower nanomolar range. However, in our 
assay the inhibitors (10, 12, and 14) showed a lower in vitro PDE5 inhibitory activity than 
previously reported.24  
Table 1.  aIC50 (nM) values of PDE5 inhibitors for selected PDE families 
Compounds hPDE5A3 hPDE6AB hPDE11A4 
10 16 ND ND 
10b 3.28 167.28 8068
12 6.60 3170 2100
14 1.95 1600 800
14b 0.20 31.60 492
17 6.45 ND ND
18b 0.22 43.56 1082.40 
aIC50 values are averages of duplicates; breported IC50 values for selected PDEs without subtype 
specification (Hughes et al25);  ND: Not determined. 
2.3. Radiosynthesis 
Radiolabeling with carbon-11 was achieved by one-step N-alkylation of 0.5 mg of the amine 
precursor (10) in anhydrous DMSO with [11C]methyl trifluoromethanesulfonate 
([11C]CH3OTf) in the presence of base (Cs2CO3) and the reaction mixture was heated at 90 °C 
for 2 min (scheme 2). Radiolabeling with fluorine-18 was achieved by [18F]F- substitution for 
tosylate of 15 (0.5 mg in DMSO, scheme 2) and the reaction mixtures were heated at 90 °C 
for 15 min. The crude reaction mixtures were purified by HPLC in both cases. The overall 
radiosynthesis, HPLC purification, sterile filtration and radiotracer formulation were 
completed in 50 to 60 min from end of bombardment.  
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The incorporation yield (non-decay corrected radiochemical yield/RCY, based on HPLC 
recovered activity) was 20 % and 31 % for [11C]12 and [18F]17, respectively, and the 
radiochemical purity after HPLC-purification was greater than 99 % for both compounds 
(table 2 and supporting information-table 2). Chemical and radiochemical purity of more than 
95 % was accepted. 
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Scheme 2. Radiolabeling of [11C]12 and [18F]17  
The identity of the labeled compounds was confirmed by co-injection of the corresponding 
standard non-radioactive reference analogues (12 and 17) on HPLC (supporting information-
figure 2). The specific activities were determined after HPLC purification and were found 67 
GBq/µmol for [11C]12 and 91 GBq/µmol for [18F]17 (table 2) at the time of tracers 
formulation (detailed description of determination of specific activity can be found in the 
supporting information for Chapter II). 
Table 2. Results of radiochemistry, logD and PSA values of [11C]12 and [18F]17. 
Radioligand RCY (%) Purity (%)  aSA  blogD cPSA  
[11C]12 20±13 (n = 11) > 99 67 1.29 85.6 
[18F]17 31±2 (n = 4) > 99 91 1.69 85.6 
Purity determined by RP-HPLC; aSA (specific activity in gigabecquerel per micromole; GBq/µmol), blogD 
at pH 7.4 generated with MarvinSketch 5.5.0.1 software (ChemAxon Ltd), cPSA (polar surface area in Å2) is 
software generated  (Molinspiration Cheminformatics, 2011).  
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2.4. Biodistribution Studies 
2.4.1. Biodistribution in NMRI mice 
The pyridopyrazinone derivatives ([11C]12 and [18F]17) were initially evaluated by assessing 
their uptake and retention in the lungs of NMRI mice (N = 4) because abundant expression of 
PDE5 in the lungs among different species has been reported by several authors.1,11,27-29 
Hence, it was expected that a tracer with high affinity for PDE5 would show high uptake and 
retention in the lungs. Both tracers were also evaluated in transgenic mice with myocardiocyte 
specific PDE5 over-expression (PDE5 TG, N = 3) in which a significant myocardial retention 
was expected.  The specificity of the binding of the tracers to PDE5 both in the lungs of 
control mice and myocardium of PDE5 TG mice was challenged by pre-blocking studies 
where mice were pre-treated with tadalafil (a structurally unrelated competitive PDE5 
inhibitor)30 prior to tracers administration. In the pre-treatment group, significant reductions in 
the retention of the tracers in the lungs of control mice and myocardium of PDE5 TG mice 
were expected if binding of tracers was PDE5 specific.  
Results of biodistribution experiments with both radiotracers were expressed as percentage of 
injected dose (% ID) and as standardized uptake value based on weight (SUVW, obtained by 
normalizing the % ID for the animal’s body weight and the weight of organ of interest). Both 
[11C]12 and [18F]17 showed initial distribution to the major organs including kidneys, liver, 
and lungs (supporting information-tables 3 and 4). The urinary excretion of both tracers was 
negligible during the first 30 min post injection (pi) but the uptake and retention in the 
kidneys for [11C]12 was almost twice that of [18F]17 (supporting information-table 3). Despite 
this difference in kidney retention, the urinary excretion of both tracers was similar up to 30 
min pi. However, microPET imaging showed accumulation of [11C]12 in the bladder. 
The lung uptake and retention of [11C]12 and [18F]17 was relatively high at 30 min pi for both 
tracers and also remained high at 60 min pi for [18F]17 (supporting information-table 3). The 
relative concentration of [11C]12 and [18F]17 in the lungs was the highest at all studied time 
points (supporting information-table 4). The initial uptake of [11C]12 in the lungs was high but 
declined fast and at 30 min pi, only 20 % of the % ID at 2 min pi was retained whereas at 30 
min pi 30 % of the % ID at 2 min pi was retained for [18F]17. This could be due to a higher 
binding affinity of [18F]17 for PDE5 than [11C]12 in the lungs or a slower clearance of [18F]17 
from plasma. However, plasma radiometabolite analysis showed a faster metabolism and 
consequently faster clearance for [18F]17 than for [11C]12 (table 3). Nevertheless, both 
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radiotracers showed a relatively rapid decline of the activity in the lungs at 10 min compared 
to 2 min: 66 % and 47 % reduction for [11C]12 and  [18F]17, respectively (supporting 
information-tables 3 and 4). This relatively fast decline in retention, compared to another 
tracer [11C]7 that was evaluated by our group (which showed a 28 % and 27 % reduction at 10 
min and 30 min compared to 2 min pi, respectively and an increase in lung-to-blood activity 
ratio),24 might be due to faster dissociation kinetic properties of the tracers or extensive 
metabolism. The latter is supported at least in the case of [18F]17 by the fact that only 7 % of 
the activity in plasma at 30 min pi was due to the intact radiotracer (table 3). 
 
Figure 1. Biodistribution results of [11C]12 in NMRI mice (NMRI, N = 4), pre-treated [NMRI (Pt, N = 4)], 
PDE5 TG mice (N = 3) and pre-blocking (PDE5 TG (Pt), N = 3] at 30 min pi. Pre-treatment was with 
tadalafil, 10 mg/kg, sc, 60 min prior to tracer administration. % ID: percentage injected dose. *(p < 
0.01); **(p < 0.001); ***(p < 0.0001).  
The high lung-to-blood SUVW (19) at 30 min pi for [11C]12 in NMRI mice is in agreement 
with reports in the literature that PDE5 is abundantly expressed in lungs (supporting 
information-table 4). Although [18F]17 showed relatively high lung-to-blood ratio of 4 at 30 
min pi in NMrI mice, it was almost one-fifth of [11C]12's lung-to-blood ratio (supporting 
information-table 4). This was due to the relative high blood SUVW value of [18F]17 
(0.8±0.1), four-fold compared to that of [11C]12 (0.2±0.0), and mild reduction in lung 
retention of [18F]17 (3.8±1.1 vs 2.8±1.0 SUVW for [11C]12 and [18F]17, respectively, 
supporting information-table 4) at 30 min pi. The relatively high blood % ID for [18F]17 both 
in the control and PDE5 TG mice (figure 2) could be due to metabolism. This caused a 
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concern as the activity measured in the lungs of mice injected with [18F]17 could be 
radioactive metabolites in the lung vasculature and this was assessed by pre-blocking study 
(section on pre-blocking).   
 
Figure 2. Biodistribution results of [11C]17 in NMRI mice (NMRI, N = 4), pre-treated [NMRI (Pt, N = 4)], 
PDE5 TG mice (N = 3) and pre-blocking (PDE5 TG (Pt), N = 3) at 30 min pi. Pre-treatment was with 
tadalafil, 10 mg/kg, sc, 60 min prior to tracer administration. % ID: percent injected dose.). **(p < 
0.001); ***(p < 0.0001). 
Both tracers were cleared from plasma mainly via the hepatobiliary pathway and showed 
progressive accumulation in the intestines as a function of time (supporting information-tables 
3 and 4). Myocardial uptake and retention of both tracers were very limited which was 
expected based on the low expression levels of PDE5 in healthy myocardium. Interestingly, 
unlike for most radiolabeled PDE5 tracers we have evaluated so far23 uptake of [11C]12 and 
[18F]17 in the brain was relatively high. Retention in the cerebrum and cerebellum was higher 
for [11C]12 (4.0±0.9 and 1.5±0.1 SUVWs at 2 and 30 min pi, respectively) than for [18F]17 
(2.4±0.3 and 0.9±0.1 SUVWs at 2 and 30 min pi, respectively).   
One of the main clinical applications of PDE5 inhibitors is treatment of male erectile 
dysfunction where PDE5 inhibitors are used to inhibit cGMP degradation and maintain penile 
tumescence. Despite this fact, the maximum observed SUVW in the penis for both tracers was 
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relatively low (SUVW < 0.9, supporting information-table 4). This is not surprising since the 
expression of PDE5 in lung tissue is significantly higher than in the penis.10,11,28,29   
2.4.2. Biodistribution in PDE5 TG mice 
A biodistribution study in transgenic mice (N = 3), characterized by an up to 10-fold increase 
in PDE5 protein expression in the myocardiocyte and a 10-fold increase in sildenafil-
inhibitable cGMP hydrolysis compared to wild type littermates, was performed at 30 min pi.  
Myocardial uptake in PDE5 TG mice was almost 10-fold and 16-fold higher (% ID) for 
[11C]12 and [18F]17, respectively compared to control mice (figures 1 and 2). This strengthens 
our initial claim that retention of both radiotracers in the lungs was PDE5-specific. Despite 
lower retention/uptake of [18F]17 than [11C]12 in lungs of control mice, evaluation of [18F]17 
in PDE5 TG showed a two-fold (% ID) and three-fold (SUVW) higher uptake in the 
myocardium than [11C]12 at 30 min pi. In contrast, SUVW values in lung tissue of PDE5 TG 
mice for [11C]12 and [18F]17 were almost 50 % (p < 0.05) and 24 % (p = 0.09) lower, 
respectively compared to the control mice.  This might be explained by the ‘‘stealing effect’’ 
of the myocardium and lower availability of circulating tracer. 
In PDE5 TG mice, [18F]17 showed high blood concentration at 30 min pi (5.8±0.4 % ID, 
supporting information-table 5). The contribution of the radioactivity in the blood to 
myocardial retention and the specific binding of [18F]17 to PDE5 was assessed by pre-treating 
PDE5 TG mice with tadalafil.  
2.5. Blocking study in control and PDE5 TG mice 
The specific binding of [11C]12 and [18F]17 to PDE5 in the lungs of NMRI mice (N = 4) and 
myocardium of PDE5 TG mice (N = 3) was assessed by a pre-blocking biodistribution study 
where mice were pre-treated with tadalafil 10 mg/kg, sc, 60 min prior to tracer administration. 
The results showed that there was a mild (32 %, p < 0.05) and marked (70 %, p < 0.001) 
reduction in % ID in the lungs of control mice for [11C]12 and [18F]17, respectively 
(supporting information-table 5). However, the SUVW values of [11C]12 in the lungs of non-
treated and pre-treated NMRI mice showed no significant difference. This could be partly due 
to the significantly different (p < 0.01) average body weights between the two group 29.8±1.8 
g and 35.7±1.5 g for non-treated and pre-treated groups, respectively. 31 
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The myocardium of the PDE5 TG mice showed a marked 80 % (p < 0.001) and 87 % (p < 
0.0001) reduction in the retention of [11C]12 and [18F]17 based on % ID, respectively. The 
reduction in the retention of the tracers in the lungs of PDE5 TG mice was mild and 16 % and 
30 % of [11C]12 and [18F]17 were PDE5 specific inhibitable-binding (both not statistically 
significant), respectively. This could be explained by an already depleted inhibitable pool in 
the lungs of PDE5 TG mice by the ‘‘stealing effect’’ of the myocardium. The blocking study 
both in the control and PDE5 TG mice showed that despite the high lung-to-blood ratio 
observed for [18F]17, more than 70 % of the activity in the lungs of control mice and 87 % in 
the myocardium of PDE5 TG mice were PDE5-specific inhibitable binding. 
2.6. Plasma and brain radiometabolite analysis   
Plasma and brain extracts were analyzed with HPLC to quantify the fraction of 
radiometabolites of [11C]12 and [18F]17 at 2 and 30 min pi (tables 3 and 4). At 2 min pi more 
than 94 % and 71 % of the activity recovered in the plasma were in the form of [11C]12 and 
[18F]17 respectively. However, at 30 min pi only 30 % of the activity recovered in the plasma 
was in the form of intact [11C]12. Despite structural similarity between the two radiotracers, 
[18F]17 showed extensive metabolism and less than 7 % of activity in the plasma was in the 
form of intact radiotracer at 30 min pi. Defluorination of [18F]17 was not observed as this 
could have been reflected in the bone uptake. In addition, microPET imaging of [18F]17 did 
show any significant bone uptake (figure 6).  
Table 3. Plasma radiometabolite analysis of [11C]12 and [18F]17 in mice.  
 [11C]12 (%±SD) [18F]17 (%±SD) 
 2 min (n = 2) 30 min (n = 3) 2 min (n = 2) 30 min (n = 3) 
Intact tracer 92.9 - 90.4 32 - 29.5  71.4 - 68.8 7.1 - 5.4 
 
Apparently, the polar radiometabolites detected in the plasma did not cross the blood brain 
barrier to any significant level for both radiolabeled molecules at 2 and 30 min pi as most of 
the activity in the brain was in the form of intact tracer (table 4). None of the tracers 
underwent major metabolism in the brain since the relative percentage of activity in the form 
of metabolite(s) was < 10 % for both tracers (supporting information figure 3). 
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Table 4. Brain radiometabolite analysis of [11C]12 and [18F]17 in mice expressed as percentage. 
 [11C]12 (%) [18F]17 (%) 
 2 min (n = 2) 30 min (n = 2) 2 min (n = 2) 30 min (n = 2) 
Intact tracer 98.7 - 99.7  91.3 - 92.7  99.1 – 99.7 90.7 – 93.8 
2.7. MicroPET imaging 
2.7.1. Myocardial uptake 
In vivo tracer kinetics of [11C]12 and [18F]17 were studied in PDE5 TG mice and in rats. 
Binding specificity and reversibility of [11C]12 and [18F]17 was assessed in PDE5 TG mice by 
chasing and blocking experiments using the structurally unrelated PDE5 inhibitor tadalafil.30  
 
Figure 3. Time activity curves of the myocardium after IV injection of [11C]12 (7 MBq) in PDE5 TG 
mice (control), PDE5 TG mice pre-treated with tadalafil (10 mg/kg, sc, 60 min prior to tracer injection) 
and PDE5 TG mice chased with tadalafil (10 mg/kg, iv, 10 min after injection of tracer). SUVV: 
standardized uptake value based on volume.  
The baseline scan showed a significant uptake and retention in the myocardium for both 
tracers albeit with relatively fast kinetics particularly for [11C]12 (figures 3 and 5). [18F]17 
showed an almost 3-fold higher maximum SUVV value compared to [11C]12 (6.7 vs 2.3). 
Myocardial SUVV values for [18F]17 stayed within the range of 6.1 and 5.7 for 14 min (from 
1.5 to 15.5 min post tracer injection). It is likely that a transient equilibrium was reached 
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within this 14-minutes time window specifically between 3.5 and 9.5 min post tracer injection 
as the average concentration of [18F]17 remained at 6.7±0.2 SUVV in the six minutes window. 
However, [11C]12 showed rather fast kinetics and brief (transient) equilibrium between 2.5 
and 4.5 min where the concentration remained around 2.2±0.2 SUVV. In tadalafil pre-treated 
PDE5 TG mice the uptake was completely abolished in the myocardium for both tracers 
(figures 3 and 5). 
 
Figure 4. MicroPET images of PDE5 TG mice after injection of [11C]12 (7 MBq). Left: A summed 
image of dynamic microPET acquisition between 0 s and 660 s (60 s after tadalafil injection) in chase 
mouse.  Right: A summed image of dynamic microPET acquisition between 840 s and 1500 s in the 
same chase mouse.   
 
Figure 5.Time activity curves of the myocardium after IV injection of [18F]17 (7 MBq) in PDE5 TG mice 
(control); PDE5 TG mice pre-treated with tadalafil (10 mg/kg, sc, 60 min prior to tracer) and PDE5 TG 
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mice chased with tadalafil (10 mg/kg, iv, 10 min post tracer injection). SUVV: standardized uptake 
value based on volume. 
In the chase mice, the myocardium was clearly visible in the early summed images (figures 4 
and 6, left panel) but myocardial retention decreased very rapidly after tadalafil iv 
administration due to the displacement of tracers from myocardial regions by tadalafil (figures 
4 and 6, right panel). Tracer displacement is also illustrated by the TAC curves of the chase 
experiment (green triangles) showing a marked decline immediately after tadalafil 
administration (figures 3 and 5). These microPET studies demonstrated that both [11C]12 and 
[18F]17 have high in vivo affinity and specificity for PDE5 and bind reversibly to this enzyme. 
However, [18F]17 appears superior in that the ratio of the TAC of base line scan to pre-
treamnet scan is higher than that of [11C]12 (supporting information-figure 2). 
 
Figure 6. MicroPET images in PDE5 TG mice after injection of [18F]17 (7 MBq):  Left: A summed 
image of dynamic microPET acquisition between 0 s and 660 s (60 s after tadalafil injection) in chase 
mouse.  Right: A summed image of dynamic microPET acquisition between 840 s and 1500 s in the 
same chase mouse. 
2.7.2. Brain uptake 
Dynamic microPET imaging was also performed in Wistar rats to evaluate the kinetics and 
binding properties of [11C]12 (figure 7)  and [18F]17 in the brain (figure 8). MicroPET images 
showed that both tracers crossed the blood brain barrier (BBB) and were retained in the brain 
with a relatively homogenous distribution. Nonetheless, in vivo binding specificity of [11C]12 
and [18F]17 in brain could not be demonstrated due to the unavailability of a structurally 
unrelated PDE5 inhibitor that crosses the BBB or brain specific PDE5 over-expressing  
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rat/mouse model. Despite this lack, a self-blocking study with cold 17 in rats showed no 
significant blocking (figures 7 and 8). In addition, in vitro autoradiography was performed in 
order to assess binding specificity of [11C]12 and [18F]17 to PDE5 in the brain by incubating 
both tracers with different PDE5 specific and non-specific inhibitors. 
  
Figure 7. Left: Time activity curves of different brain regions after IV injection of [11C]12 (37 MBq) in 
Wistar rats (N = 2). Right: Representative image of the brain after IV injection of [11C]12. 
  
Figure 8. Left: Time activity curves of different brain regions after IV injection of [18C]17 (37 MBq) in 
Wistar rats (N = 2); Ct: Control; Pt: Pre-treated (17, 10 mg/kg, sc, 60 min prior to tracer 
administration). Right: Representative image of the brain after IV injection of [18F]17. 
2.8. In vitro autoradiography 
Rat brain slices were used for in vitro autoradiography (figure 9). The slices were incubated 
with 370 kBq [11C]12 or [18F]17 alone or in the presence of different competitive PDE5 
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inhibitors (20 µM of each of NMVardenafil, tadalafil, 14, or 12, and 1 mM of 3-isobuty-1-
methylxanthin/IBMX). IBMX is a non-selective phosphodiesterase inhibitor with the 
exception of PDE8 and PDE9 with in vivo PDE inhibitory activity (IC50) ranging 2 µM from 
to 50 µM.32-35 
 
 370 kBq 
[11C]12  
7 tadalafil 14 12 IBMX  
210902 204542 193394 157283 121014 159634 DLU/mm2 
100 % 93 % 87 % 73 % 55 % 74 % % max reg. 
 
 
 370 kBq 
[18F]17 
7 tadalafil 14 17 IBMX  
215700 
DLU/mm2 
1980748 1746769 1293653 1336039 1840207 DLU/mm2 
100 % 88 % 83 % 62 % 65 % 87 % % max reg. 
Figure 9. Autoradiogram of rat brain slices incubated with [11C]12 (top) and [18F]17(bottom) in  the 
presence of different PDE inhibitors; DLU: Digital light unit; % max reg.:activity as percentage of 
maximum region (tracer only incubated slice as 100 % in both cases). 
Autoradiography with [11C]12 and [18F]17 revealed a uniform distribution of both tracers 
throughout the grey matter. The radioactivity concentration in the autoradiograms was 
expressed as digital light unit (DLU)/mm2. The maximum blocking of [11C]12 and [18F]17 
was observed in slices incubated with cold 12 or 17, respectively and to a lesser extent by 14 
and IBMX (figure 9). However, the PDE5 specific inhibitors (NMVardenafil24 and tadalafil30) 
did not significantly block binding of [11C]12 and [18F]17. Based on reported low levels and 
restricted expression of PDE5 in the cerebellum1,9,10,28, non-significant reduction in self-pre-
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treated rats (microPET), and lack of significant reduction of binding of both radiotracers in rat 
brain slices incubated with PDE5 specific inhibitors (autoradiography), it was concluded that 
in vitro binding and in vivo brain retention of [11C]12 and [18F]17 were not PDE5-specific. 
Further studies are warranted to determine the cellular binding site of [11C]12 and [18F]17 in 
brain. 
3. Conclusion 
We have successfully radiolabeled two close analogues of a pyridopyrazinone derivative (PF-
5); a compound which was initially reported as a brain penetrant PDE5 specific inhibitor. In 
vitro PDE5 inhibitory activity assay showed a higher IC50 value than reported. However, 
initial biological evaluation of [11C]12 and [18F]17 showed that both tracers have high and 
specific binding to PDE5 in the lungs of healthy mice where abundant expression of PDE5 
have been described. Their in vivo specific binding to PDE5 was established in PDE5 TG 
mice in which the myocardial uptake could significantly be blocked by pre-treating the mice 
with a structurally unrelated PDE5 specific inhibitor tadalafil. Our study could not 
substantiate reported binding specificity of the tracers to PDE5 in the brain as the self-
blocking study did not result in any significant reduction in brain uptake. Our preliminary 
biological evaluation confirmed the high affinity and binding specificity of [11C]12  and 
[18F]17 to PDE5 with the latter having higher affinity and specificity for PDE5. Therefore, 
[18F]17 can potentially be used to quantify and evaluate changes in PDE5 expression, select 
patients that would benefit from PDE5 inhibitor treatment early during disease progression 
and assess PDE5 occupancy and optimize dose regimens in patients treated with PDE5 
inhibitors. Nonetheless, further experiments in a clinically relevant animal model and humans 
are required to evaluate the suitability of these radiotracers for the aforementioned 
applications. 
4. Experimental section 
4.1. Chemistry 
A detailed description of the synthesis of all compounds with their 1H-NMR and HRMS data 
for precursors and references is provided in the supporting information. 
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4.2. In vitro affinity assay 
Compounds 10, 12, 14 and 17 were dissolved in DMSO to a concentration of 5 mM. 
Compounds were profiled on the PDE assay platform, comprising members of each of the 11 
described PDE families.  
PDE1B1 and PDE11A4 were expressed in human embryonic kidney (HEK) cells from full-
length human recombinant clones. Human recombinant phosphodiesterases 2A, 4D3, 5A3, 
7A1, 9A1, 10A2 were expressed in Sf9 cells, using a recombinant baculovirus construct 
containing the full length sequence with a 6xHis sequence following the start Met to allow 
metal affinity purification of the recombinant protein. Cells were harvested and the 
phosphodiesterase protein was purified by metal chelate chromatography on Ni-sepharose 
6FF (GE Healthcare).  PDE6AB, PDE3B and PDE8A were purchased as partially purified Sf9 
cell lysates (Scottish Biomedical, UK). All enzymes were diluted in a mixture containing 50 
mM Tris pH 7.8, 1.7 mM EGTA and  8.3 mM MgCl2, except for PDE9A that was diluted in a 
mixture of  50 mM Tris pH 7.8, 5 mM MnCl2. PDE1B was diluted in a mixture  of 50 mM 
Tris pH 7.8, 1.7 mM EGTA, 8.3 mM MgCl2 complemented with 624 U/ml calmodulin and 
800 µM CaCl2. The affinity of the compounds for the PDEs was measured by a scintillation 
proximity assay (SPA).  
PDE yttrium silicate SPA beads allow PDE activity to be measured by direct binding of the 
primary phosphate groups of non-cyclic AMP or GMP to the beads via a complex iron 
chelation mechanism. The amount of bound tritiated product ([3H]-AMP or [3H]-GMP) is 
measured by liquid scintillation counting in a TopCountTM instrument (Perkin Elmer).  
The compounds were dissolved in DMSO in polystyrene plates to a concentration of 100-fold 
of the final concentration in the assay. Human recombinant PDE5A3 enzyme solution (10 µl) 
was added to 20 µl of incubation buffer (50 mM Tris pH 7.8, 8.3 mM MgCl2, 1.7 mM 
EGTA), 10 µl substrate solution consisting of a mixture of non-tritiated and tritiated substrate 
(final concentration 1 µM cGMP, 370 Bq/0.01 µCi 3H-cGMP), and 0.4 µl compound in 
DMSO in a 384-well plate, and the mixture was incubated for 30 min at room temperature. 
After incubation, the reaction was stopped with 20 µL of stop solution, consisting of PDE 
SPA beads (17.8 mg beads/ml in 200 mM zinc chloride). To measure the blank value, the 
enzyme was omitted from the reaction mixture. After sedimentation of the beads for 30 min, 
the radioactivity was measured in a PerkinElmer TopCount scintillation counter and results 
were expressed as counts per minute (cpm). The same assay principle was applied for the 
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measurement of the inhibition of other members of the PDE family, with appropriate 
modifications of enzyme concentration, incubation buffer, substrate solution, incubation time 
and stop solution. Each experiment was performed in duplicate. 
Data were calculated as the percentage of inhibition of total activity measured in the absence 
of test compound (% control). A best-fit curve was fitted by a minimum sum of squares 
method to the plot of percent control versus compound concentration, from which an IC50 
value (inhibitory concentration causing 50 % inhibition of hydrolysis) is obtained. 
4.3. Radiosynthesis 
Carbon-11 was produced in a Cyclone 18/9 cyclotron (IBA, Louvain-la-Neuve, Belgium) via 
an 14N(p,α)11C nuclear reaction. A mixture of N2 (95 %) with H2 (5 %) was irradiated with 
18-MeV protons for 30 min to get [11C]methane ([11C]CH4). [11C]CH4 was transferred to a 
home-built synthesis module to convert it to [11C]CH3I which was then converted to the more 
reactive [11C]methyl triflate ([11C]CH3OTf) by passing through a silver triflate column (150 x 
3 mm) heated at 180 oC.  
[11C]CH3OTf was streamed with helium through a solution of 250 - 500 μg precursor in 
DMSO. The reaction mixture was heated at 90 °C for 2 min, cooled and diluted with buffer. 
The crude reaction mixture was purified by HPLC (XBridge™ C18 column, 5μm, 4.6 mm x 
150 mm; Waters) using as the mobile phase a mixture of 0.05 M sodium acetate pH 5.5 (0.05 
M NaOAc pH 5.5) and ethanol (EtOH), 63:37 % v/v at a flow rate of 1 mL/min. The peak of 
interest was collected and analyzed for purity and identity for biological evaluation. For 
evaluation of the tracers in animals, the ethanol containing HPLC eluate was diluted with 
normal saline to a maximum concentration of 10 % ethanol and then sterile filtered through a 
0.22-μm membrane filter (Millipore Millex GV 13 mm). Chemical and radiochemical purity 
of tracers were assayed with HPLC (XTerra™ C18 column, 5 μm, 4.6 mm x 100 mm) eluted 
with a mixture of acetate buffer (0.05 M, pH 5.5) and acetonitrile (ACN), 70:30 v/v at a flow 
rate of 1 mL/min, UV detection at 254 nm. 
[18F]Fluoride (18F-) was produced in a Cyclone 18/9 cyclotron (IBA) via an 18O(p,n)18F 
nuclear reaction by bombarding oxygen-18 enriched water (H218O) with 18-MeV protons. 
[18F]F- was then passed through a preconditioned (by successive washing with 10 ml of 0.5 M 
K2CO3 solution and 10 mL of de-ionized water) anion exchange cartridge (SepPak Light 
Accell plus QMA, Waters) to get rid of the bulk of the H218O. The [18F]F- was then eluted 
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with a mixture of  24 mM K2CO3/98 mM Kryptofix 2.2.2® (4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]-hexacosane) in 750 µl of a mixture of ACN:water (95:5 v/v) into a 
reaction vial. Any remaining water was removed by azeotropic distillation with ACN. An 
amount of 250 - 500 μg of the tosyl precursor in DMSO was added to the [18F]F- containing 
vial and the mixture was heated at 90 oC for 15 min. The purification, formulation, sterile 
filtration, and quality control were done in similar conditions as for carbon-11 labeled 
compounds. 
4.4. Biological evaluation 
All animal experiments were conducted according to the Belgian code of practice for the care 
and use of animals, after approval from the Animal Ethics Committee, KU Leuven (Ethische 
Commissie Dierproeven, KU Leuven, License number: LA1210237).  
Biodistribution study 
For biodistribution studies adult NMRI mice (N = 4) and/or transgenic mice with 
cardiomyocyte specific PDE5 over-expression (PDE5 TG, N = 3), weighing 25 to 40 g were 
used. Animals were housed in individually ventilated cages in a thermo-regulated (22 °C), 
humidity-controlled facility under a 12 h/12 h light/dark cycle, with free access to food and 
water.  
Biodistribution studies of carbon-11 or fluorine-18 labeled tracers was performed in healthy 
NMRI mice at 2, 10, 30, and 60 min post injection (N = 4 animals/time point). The 
biodistribution study in PDE5 TG mice (N = 3) was performed at 30 min pi. Mice were 
anesthetized with 2.5 % isoflurane in oxygen at a flow rate of 1 L/min and 7 MBq of [11C]12 
or 740 KBq of [18F]17 was injected via a tail vein. The animals were sacrificed by 
decapitation at the specified time points. Blood and major organs were collected in tarred 
tubes and weighed. The radioactivity in blood and organs was counted using an automated γ-
counter and expressed as a percentage of injected dose (% ID) and standardized uptake value 
based on weight (SUVW) where initially the concentration in organ was expressed as activity 
(KBq) per gram (g) and then adjusted for body weight and total injected dose.. For the 
calculation of total radioactivity in blood, muscle and bone, weight of blood was assumed to 
be 7 %, bone to be 12 % and muscle to be 40 % of body weight. 
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Blocking study in control and PDE5 TG 
In order to assess the affinity and specificity of [11C]12 and [18F]17 for PDE5, a blocking 
study was performed in control and PDE5 TG mice.  In brief, mice were subcutaneously 
injected with tadalafil (TCR, Canada) 10 mg/kg, subcutaneous (sc), 60 min prior to tracer 
administration. Tadalafil solution for injection was prepared in such a way that the final 
concentration was 1 mg/mL in 10 % dimethylsulfoxide in 40 % (2-hydroxypropyl)-β-
cyclodextrin solution and sterile filtered through a 0.22 μm filter (Millex®-GV, Millipore, 
Ireland). Biodistribution study was then performed as described above and results were 
expressed as % ID and SUVW. 
4.5. Radiometabolites analysis 
4.5.1. Plasma radiometabolites analysis  
Radiometabolites of [11C]12 and [18F]17 in plasma of mice (N = 2) at 2 and 30 min pi were 
quantified. Mice were anesthetized with 2.5 % isoflurane in oxygen at a flow rate of 1 L/min 
and injected with 7.4 MBq [11C]12 or [18F]17 via a tail vein. The mice were decapitated at the 
desired time point, blood was collected into lithium heparin-containing tubes (4.5-mL lithium 
heparin PST tubes, BD Vacutainer; BD, Franklin Lakes, New Jersey) and stored on ice. After 
centrifugation (420 x g; 10 min) of the blood, plasma was separated and analyzed by RP-
HPLC on a Chromolith RP C18 column (3 mm × 100 mm; Merck) eluted with gradient 
mixtures of CH3CN (A) and 0.05 M NaOAc pH 5.5 (B) (0-4 min: isocratic 0 % A, 0.5
mL/min; 4-9 min: linear gradient 0 % A to 90 % A, 1 mL/min; 9-2 min: isocratic 90 % A, 1
mL/min; 12-15 min: linear gradient 90 % A to 0 % A, 0.5 mL/min). The non-radioactive 
reference compound 12 or 17 was co-injected to identify the peak of the intact parent tracer. 
The eluate from the UV detector was passed through a 3-in. NaI(Tl) scintillation detector, 
connected to a single channel analyzer. The eluate from the radiodetector was collected as 1-
mL fractions (model 2110 fraction collector, Biorad, Hercules, CA). The radioactivity in each 
fraction was measured using an automated gamma counter. 
4.5.2. Brain radiometabolites analysis 
Radiometabolites of [11C]12 or [18F]17 in brain of mice were quantified at 2 and 10 min after 
iv injection of the tracer (n=2 per time point). Mice were sacrificed by decapitation at the 
desired time point. Brain was isolated and homogenized in acetonitrile. The crude mixture 
was filtered through a syringe filter (0.2-µm nylon Acrodisc 13, Acrodisc Syringe Filters, 
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PALL Life Sciences). The filtrate was spiked with 5 μL of a 1 mg/mL solution of cold 12 or 
17 and analyzed on HPLC (Xbridge™ RP C18 5 μm column, 4.6 mm × 150 mm; UV 
detection at 254 nM, eluted with a mixture of ACN and 0.05 M NaOAc pH 5.5, 32:68 v/v, at 
a flow rate of 1 mL/min).  
4.6. Small-animal PET studies 
Dynamic microPET imaging experiments were performed on a Focus 220 microPET 
scanner (Concorde Microsystems) where male PDE5 TG mice were used as animal model. 
During scanning, animals were kept under gas anesthesia (2.5 % isoflurane in O2 at a flow 
rate of 1 L/min). Dynamic 90-min scans were acquired in list mode. Acquisition data were 
separated into 24 time frames (frame x time: 4 x 15 s, 4 x 60 s, 5 x 180 s, 8 x 300 s and 
3 x 600 s) and reconstructed with maximum a posteriori (MAP) estimation. Time-
activity curves (TAC) were generated for the myocardium region for each individual 
scan, using PMOD software (version 3.1; PMOD Technologies). The radioactivity 
concentration in the heart region was expressed as standardized uptake value based on volume 
(SUVV) where the concentration in organ was expressed initially as activity (KBq) per 
volume of interest (mL) and then adjusted for body weight and total injected dose..  
Base line imaging, blocking and chase experiments were performed in PDE5 TG mice. 
Tadalafil was used for pre-treatment and chase. Mice were injected with 7 MBq of 
formulation of [11C]12 or [18F]17 via a tail vein. For blocking studies mice were pretreated 
with 10 mg/kg tadalafil, subcutaneously, 60 min prior to tracer administration and for chase 
studies mice were given tadalafil 10 mg/kg, iv, 10 min after the start of PET acquisition. 
Tadalafil, which is a specific PDE5 inhibitor with subnanomolar IC50 value30, was prepared in 
such a way that the final concentration was 1 mg/ml in 10 % dimethylsulfoxide in 40 % (2-
hydroxypropyl)-β-cyclodextrin solution and the solution was sterile filtered via a 0.22-μm 
membrane filter.  
A baseline microPET imaging was also performed in two Wistar rats after iv injection of 
[11C]12 or [18F]17 to assess the tracers’ distribution in the brain. 
4.7. In vitro autoradiography 
Rat brain slices of 20 µm thick serial sections mounted on slides were used for in vitro 
autoradiography studies. Brain slices were incubated with 400 µL of 370 kBq/mL solution of 
[11C]12 or [18F]17 alone (control), or in the presence of 1 mM IBMX, 20 µM tadalafil, 20 µM 
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NMVardenafil24, 20 µM 14,  20 µM cold 12 or 17 for 30 min. Then, the slices were rinsed 
twice (2×5 min) with 50 mM Tris-HCl pH 7.4 containing 0.3 % BSA at 4 °C. After a quick 
dip in water at room temperature, the slices were dried. 
Autoradiograms were obtained by exposing the slices for 30 min to a high-performance 
phosphor screen (Canberra Packard, Meriden, CT, USA). The images were analyzed with 
Optiquant software (Canberra Packard) and the radioactivity concentration in the 
autoradiograms was expressed in digital light units (DLU) per square millimeters. 
4.8. Statistics 
All calculated results are expressed as mean ± standard deviation (SD). For comparison the 
Student’s t-test was used and p < 0.05 was considered statistically significant.   
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Chapter IV – Supporting Information 
Chemistry 
All final compounds (precursors and references) and intermediates were characterized by LC-
HRMS and 1H-NMR. 
1H-NMR spectra were recorded on a 400 MHz spectrometer (Bruker AVANCE). Deuterated 
chloroform (CDCl3) or deuterated methanol (MeOD) or deuterated dimethyl sufoxide 
(DMSO-d6) were used as solvent as indicated. Chemical shifts are reported in parts per 
million relative to tetramethylsilane (δ = 0). Coupling constants are reported in hertz (Hz). 
Splitting patterns are defined as follow: s (singlet), br s (broad singlet), d (doublet), q 
(quartet), dd (double doublet), t (triplet), dt (double triplet), or m (multiplet). 
The mass spectra were recorded on a Bruker maXis UHR-TOF mass spectrometer with LC–
MS, Dionex 3000RS UHPLC (maXis, Bruker-Daltonik, Bremen, Germany). 
High-performance liquid chromatography (HPLC) analysis was performed on a LaChrom 
Elite HPLC system (Hitachi) connected to a UV-spectrometer set at 220 nm. For the analysis 
of radiolabeled compounds, the HPLC eluate (after passage through the UV detector) was led 
over a 7.62-cm (3-in.) NaI(Tl) scintillation detector connected to a single-channel analyzer 
(GABI box; Raytest, Straubenhard, Germany). Quantification of radioactivity measurements 
in biodistribution studies was performed using an automated γ-counter equipped with a 7.62-
cm (3-in.) NaI(Tl) well crystal coupled to a multichannel analyzer (1480 Wizard; Wallac, 
Turku, Finland). The results were corrected for background radiation and decay during 
counting. All solvents and chemicals were obtained from commercial sources (Acros 
Organics, Aldrich or Fluka unless specified otherwise) and used as such without further 
purification. Purity of all final compounds (precursors and references) was ≥ 95 % and was 
determined by HPLC.  
(6-Chloro-pyridin-3-yl)-carbamic acid tert-butyl ester (2).  
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A solution of 6-Chloro-pyridin-3-ylamine (1, 15.7 g, 122.1 mmol, APOLLO Scientific 
Limited) and di-tert-butyldicarbonate (32.68 g, 148.8 mmol) in 1,4-dioxane (150 mL) was 
stirred at reflux for 20 hours. Additional di-tert-butyldicarbonate (5.0 g, 15.7 mmol) was 
added and the reaction was stirred at reflux for 7 hours. The reaction mixture was cooled and 
solvent evaporated at reduced pressure. The residue was re-dissolved in ethyl acetate (EtOAc) 
and poured into water. The layers were separated and the aqueous layer was extracted with 
ethyl acetate. The combined organic layers were washed with brine, dried over magnesium 
sulfate, and solvent was removed at reduced pressure to give brown oil. The residue was 
passed through a column of silica gel with 10 % EtOAc/heptane. 2 ((6-Chloro-pyridin-3-yl)-
carbamic acid tert-butyl ester was obtained as off white light powder. (24.7 g, 108 mmol, 88.5 
% yield). 1H NMR (MeOD, 400 MHz): δ 1.40 (s, 9H, Boc), 7.21 (d, 1H, J 8.7, Ar), 7.82 (d, 
1H, J 8.5, Ar), 8.28 (s, 1H, Ar). HRMS-ESI: calcd for C10H14ClN2O2+ 229.0738, found 
229.0731. 
(6-Chloro-4-fluoro-pyridin-3-yl)-carbamic acid tert-butyl ester (3). 
 
To a -63 °C solution of 2 (7.0 g, 30.6 mmol) and TMEDA (10.9 mL, 73.2 mmol) in diethyl 
ether (196 mL) under nitrogen was added a 1.6M n-butyl lithium solution in hexane (54 mL, 
87 mmol) over a period of 30 minutes while maintaining the temperature of the reaction 
between -60 °C to -50 °C. The reaction was stirred at -60 °C for an additional 10 minutes after 
the addition was complete then warmed to -10 °C and stirred at -25 ° to -10 °C for 2.0 hours. 
The reaction was cooled to -60 °C and a solution of N-fluorodibenzenesulfonimide (15 g, 47.6 
mmol) in THF (45 mL) was added while keeping the temperature below -50 °C. It 
precipitated on addition and stirring became difficult. The reaction was then allowed to slowly 
warm to 0 °C over 1 hour. The reaction was quenched with saturated ammonium chloride 
solution (112 mL). The layers were separated and the aqueous layer was extracted with ethyl 
acetate (2 x 50 mL). The combined organic layers were washed with brine, dried over 
MgSO4, and solvent was removed at reduced pressure to give an oily brown solid. The residue 
was passed through a column of silica gel with 5 % ethyl acetate/ heptane. 3 was obtained as a 
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yellow solid. (4.44 g, 18 mmol, 58 % yield). 1H NMR (MeOD, 400 MHz): δ 1.43 (s, 9H, 
Boc), 7.26 (d, 1H, J 9.8, Ar), 8.76 (s, 1H, Ar). HRMS-ESI: calcd for C10H13ClFN2O2+ 
247.0644, found 247.0644. 
[6-Chloro-4-(2-propoxy-ethylamino)-pyridin-3-yl]-carbamic acid tert-butyl ester (4).  
 
A solution of 3 (4.5 g, 18.2 mmol) and 2-n-propoxyethylamine (4.4 mL, 36.5 mmol) in 
ethanol (45 mL) was stirred at reflux for 22 hours. The reaction was cooled to room 
temperature and solvent was removed at reduced pressure to give a yellow solid which was 
triturated with heptane and filtered to give 4 as a white solid. (4.2 g, 12.7 mmol, 70 % yield). 
1H NMR (CDCl3, 400 MHz): δ 0.92 (t, 3H, J 7.4, CH3), 1.45 (s, 9H, t-Bu), 1.56-1.60 (m, 2H, 
CH2), 3.26-3.31 (m, 2H, CH2), 3.36-3.45 (m, 2H, CH2), 3.60-3.64 (m, 2H, CH2), 5.09 (br s, 
1H, NH), 5.85 (br s, 1H, NH), 6.50 (s, 1H, Ar), 7.89 (s, 1H, Ar). HRMS-ESI: calcd for 
C15H25ClN3O3+ 330.1579, found 330.1583  
6-Chloro-N4-(2-propoxy-ethyl)-pyridine-3,4-diamine (5).   
 
32 
A solution of 4 (6.2 g, 18.8 mmol) in 1,4-dioxane (18 mL) was treated with 4 M HCl in 1,4-
dioxane (88 mL) and stirred at room temperature overnight. Solvent was evaporated and the 
residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The 
layers were separated and the aqueous layer was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over magnesium sulfate, and solvent was 
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removed at reduced pressure to give 5 as dark brown oil. (3.74 g, 87 % yield). 1H NMR 
(CDCl3, 400 MHz): δ 0.93 (t, 3H, J 7.4, CH3), 1.57-1.64 (m, 2H, CH2), 2.75-2.96 (br s, 2H, 
NH2), 3.29 (q, 2H, J 5.0, CH2), 3.44 (t, 2H, J 6.6, CH2), 3.67 (t, 2H, J 5.1, CH2), 4.67-4.73 (br 
s, 1H, NH), 6.44 (s, 1H, Ar), 7.63 (s, 1H, Ar). HRMS-ESI: calcd for C10H17ClN3O+ 230.1055, 
found 230.1066 
7-Chloro-1-(2-propoxy-ethyl)-1,4-dihydro-pyrido[3,4-b]pyrazine-2,3-dione (6). 
 
A 0 °C solution of 5 (3.74 g, 16.3 mmol) and diisopropylethylamine (6.1 mL, 34.3 mmol) in 
dichloromethane (134 mL) was treated with methyl chlorooxoacetate(1.5 mL, 15.6 mmol), 
allowed to warm to room temperature and stirred for four hours. The reaction was diluted 
with dichloromethane and washed with saturated sodium bicarbonate solution, dried over 
magnesium sulfate, and solvent was removed at reduced pressure. The residue was dried in a 
vacuum overnight. The residue was dissolved in toluene (40 mL) and refluxed for eight hours. 
The reaction mixture was cooled to room temperature and was used in the subsequent reaction 
as such.  
3,7-Dichloro-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one (7) [25]. 
N
Cl
N
N
On-Pr
O
Cl
7  
An aliquote of 6 from previous step was cooled down, and then thionyl chloride (1.63 mL, 
22.7 mmol), DMF (1.63 mL) and additional 65 mL toluene were added. The reaction mixture 
was stirred at 130 °C for 16 hours and filtered while hot. The solvent was removed at reduced 
pressure to give a brown solid. This was passed through a column of silica gel with 
dichloromethane to give 7 as light yellow solid. (2.9 g, 9.6 mmol, 59 % yield). 1H NMR 
(CDCl3, 400 MHz): δ 0.74 (t, 3H, J 7.4, CH3), 1.37-1.45 (m, 2H, CH2), 3.28 (t, 2H, J 6.5, 
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CH2), 3.72 (t, 2H, J 4.9, CH2), 4.33 (t, 2H, J 4.9, CH2), 7.50 (s, 1H, Ar), 8.67 (s, 1H, Ar). 
HRMS-ESI: calcd for C12H14Cl2N3O2+ 302.0463, found 302.0469. 
tert-Butyl 4-(7-chloro-1,2-dihydro-2-oxo-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-3-
yl)piperazine-1-carboxylate (8) 
N
Cl
N
N
On-Pr
O
N
8
NO
O  
A solution of 7 (321 mg, 1.06 mmol), tert-butyl piperazine-1-carboxylate (269 mg, 1.45 
mmol) and triethylamine (435 µL, 1.94 mmol) in THF (5 mL) was stirred at room 
temperature for 4 hours. The solvent was removed at reduced pressure and the residue was 
partitioned between ethyl acetate and water. The layers were separated and the aqueous layer 
was extracted with ethyl acetate. The combined organic layers were washed with brine, dried 
over MgSO4 and concentrated at reduced pressure to give a yellow solid. This was passed 
through a column of silica gel eluted with 5 % MeOH in CH2Cl2 to give 8 as a light yellow 
solid. (384 mg, 0.85 mmol, 83% yield). 1H NMR (CDCl3, 400 MHz): δ 0.84 (t, 3H, J 7.2, 
CH3), 1.27-1.35 (m, 2H, CH2), 1.47 (s, 9H, boc), 3.35 (t, 2H, J 5.8, CH2), 3.52-3.59 (m, 4H, 
2CH2), 3.74 (t, 2H, J 5.8, CH2), 3.92-4.01 (m, 4H, 2CH2), 4.32 (t, 2H, J 5.0, CH2), 7.33 (s, 
1H, Ar), 8.46 (s, 1H, Ar). HRMS-ESI: calcd for C21H31ClN5O4+ 452.2059, found 452.2088 
tert-Butyl 4-(1,2-dihydro-7-(5-methoxypyridin-2-yl)-2-oxo-1-(2-propoxyethyl)pyrido[3,4-
b]pyrazin-3-yl)piperazine-1-carboxylate (9) 
 
A solution of 8 (514 mg, 1.14 mmol) in 1,4-dioxane (5.4 mL) was treated with 
tetrakis(triphenylphosphine) palladium(0) (128 mg, 0.11 mmol) and stirred 5 min at RT. A 
warm solution of 2-methoxy-5-pyridineboronic acid (151.2 mg, 1 mmol, Frontier Scientific) 
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in ethanol (1 mL) and 2.0 M Na2CO3 (5.5 mL) were added. The mixture was refluxed during 
16 h, filtered hot through celite and concentrated under reduced pressure. The residue was 
partitioned between ethyl acetate and water and the layers were separated. The aqueous layer 
was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, 
dried over MgSO4, concentrated under reduced pressure and passed through a column of 
silica gel eluted with 5% MeOH/ CH2Cl2 to yield 9 as a light yellow solid. (354 mg, 0.7 
mmol, 61 % yield). 1H NMR (CDCl3, 400 MHz): δ 0.76 (t, 3H, J 7.2, CH3), 1.48 (s, 9H, t-
Bu), 3.35 (t, 2H, J 6.4, CH2), 3.53-3.60 (m, 2H, CH2), 3.76 (t, 2H, J 4.9, CH2), 3.94-3.99 (m, 
2H, CH2),  3.98 (s, 3H, CH3), 4.40 (t, 2H, J 4.8, CH2), 6.83 (d, 1H, J 8.6, Ar), 7.25 (s, 1H, 
Ar), 7.63 (s, 1H, Ar), 8.23 (d, 1H, J 8.4, Ar), 8.75 (s, 1H, Ar). HRMS-ESI: calcd for 
C27H37N6O5+ 525.282, found 525.2853 
7-(5-Methoxypyridin-2-yl)-3-(piperazin-1-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-
one (10).  
 
To a solution of 9 (354 mg, 0.7 mmol) in CH2Cl2 (2 mL) at 0 °C, TFA was added dropwise. 
The reaction mixture was brought to RT over an hour and stirred for 16 h. The reaction 
mixture was diluted with CH2Cl2 and quenched with a saturated Na2CO3 solution. The organic 
layer was separated and the aqueous layer was washed once more with CH2Cl2. The combined 
organic layers were washed with brine, dried over MgSO4, concentrated under reduced 
pressure and passed through a column of silica gel eluted with 5 to 10 % MeOH/ CH2Cl2 to 
yield 10 as brown oil. (160 mg, 0.4 mmol, 55 % yield). 1H NMR (CDCl3, 400 MHz): δ 0.92 
(t, 3H, J 7.1, CH3), 1.58-1.65 (m, 2H, CH2), 3.31-3.34 (m, 4H, CH2), 3.52-3.57 (m, 2H, CH2), 
3.93-3.97 (m, 2H, CH2), 4.12 (s, 3H, CH3), 4.23-4.27 (m, 2H, CH2), 4.61-4.65 (m, 2H, CH2), 
5.05-5.11 (m, 2H, CH2), 7.00 (d, 1H, J 8.5, Ar), 7.87 (s, 1H, Ar), 8.36 (s, 1H, Ar), 8.73 (d, 
1H, J 8.4, Ar), 8.85 (s, 1H, Ar). HRMS-ESI: calcd for C22H29N6O3+ 425.2301, found 
425.2308 
 
Chapter IV 
150 
 
7-Chloro-3-(4-methylpiperazin-1-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one (11). 
N
Cl
N
N
On-Pr
O
N
N
11  
The procedure was the same as for preparation of 8 starting from 7 (181 mg, 0.6 mmol) 
except that 1-methylpiperazine (86 mg, 0.47 mmol) was used instead of N-boc-piperazine to 
afford the title compound as brown solid (171 mg, 0.47 mmol, 78 % yield). 1H NMR (CDCl3, 
400 MHz): δ 0.83 (t, 3H, J 7.9, CH3), 1.23-1.29 (m, 2H, CH2), 1.45-1.53 (m, 2H, CH2), 2.33 
(s, 3H, CH3), 2.54-2.57 (m, 4H, 2CH2), 3.34 (t, 2H, J 7.9, CH2), 3.70-3.75 (t, 2H, J 7.8, CH2), 
3.95-4.03 (m, 4H, CH2), 4.29 (t, 2H, J 7.8, CH2), 7.32 (s, 1H, Ar), 8.46 (s, 1H, Ar). HRMS-
ESI: calcd for C17H25ClN5O2+ 366.1691, found 439. 366.1750 
7-(5-Methoxypyridin-2-yl)-3-(4-methylpiperazin-1-yl)-1-(2-propoxyethyl)pyrido[3,4-
b]pyrazin-2(1H)-one (12).  
 
The procedure was the same as for preparation of 9 starting from 11 (171 mg, 0.47 mmol) and 
2-methoxy-5-pyridineboronic acid (71.8 mg, 0.47 mmol) to afford the title compound as 
brown solid (136 mg, 0.31 mmol, 65 % yield). 1H NMR (CDCl3, 400 MHz): δ 0.76 (t, 3H, J 
7.4, CH3), 1.52-1.46 (m, 2H, CH2), 2.35 (s, 3H, CH3), 2.56-2.60 (m, 4H, J 4.9, CH2), 3.35 (t, 
2H, J 6.6, CH2), 3.77 (t, 2H, J 5.4, CH2), 3.98 (s, 3H, CH3), 3.97-4.04 (m, 2H, CH2), 4.40 (t, 
2H, J 5.4, CH2), 6.82 (d, 1H, J 8.6, Ar), 7.62 (s, 1H, Ar), 8.22 (dd, 1H, J 2.4 & 8.6, Ar), 8.72-
8.76 (m, 2H, Ar). HRMS-ESI: Calculated for C23H31N6O3+ 439.2458, found 439.2464 
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7-chloro-3-(4-(2-hydroxyethyl)piperazin-1-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-
2(1H)-one (13). 
 
The procedure was the same as for preparation of 8 starting from 7 (315 mg, 1.4 mmol) 
except 1-(2-hydroxyethyl)piperazine (184.3 mg, 1.42 mmol) was used instead of N-boc-
piperazine to afford the title compound as light yellow solid (392 mg, 1 mmol, 71 % yield). 
1H NMR (CDCl3, 400 MHz): δ 0.83 (t, 3H, J 7.4, CH3), 1.46-1.53 (m, 2H, CH2), 2.61 (t, 2H, 
J 5.1, CH2),  2.66 (t, 4H, J 4.5, 2CH2), 3.35 (t, 2H, J 6.4, CH2), 3.67 (t, 2H, J 5.1, CH2), 3.73 
(t, 2H, J 5.2, CH2), 4.02 (br m, 4H, 2CH2), 4.30 (t, 2H, J 5.2, CH2), 7.33 (s, 1H, Ar), 8.45 (s, 
1H, Ar).HRMS-ESI: calcd for C18H27ClN5O3+ 396.1797, found 396.1810. 
3-(4-(2-Hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-
propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one ( 14). 
 
The procedure was the same as for preparation of 9 starting from 13 to afford the title 
compound as brown solid. 1H NMR (CDCl3, 400 MHz):δ 0.72 (t, 3H, J 7.4, CH3), 1.38-1.47 
(m, 2H, CH2), 2.56 (t, 2H, J 5.3, CH2), 2.59-3.61 (m, 2H, CH2),  3.31 (t, 2H, J 6.7, CH2), 3.63 
(t, 2H, J 5.3, CH2), 3.73 (t, 2H, J 5.2, CH2), 3.93 (s, 3H, CH3), 3.92-3.97 (m, 2H, CH2), 4.36 
(t, 3H, J 5.1, CH3), 6.77 (d, 1H, J 8.6, Ar), 7.55 (s, 1H, Ar), 7.60 (s, 1H, Ar), 8.17 (dd, 1H, J 
2.2 & 8.7, Ar), 8.70 (s, 1H, Ar). HRMS-ESI: calcd for C24H33N6O4+ 469.2563, found 
469.2563 
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2-(4-(1,2-Dihydro-7-(6-methoxypyridin-3-yl)-2-oxo-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-
3-yl)piperazin-1-yl)ethyl 4-methylbenzenesulfonate (15). 
N
N
N
On-Pr
O
N
N
N
OMe
15TsO  
To a solution of 14 (100 mg, 0.21 mmol), triethylamine (75 µL, 2.5 eq) and 
trimethylammonium chloride (20.4 mg, 0.2 mmol, 1 eq) in CH2Cl2 (2 mL) at 0 °C, was added 
dropwise to 4-methylbenzene-1-sulfonyl chloride (61 mg, 0.32 mmol, 1.5 eq) in 2 mL 
CH2Cl2. The reaction mixture was brought to RT and stirred for 16 hours. The solvent was 
removed at reduced pressure and the crude mixture was passed through silica gel eluted with 
2.5 % MeOH in CH2Cl2 to give 15 as yellow solid. (50 mg, 0.08 mmol, 38 % yield). 1H NMR 
(CDCl3, 400 MHz): δ 0.77 (t, 3H, J 7.4, CH3), 1.22-1.24 (m, 2H, CH2), 1.43-1.52 (m, 2H, 
CH2), 2.72 (s, 3H, CH3), 2.82 (t, 2H, J 6.7, CH2), 3.60 (t, 2H, J 6.6, CH2), 3.66 (t, 2H, J 6.7, 
CH2), 3.78 (t, 2H, J 5.6, CH2), 3.99 (s, 3H, CH3), 4.05 (q, 2H, J 6.8, CH2), 7.14 (d, 1H, J 8.6, 
Ar), 7.74-7.78 (m, 2H, Ar), 8.75 (s, 1H, Ar). HRMS-ESI: calcd for C31H39N6O6S+ 623.2652, 
found for tosyl removed [C24H33N6O4]+ 469.2558 
4-(2-Fluoroethyl)-piperazine.  
A mixture of 1-boc-piperazine (1.02 g, 5.47 mmol), 1-bromo-2-fluoroethane (4.17 g, 32 
mmol) and DIEA (41.36 mg, 55.41 mL, 32 mmol) in CH3CN (10 mL) was heated overnight 
at 50 oC and then refluxed for 6.5 h. The reaction mixture was cooled to RT and the solvent 
removed at reduced pressure. The residue was treated with 1 M NaOH (6.24 mL), extracted 
with EtOAc (2 x 20 mL) and dried over MgSO4. The crude mixture was passed through silica 
gel eluted with a gradient mixture of 0 to 10 % MeOH in CH2Cl2 to afford colorless oil (9) 
(1.11 g, 87.4 %). An aliquot of 9 (1 g, 4.31 mmol) was dissolved in CH2Cl2 (10 mL), the 
reaction mixture was treated dropwise at 0 oC with TFA (5 mL) and stirred at RT for 2 h. The 
solvent was removed under reduced pressure and the residue partitioned between CH2Cl2 and 
saturated Na2CO3 solution. The organic layer was separated and the aqueous layer waswashed 
with CH2Cl2. The combined organic layers were dried over MgSO4, filtered and the filtrate 
was concentrated under reduced pressure. A white precipitate was obtained which was filtered 
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off under a steady stream of N2 and further dried under vacuum (506 mg, 3.8 mmol, yield: 70 
%).1H NMR (DMSO-d6, 400 MHz): δ 4.73 (dt, 2H, J 4.6 & 47.4, CHaHb), 3.23-3.35 (m, 10H, 
CH2). MS: (M+H)+  m/z = 133.0 
7-Chloro-3-(4-(2-fluoroethyl)piperazin-1-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-
one (16). 
N
Cl
N
N
On-Pr
O
N
N
16F  
The procedure was the same as for preparation of 8 starting from 7 (109 mg, 0.36 mmol) 
except that 4-(2-fluoroethyl)-piperazine (476 mg, 3.6 mmol) was used instead of N-boc-
piperazine to afford the title compound as a light yellow solid (100 mg, 0.25 mmol, 69 % 
yield). 1H NMR (CDCl3, 400 MHz): δ 0.85 (t, 3H, J 7.4, CH3), 1.48-1.56 (m, 2H, CH2), 2.65-
2.75 (m, 4H, CH2), 2.80 (t, 1H, J 4.7, CH), 3.66 (t, 2H, J 5.2, CH2), 3.75 (t, 2H, J 5.2, CH2), 
4.01-4.15 (m, 4H, CH2), 4.32 (t, 2H, J 5.2, CH2), 4.56 (t, 1H, J 4.7, CH), 4.68 (t, 1H, J 4.7, 
CH), 7.34 (s, 1H, Ar), 8.48 (s, H, Ar). HRMS-ESI: calcd for C18H26ClFN5O2+ 398.1754, 
found 398.1747   
3-(4-(2-Fluoroethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-
b]pyrazin-2(1H)-one (17).  
N
N
N
On-Pr
O
N
N
N
OMe
17 (FRPP07)F  
The procedure was the same as for preparation of 9 starting from 16 (73 mg, 0.2 mmol) and 2-
methoxy-5-pyridineboronic acid (31 mg, 0.2 mmol) to afford the title compound as an off 
white solid (50 mg, 0.11 mmol, 50 % yield). 1H NMR (CDCl3, 400 MHz): δ 0.79 (t, 3H, J 7.4, 
CH3), 1.24-1.26 (m, 2H, CH2), 1.48-1.54 (m, 2H, CH2), 2.70-2.72 (m, 4H, CH3), 2.82 (t, 2H, J 
6.5, CH2), 3.38 (t, 2H, J 6.6, CH2), 3.80 (t, 2H, J 6.6, CH2), 3.99 (s, 3H, CH3), 4.07 (t, 2H, J 
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6.2, CH2), 4.43 (t, 2H, J 6.5, CH2), 4.57 (t, 1H, J 6.6, CH), 4.70 (t, 1H, J 6.6, CH), 6.83-6.87 
(m, 2H, Ar), 7.65 (s, 1H, Ar), 8.25 (m, 1H, Ar), 8.78 (s, 1H, Ar). HRMS-ESI: calcd for 
C24H32FN6O3+ 471.2520, found 471.2526. 
In vitro PDEs inhibitory activity assay of 12 and 17 
Table 1. IC50 (µM) values of PDE5 inhibitors for the 11 
PDE families 
 14 12 17 
hPDE1B1 0.016 30 ND 
hPDE2A 10.00 10 ND 
hPDE3B 10.00 10 ND 
hPDE4D3 20.2 28.0 ND 
hPDE5A3 0.00195 0.00660 0.00645 
hPDE6AB 1.60 3.17 ND 
hPDE7A1 30 30 ND 
hPDE8A1 30 30 ND 
hPDE9A 30 30 ND 
hPDE10A2 5.9 8.4 ND 
hPDE11A4 0.80 2.10 ND 
ND: Not determined 
 
HPLC purification and quality control of labeled compounds 
Table 2. Purification and analysis of radiotracers 
Radioligand 
Mobile phase preparative 
HPLC (%,  buffer in EtOH)  
Rt 
(min)
Mobile phase analytical 
HPLC (%, buffer in ACN)  
Rt 
(min) 
[11C]-12 67, 0.05 M NaOAc pH 5.5 16.5 70, 0.05 M NaOAc pH 5.5 10.1 
[18F]-17 63 , 0.05 M NaOAc pH 5.5  26.0 68, 0.05 M NaOAc pH 5.5 17.1 
Rt (retention time), RCY (radiochemical yield, non decay corrected), ACN (acetonitrile), EtOH (ethanol)  
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Figure 1. Radio-chromatograms of RP-HPLC purification of [11C]12 (A) and [18F]17 (C) and identity 
confirmation by co-injection of standard non-radioactive references 12 and 17 with the isolated 
radioactive formulation of [11C]12 (B) and [18F]17 (D), respectively.  
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Biological evaluations of [11C]12 and [18F]17 
Table 3. Biodistribution study of [11C]12 and [18F]F12 in NMRI mice at several time points post 
injection (N = 4 at each time point, SD = standard deviation) 
aPercentage of Injected Dose (% ID±SD) 
[11C]12 [18F]F17 
Organs 2 min 10 min 30 min 2 min 10 min 30 min 60 min 
Urine 0.2±0.2 0.6±0.2 0.5±0.3 0.2±0.1 0.4±0.2 0.8±0.5 1.4±0.3 
Kidneys 9.9±1.9 6.5±1.1 4.4±0.4 6.1±0.8 3.5±0.4 2.5±0.5 2.3±0.2 
Liver 13.3±2.4 16.8±2.2 16.8±1.8 14.1±2.1 13.0±0.5 9.0±1.6 7.4±0.7 
Spleen 0.9±0.1 1.1±0.2 0.7±0.1 0.5±0.1 0.4±0.1 0.3±0.1 0.3±0.1 
Pancreas 1.0±0.0 1.3±0.2 1.2±0.3 1.0±0.4 1.0±0.2 0.9±0.1 0.6±0.1 
Lungs 15.2±1.9 5.1±0.6 3.1±0.6 7.7±0.7 4.1±0.2 2.3±0.3 2.6±0.4 
Heart 1.2±0.1 0.6±0.1 0.5±0.0 1.2±0.1 0.7±0.1 0.5±0.1 0.5±0.1 
Intestines 10.2±1.4 13.6±0.9 21.1±1.4 10.3±1.6 12.6±1.0 14.1±1.1 15.8±1.8 
Stomach 1.1±0.2 3.2±0.7 5.0±0.6 1.9±0.5 3.2±0.4 5.2±1.5 9.5±0.5 
Cerebrum 3.2±0.6 2.2±0.2 1.3±0.0 1.9±0.2 1.4±0.1 0.9±0.1 0.7±0.1 
Cerebellum 0.8±0.3 0.4±0.1 0.2±0.1 0.5±0.1 0.3±0.0 0.2±0.0 0.2±0.1 
Blood 2.8±0.2 1.9±0.3 1.7±0.1 5.7±0.6 4.5±0.5 5.4±0.5 5.4±0.7 
Muscle 19.1±10.1 30.0±4.3 15.4±8.9 45.5±6.7 29.2±1.9 25.6±4 24.0±2.5 
Penis 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 
Bone 5.7±1.4 8.4±1.2 7.4±1.0 7.6±1.1 
Brain 4.0±0.9 2.6±0.3 1.5±0.1 2.4±0.3 1.7±0.1 1.2±0.1 0.9±0.1 
Data are expressed as mean±SD; apercentage of injected dose calculated as CPM in organ * 100%/total CPM 
recovered 
Table 4. Biodistribution study of [11C]12 and [18F]F12 in NMRI mice at several time points post 
injection (N = 4 at each time point, SD = standard deviation) 
aStandard uptake values SUVW±SD) 
[11C]12 [18F]F17 
Organs 2 min 10 min 30 min 2 min 10 min 30 min 60 min 
Kidneys 6.1±0.7 3.9±0.5 2.6±0.1 3.1±1.8 2.3±0.0 1.5±0.4 1.3±0.1 
Liver 2.4±0.3 3.6±0.6 3.1±0.4 1.9±1.1 2.4±0.1 1.7±0.2 1.3±0.2 
Spleen 2.3±0.3 3.4±0.7 1.8±0.2 2.3±1.3 2.3±0.2 1.2±0.3 0.9±0.2 
Pancreas 1.4±0.2 2.3±0.2 1.6±0.3 1.6±1.0 1.9±0.0 1.4±0.2 0.9±0.1 
Lungs 15.1±3.0 6.3±0.7 3.8±1. 10.9±6.7 5.5±1.0 2.8±1.0 2.9±0.5 
Heart 2.5±0.3 1.5±0.0 0.9±0.1 2.1±1.2 1.8±0.1 1.3±0.2 1.0±0.1 
Intestines 1.0±0.1 1.5±0.1 2.1±0.1 0.9±0.5 1.5±0.1 1.6±0.1 1.6±0.2 
Stomach 0.6±0.2 1.6±0.8 1.6±0.3 0.6±0.4 1.6±0.6 2.7±0.7 3.5±0.2 
Cerebrum 2.9±0.6 2.8±0.4 1.2±0.0 2.2±0.2 1.7±0.1 1.1±0.2 0.8±0.1 
Cerebellum 3.0±0.7 2.1±0.3 0.9±0.1 3.0±0.3 2.1±0.1 1.4±0.3 0.9±0.1 
Blood 0.4±0.0 0.3±0.0 0.2±0.0 0.8±0.1 0.6±0.1 0.8±0.1 0.8±0.1 
Muscle 0.5±0.3 0.7±0.1 0.4±0.2 1.1±0.2 0.7±0.0 0.5±0.3 0.6±0.1 
Penis 0.5±0.1 0.7±0.1 0.6±0.2 0.5±0.2 0.8±0.1 0.9±0.0 0.8±0.1 
Bone 0.5±0.1 0.7±0.1 0.6±0.1 0.6±0.1 
Lung/Blood 38 21 19 14 9 4 4 
Data are expressed as mean±SD; aSUVW calculated as (CPM in organ * Weight of mouse)*100% /(total CPM 
recovered * organ weight) 
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Table 5. Biodistribution of [11C]12 and [18F]F12 in NMRI mice pre-treated with tadalafil, PDE5 TG 
mice, PDE5 TG mice pre-treated with tadalafil at 30 min post injection (N = 3, SD = standard 
deviation) 
a% Injected Dose (% ID±SD) 
[11C]12 [18F]17 
Organs NMRI mice 
(Pre-treated) 
PDE5 TG PDE5 TG 
(Pre-treated) 
NMRI mice 
(Pre-treated) 
PDE5 TG PDE5 TG 
(Pre-
treated) 
Urine 3.1±1.5 3.7±0.4 7.5±0.9 1.4±0.6 1.1±0.5 1.1±0.2 
Kidneys 4.3±0.7 4.0±0.7 5.1±1.0 4.7±0.9 1.7±0.1 3.6±0.1 
Liver 16.4±1.1 13.6±1.4 14.3±2.9 8.3±0.5 6.9±0.6 8.4±1.8 
Spleen 0.6±0.1 1.0±0.1 0.8±0.0 0.3±0.0 0.2±0.1 0.4±0.2 
Pancreas 1.2±0.2 1.4±0.4 1.2±0.3 0.8±0.2 0.5±0.1 0.7±0.4 
Lungs 2.1±0.2 1.6±0.1 1.3±0.3 0.7±0.2 1.7±0.3 1.2±0.3 
Heart 0.5±0.0 4.0±0.4 0.8±0.0 0.6±0.1 8.2±0.6 1.1±0.3 
Intestines 18.1±2.9 22.3±2.1 15.5±2.6 12.5±1.1 13.6±1.9 13.2±0.9 
Cerebrum 1.2±0.1 1.2±0.1 1.1±0.2 0.9±0.1 0.8±0.2 0.8±0.1 
Cerebellum 0.2±0.0 0.2±0.1 0.2±0.0 0.3±0.1 0.2±0.0 0.2±0.0 
Blood 1.9±0.1 1.5±0.1 1.7±0.2 6.2±0.3 5.8±0.4 8.3±2.3 
Muscle 25.3±0.6 23.1±2.5 28.5±9.1 25.3±2.3 25.2±0.3 30.8±3.5 
Penis 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.1 0.1±0.0 
Bone  5.2±2.3 8.0±0.7 9.0±0.9 
Data are expressed as mean±SD; apercentage of injected dose calculated as CPM in organ * 
100%/total CPM recovered 
 
Table 6. Biodistribution of [11C]12 and [18F]F12 in NMRI mice pre-treated with tadalafil, PDE5 TG 
mice, PDE5 TG mice pre-treated with tadalafil at 30 min post injection (N = 3, SD = standard 
deviation) 
aStandardized uptake values (SUVW±SD) 
[11C]12 [18F]17 
Organs NMRI mice 
(Pre-treated) 
PDE5 TG PDE5 TG 
(Pre-treated) 
NMRI mice 
(Pre-treated) 
PDE5 TG PDE5 TG 
(Pre-treated) 
Kidneys 2.8±0.4 2.6±0.4 3.4±0.5 2.5±0.2 1.4±0.1 2.5±0.2 
Liver 3.8±0.3 3.0±0.3 3.4±0.5 2.3±0.1 1.7±0.1 2.3±0.1 
Spleen 2.3±0.3 3.8±0.5 4.7±0.1 3.8±1.5 1.2±0.2 3.8±1.2 
Pancreas 1.9±0.4 2.1±0.3 2.0±0.3 2.7±0.9 1.0±0.1 2.7±0.7 
Lungs 3.4±0.7 1.9±0.3 2.2±0.6 1.8±0.1 1.9±0.3 1.8±0.1 
Heart 1.1±0.1 7.5±0.9 1.8±0.2 4.0±0.7 21.4±1.7 4.0±0.6 
Intestines 1.7±0.3 2.5±0.2 2.1±0.5 2.0±0.2 1.6±0.2 2.0±0.1 
Cerebrum 1.3±0.1 1.1±0.1 1.3±0.2 1.4±0.1 0.9±0.0 1.4±0.1 
Cerebellum 0.9±0.0 0.7±0.1 0.9±0.1 2.7±0.3 0.9±0.1 2.8±0.3 
Blood 0.3±0.0 0.2±0.0 0.2±0.0 1.2±0.3 0.8±0.0 1.2±0.3 
Muscle 0.6±0.0 0.6±0.1 0.7±0.2 0.8±0.1 0.6±0.0 0.8±0.1 
Penis 0.7±0.1 1.0±0.0 0.8±0.2 1.4±0.8 1.0±0.0 0.9±0.1 
Bone  0.7±0.1 0.7±0.1 0.7±0.1 
Heart/Blood  35.7±4.5 7.7±0.1  26.1±4.1 3.4±1.2 
Data are expressed as mean±SD; aSUVW calculated as (CPM in organ * Weight of mouse)*100% 
/(total CPM recovered * organ weight) 
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Figure 2. Ratios between the time-activity curves of the base line and pre-treatment for [11C]12 and 
[18F]17. [11C]12 (Ct/Pt): Time-activity-curves ratios between base line (Ct) and pre-treatment for 
[11C]12; [18F]17 (Ct/Pt): ime-activity-curves ratios between base line (Ct) and pre-treatment for [18F]17.  
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m 
Figure 3. Radio-chromatograms of brain radiometabolite analysis [11C]12 co-injected with cold 12 with 
RP-HPLC at 2 and 30 min pi.  
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Abstract 
Vardenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor approved for treatment of 
male erectile dysfunction. [11C]NMVardenafil, a close analogue of vardenafil, has been 
evaluated in animal models and showed selective and specific binding to PDE5 with 
promising properties for in vivo visualization of PDE5 with positron emission tomography 
(PET). Therefore, we have selected [11C]NMVardenafil as candidate for further clinical 
investigation in selected end-stage heart failure patients awaiting heart transplantation. 
Although vardenafil has been approved by the European Medicines Agency (EMA) to treat 
male erectile dysfunction in humans, it is required to establish the safety of the new derivative 
for first-in-human use according to the ‘Note for guidance on non-clinical safety studies for 
the conduct of human clinical trials and marketing authorization for pharmaceuticals 
(CPMP/ICH/286/95) to support clinical trials with a single ‘microdose’. 
A single dose toxicity study of NMVardenafil was conducted in rats according to the 
recommendation of the International Conference on Harmonization (ICH) Topic 3 guideline 
on Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. 
Necropsy, hematology and clinical chemistry parameters were fully investigated to determine 
the safety of NMVardenafil. 
In this study, sporadic variations were detected that were statistically significant in some cases 
both in the control group and test group treated with NMVardenafil for some hematology and 
biochemical parameters. Nevertheless, systematic, consistent and treatment-related effects 
were not observed.  
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1. Introduction  
Vardenafil has been shown to be a potent and selective inhibitor of phosphodiesterase type 5 
(PDE5), an enzyme responsible for the degradation of cyclic guanosine monophosphate 
(cGMP). Vardenafil has been approved by FDA and EMA for treatment of male erectile 
dysfunction. The adult male recommended dose of vardenafil ranges between 5 mg and 20 
mg. At the highest clinically recommended dose (20 mg orally) the peak plasma concentration 
is around 34 nM [1]. Vardenafil has been evaluated in a comprehensive series of toxicological 
studies, including in vitro and in vivo genetic toxicology assays, single-dose studies in mice 
and rats using both oral and intravenous routes of administration, repeated-dose studies in 
mice, rats, and dogs, reproductive and developmental studies in rats and rabbits, and life-time 
carcinogenicity studies in rats and mice [1, 2]. No adverse effects were observed in mice 
treated with up to 37 mg/kg (males) or 51 mg/kg (females) for 14 weeks. After a 24-month 
daily treatment the no adverse effect level (NOAEL) was established at an oral dose of 15 
mg/kg (male rat) and 10 mg/kg oral (female rat), respectively. Vardenafil was tested in dogs 
at a 10 mg/kg oral dose and no adverse effect on blood pharmacological parameters, central 
neverous system (CNS), psychomotor activity, respiration, blood glucose, gastrointestinal 
function, renal function or coagulation was reported [1, 2]. The NOAEL for vardenafil in a 
study of dogs treated for 12 months was 3 mg/kg/day orally. 
NMVardenafil is a close analogue of vardenafil differing by only a methylene group (figure 
1). Despite the fact that vardenafil had been approved by the European Medicines Agency 
(EMA) to treat male erectile dysfunction in humans; it is required to establish the safety of the 
new derivative for first-in-human use according to ‘Note for guidance on non-clinical safety 
studies for the conduct of human clinical trials and marketing authorization for 
pharmaceuticals (CPMP/ICH/286/95) to support clinical trials with a single ‘microdose’ [3]. 
EMA's ‘Position paper on non-clinical safety studies to support clinical trials with a single 
microdose’ requires conducting an extended single dose toxicity study before the 
commencement of the use of the radioligands in humans [4].  
Non-clinical safety studies to support the conduct of human clinical trials for pharmaceuticals 
have also been internationally harmonised by the International Conference on Harmonization 
(ICH) as outlined in ICH Topic 3: Note for Guidance on Non-clinical Safety Studies for the 
Conduct of Human Clinical Trials for Pharmaceuticals [3]. In this document, the 
recommended method to support human clinical trials of a single dose of a pharmacologically 
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active compound is based on the principles of 'microdose'. A microdose is defined as less than 
1/100th of the dose calculated to yield pharmacological effect of the test substance based on 
primary pharmacodynamic data obtained in in vitro and in vivo (typically doses in, or below, 
the low microgram range) and at a maximum dose of ≤ 100 µg. An example of such a clinical 
trial is the early characterization of a substance's pharmacokinetic-/distribution properties or 
receptor selectivity profile using positron emission tomography (PET) imaging or other 
sensitive analytical techniques [3]. 
The method we followed for evaluation of the toxicity of NMVardenafil was an extended 
single-dose toxicity study as recommended in the ICH M3 document and this includes a 
control group, and a sufficient number of treatment groups to allow the establishment of the 
safety of NMVardenafil with a large safety window compared to the dose employed in PET. 
The dose of non-radioactive (cold) NMVardenafil for administration in the toxicity study was 
calculated based on the specific activity of [11C]NMVardenafil and the possible maximum 
radioactive dose to be administered to humans and using a safety factor of 1000. Since the 
intended route of [11C]NMVardenafil administration in humans is intravenous, this route 
alone in animal testing was considered sufficient. The study period for the extended single-
dose toxicity study was 14 days and included an interim sacrifice on day 2 (day of dosing 
defined as day 1). The extended single-dose toxicity study was designed to obtain information 
on hematology and clinical chemistry at two time points (day 1 and day 2 or day 14) and 
histopathology on day 2 or day 14.  
 
Figure 1. Structures of NMVardenafil and vardenafil. 
In the ICH M3 document, two different microdose approaches are described. The first 
approach involves a total dose of not more than 100 µg that can be divided among up to five 
doses in any subject. This could be useful to investigate target receptor binding or tissue 
distribution in a PET study. The second microdose approach involves not more than 5 
administrations of a maximum of 100 µg per administration (a total of 500 µg per subject). 
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We followed a non-clinical safety study of Approach 1 (table 1) in order to support human 
clinical trials of a single dose of [11C]NMVardenafil. 
Table 1. Non-clinical Studies to Support Exploratory Clinical Investigations: Approach 1 
Clinical: Non Clinical: 
dose to be 
administered 
Start and 
maximum 
doses 
Pharmacology General toxicity 
studies 
Genotoxicity/other 
Total dose ≤ 100 
µg; maximum of 5 
administrations (no 
inter-dose interval 
limitations) 
AND 
Total dose ≤ 1/100th 
NOAEL and 
1/100th 
pharmacologically 
active dose (scaled 
on mg/kg for i.v. 
and mg/m2 for oral)  
Maximal and 
starting doses 
can be the 
same but not 
exceed 100 
µg  
In vitro target / receptor 
profiling should be 
conducted 
Appropriate 
characterization of 
pharmacology in a 
pharmacodynamically 
relevant species should 
be available to support 
human dose selection. 
Extended single dose 
toxicity studya in one 
species, usually 
rodent, by intended 
route of 
administration with 
toxicokinetic profile 
or via the i.v. route. A 
limit dose of 10 mg/kg 
in rats (~6000 times 
the 100 µg clinical 
dose on a mg/kg 
comparison basis) can 
be used 
Genotoxicity 
studies are 
generally not 
conducted, but 
any studies or 
SARb assessments 
conducted should 
be included in the 
clinical trial 
application. 
For highly 
radioactive agents, 
appropriate 
pharmacokinetics 
and dosimetry 
estimates should 
be submitted 
aGenerally, extended single dose study dosings fully evaluate hematology, clinical chemistry, necropsy data and 
histopathology in 10 rodents/sex/group for all groups on day 2 and 5 rodents/sex/group on day 14 in the group 
that is planned to support the clinical dose; bSAR: stuctue activity relationship. 
The objective of the experiment was to fully evaluate hematology, clinical chemistry, 
necropsy and histopathology data in ten rats/sex/group (in both control and treatment groups) 
on day 2 and five rats/sex/group on day 14 based on the ICH Topic M3 recommendation. 
2. Experimental Section 
2.1. Synthesis of NMVardenafil 
The synthesis of NMVardenafil was previously reported [5]. The identity and purity of the 
synthesized compound were confirmed by 1H-NMR, HRMS and HPLC. 
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2.2. Extended toxicity study 
All animal experiments were conducted according to the Belgian code of practice for the care 
and use of animals, after approval from the Animal Ethics Committee, KU Leuven (Ethische 
Commissie Dierproeven, KU Leuven, License number: LA1210237 and 212-2013). 
An extended single dose toxicity study with interim sacrifice on day 2 was carried out in male 
and female Wistar rats. Wistar rats less than 8 weeks old at the start of the experiment and 
weighing 200-400 g were used. Initially rats were housed in individually ventilated cages in a 
thermo regulated (22 °C), humidity-controlled facility under a 12 h/12 h light/dark cycle, with 
free access to food and water. Then they were kept in metabolic cages in isolation for three to 
seven days and physically monitored for any abnormality. 
2.3. Preparation of dose formulation 
NMVardenafil sterile solution for injection was prepared by dissolving NMVardenafil in 10 
% dimethyl sulfoxide (DMSO) in 40 % (2-hydroxypropyl)-β-cyclodextrin (β-CD) solution 
and filtering the solution through a sterile 0.22-μm membrane filter (MILLEX®-GV, 
Millipore) to get a 250 µg/mL NMVardenafil solution for injection.  
The vehicle for injection was prepared in such a way that the final solution was similar in 
composition to the NMVardenafil formulation (10 % DMSO in 40 % β-CD) except the active 
pharmaceutical ingredient (NMVardenafil) and the solution was sterile filtered via a 0.22-μm 
membrane filter.  
2.4. Verification of formulation   
The stability and identity of NMVardenafil formulation for injection used in the toxicity 
studies were analyzed using reversed-phase HPLC methods. The conditions were as follows: 
XBridge™ C18 column (5 μm, 4.6 mm x 150 mm; Waters); isocratic mobile phase (0.05 M 
Na2HPO4 and EtOH, 67:33 v/v at a flow rate of 1 mL/min); UV detector at 254 nm; and 
ambient temperature. 
2.5. Dose calculation 
The specific activity (number of disintergrations per second per amount of substance of the 
sample at the end of formulation) of [11C]NMVardenafil was determined to be 77 GBq/µmol 
[5]. For an adult dose of 370 MBq, the amount of substance (both labeled and unlabeled 
NMVardenafil) is:  
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amount	of	NMVardenaϐil ൌ 	 DoseSpeciϐic	activity ൌ 	
370	MBq
77	GBq/µmol 
A dose of 370 MBq thus corresponded to 4.8 nmol of NMVardenafil (2.28 µg). Based on this, 
it was assumed that the maximum amount of radiolabeled tracer and cold NMVardenafil that 
may possibly be given with a safety margin to an average healthy adult male (70 kg) is 10 µg. 
A safety factor of 1000 was used to calculate the dose of NMVarenafil for injection in rats 
(maximum dose to an adult male would be 10 µg x 1000/70 kg or 143 µg/kg). 
2.6. Dosing procedure 
Sixty rats were divided in to four groups: 20 rats (control group) and 20 rats (treatment group) 
for interim sacrifice on day 2 and 10 rats (control group) and 10 rats (treatment group) for day 
14 sacrifice. Control groups were given vehicle and treatment groups were given 
NMVardenafil 143 µg/kg via a tail vein on day 1. 
2.7. Observation protocol 
All animals in this study were observed regularly for signs of mortality, morbidity, injury, and 
availability of food and water. Individual body weights were determined and recorded during 
the experimental period on the first day of quarantine, day 1 and day 2 (for interim sacrificed 
groups) and  first day of quarantine, day 1, day 2, day 8 and day 14 for the groups sacrificed 
on the 14th day. Each group had an equal number of female and male rats. 
Urine analysis was performed before administration of vehicle or NMVardenafil and on the 
day of sacrifice. Urine was tested for pH and presences of glucose, ketones, leucocytes, 
nitrite, proteins, blood, and hemoglobin with a urine test kit (Roche Combur 7 Test Strips kit, 
Brussels, Belgium). 
2.8. Clinical hematology and chemistry 
Blood was collected for hematology (500 µl in a micro tube with EDTA, Sarstedt, Essen, 
Belgium) and clinical chemistry (400 µl in heparin tubes, BD Microtainer PST ™ LH Tubes, 
Ermbodegem, Belgium) before administration of vehicle or NMVardenafil and on the day of 
sacrifice. After collecting the blood it was well mixed gently and for clinical chemistry it was 
centrifuged at 4 °C at 420 g for 10 min. Supernatant (plasma) was drawn and transferred to 
Inpeco (Inpeco, Switzeerland) tubes. The samples were sent to Laboratoriumgeneeskunde UZ 
Leuven for analysis. Whole blood was analyzed for hematocrit (Hct), red blood cells (RBC) 
count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
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corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), 
white blood cells (WBC) count, platelets count and mean platelets volume (MPV). Plasma 
was analyzed for sodium (Na+), potassium (K+), chloride (Cl-), bicarbonate (HCO3-), anion 
gap, urea, creatinine, albumin, aspartate transaminase (AST), and alanine transaminase 
(ALT).  
2.9. Clinical pathology/necropsy 
Rats were sacrificed on day 2 or day 14 and organs of interest (penis, kidneys, pancreas, 
spleen, liver, heart, lungs and brain) were harvested and stored in 5 % formaldehyde solution 
and sent to the Department of Pathology (UZ Leuven) for histopathology examination.  
3. Statistical procedure 
Means and standard deviations for body weight, hematological and biochemical parameters 
were calculated. One-way ANOVA was used for statistical evaluation of data pooled from the 
control and treatment groups. Moreover, when significance was detected both Tukey's post 
test and the paired Student’s t-test (for within group comparison) and unpaired Student’s t-test 
(for between group comparison) were used. The statistical significance level was set at p < 
0.05.    
4. Results  
4.1. Death, abnormalities, and feeding 
No deaths or clinical abnormalities for any male or female animals were observed during the 
experimental period. Administration of NMVardenafil did not cause any significant changes 
in daily water and food consumption in treated females and males compared with control 
groups.  
4.2. Weights  of rats 
Weight of rats was monitored during the course of the experiment. The average weight and 
the percentage gain/loss of weight are given in tables 2 and 3 for the two day and 14 day 
groups. It was observed that keeping the rats in metabolic cages (MC) had a stress effect on 
the rats and this was reflected in some of the rats losing weight in the first few days of 
quarantine (in some cases up to 15 % weight loss over four days).  
During the four days quarantine period (prior to dosing) female rats were kept in MCs, the 
weight loss was 4.5±3.8 % on average in the control group and 0.5±2.5 % loss in the test 
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group and this difference between the groups was statistically significant (p < 0.01). In the 
male control groups the average weight loss during the quarantine period was 4.6±5.1% vs 
1.0±2.8 % in the test group with statistical significance between the groups (p < 0.01). The 
lack of water and food was ruled out during the experimental period. 
Table 2. Average weight in gram and average percentage gain or loss of weight of rats during the 
experimental period (Acute toxicity group – two days). 
Description Qrt day WD1 % Qrt vs 
D1
WD2 % D1 vs 
D2 
% Qrt vs 
D2
Control group-Day 2 
F 238±8 227±10 -4.5±3.8 232±12 1.8±2.3 -3.0±5.0
M 410±28 390±24 -4.6±5.0 391±26 0.2±1.5 -4.5±5.0
Treatment group-Day 2 
F 243±7 241±10 -0.5±2.5 245±8 1.4±2.0 0.8±2.1
M 258±8 261±10 1.0±2.8 268±7 3.1±3.1 4±2.0
Qrt: Quarantine; D: day; Qrt day: average weights of rats on quarantine day; WD1: average weight of rats on 
day 1; WD2: average weight of rats on day 2; % Qrt vs D1: percentage weight gain/loss between qrt day and 
day 1; % Qrt vs D2: percentage weight gain/loss between qrt day and day 2; % D1 vs D2: percenatage weight 
gain/loss between day1 and day 2.   
It was hypothesized that keeping rats in metabolic cages (MC) had a possible stress effect on 
rats due to limitation of mobility and new environment. The statistically significant difference 
observed in the weight loss between control and test group could only be explained due to the 
stress effect as there was no systematic difference during the quarantine period till the day of 
vehicle or NMVardenafil injection.  
This seems plausible as the longer rats were kept in MCs the lower the rate of weight loss. At 
the end of the 14-day experimental period all the control female rats gained weight (36±9 %) 
and the test group gained on average 16±12 %, this was a significant difference (p < 0.05) 
between day 1 and day 14. However, one female rat in the test group lost weight (4.2 %, 
supporting information (tables 1-4). The male rats showed no statistically significant 
difference (p = 0.35) with a weight gain of 37±9 % and 42±6 % on average for control and 
test group during the 14 days, respectively. 
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Table 3. Average weight in grams and average percentage gain or loss of weight of rats during the 
experimental period (Acute toxicity group – 14 days). 
Description WD1 WD2 % D1 vs 
D2
WD8 % D2 
vs D8
WD14 D8 vs 
D14 
% D1 
vs D14
Control group- 
Day 14 
F 186±8 187±7 1.1±1.5 210±10 12±3. 252±15 20±7 36±9
M 250±4 256±7 2.6±1.0 299±29 17±10 343±22 15±5 37±9
Treatment 
group-Day 14 
F 189±4 186±3 0.2±0.8 206±11 11±5 215±20 4±9 16±12
M 260±5 261±5 0.7±0.5 315±12 21±3 368±20 17±3 42±6
Qrt: Quarantine; D: day; Qrt day: average weights of rats on quarantine day; W D1: average weight of rats on 
day 1; W D2: average weight of rats on day 2; % Qrt vs D1: percenatage weight gain/loss between qrt day and 
day 1;  % Qrt vs D2: percenatage weight gain/loss between qrt day and day 2; % D1 vs D2: percenatage 
weight gain/loss between day1 and day 2; % D2 vs D8: percenatage weight gain/loss between day 2 and day 8; 
% D8 vs D14: percenatage weight gain/loss between day 8 and day 14; % D1 vs D14: percenatage weight 
gain/loss between day1 and day 2. 
4.3. Histopathology 
Histopathology examination was done for a number of organs including, pancreas, spleen, 
kidney, liver, heart, lungs and penis (males). The organs were examined for histopathologic 
lesions, necrosis, and apoptosis. Except for a liver of one male rat treated with NMVardenafil, 
there was no lesion or necrosis related to treatment both in females and male rats. The liver 
function test of the rat with ischemic necrosis; however showed normal values and the rat had 
a normal body weight. Weight 270 g (group average 268±7.3 g), aspartate transaminase 
(AST) 66 IU/L (group average 68.4±4.3), and alanine transaminase (ALT) 49 IU/L (group 
average 49.8±3.2) at the day of sacrifice. The remaining blood chemistry results were also 
close to the group mean values.  
4.4. Hematology 
The hematological findings in females and males are presented in tables 4 to 7. The results are 
divided into control and treatment groups (day 2 sacrificed and day 14 sacrificed). These 
groups were further divided into two based on sex (female and males). Comparison was made 
between day 1 and day 2 on data pooled from control and treatment groups (one-way 
ANOVA) and when significance was observed within group comparison (paired Student's t-
test) was performed to check for individual's variability. Besides, between groups (control 
versus treatment groups) comparison was also performed. 
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The mean values of females both on day 1 and day 2 in treated and control groups were 
within the reference range (table 4) before the dosing started. However, there was statistically 
significant difference for Hct, RBC, MCHC, and MPV (table 4). Within group comparison in 
the control group between day 1 and day 2 showed a significant difference for Hct (p < 0.01), 
RBC count (p < 0.001), MCV (p < 0.001), MCH (p < 0.05), and MCHC (p < 0.001) 
(supporting information table 5).  
Table 4. Mean and p values (ANOVA) for the control group and treatment groups (female rats, 
N=10). Comparison was made on data from day 1 and day 2. 
 control group treatment group p values 
Females day 2  day 1 day 2  day 1 dayday 2 
Hct 0.43±0.02 0.41±0.03 0.43±0.01 0.40±0.01 0.0005
RBC count 7.9±0.25 7.3±0.51 7.7±0.16 7.4±0.27 0.0010
MCV 55.2±1.43 55.6±1.56 55.6±1.75 54.9±1.81 0.6129
MCH 19.1±0.69 18.8±0.65 19.1±0.58 18.8±0.52 0.7045
MCHC 34.7±0.41 33.9±0.50 34.3±0.27 34.3±0.33 0.0014
RDW  11.6±0.44 11.7±0.50 11.8±0.50 12.0±0.44 0.1781
WBC count 10.3±3.30 12.3±3.30 11.5±3.40 11.6±3.05 0.9998
Platelets count 606.1±69.1 576.2±143.8 602.0±87. 6 587.9±107.5 0.8803
MPV 7.6±0.14 7.6±0.16 7.9±0.25 7.7±0.16 0.0026
 
Table 5. Mean and p values (ANOVA) for the control group and treatment groups (male rats, N=10 
per group). Comparison was made on data from day 1 and day 2 
 control group treatment group p values 
Males day 2  day 1 day 2  day 1 day 2  
Hct 0.39±0.10 0.34±0.06 0.43±0.03 0.44±0.03 0.0085 
RBC count 7.0±1.63 6.3±1.08 7.4±0.66 7.3±0.52 0.1634 
MCV 55.1±0.99 53.3±1.81 59.0±1.89 60.2±2.15 0.0001 
MCH 18.8±0.78 17.8±0.99 20.2±0.46 19.9±0.60 0.0001 
MCHC 34.0±0.85 33.3±1.35 34.3±0.47 33.1±0.81 0.9567 
RDW  13.1±0.14 12.6±0.50 12.9±0.69 12.6±0.49 0.6332 
WBC count 8.2±3.96 8.4±1.47 7.8±2.50 8.3±1.50 0.9728 
Platelets count 242.0±121.62 309.8±93.64 679.4±70.17 622.5±125.84 0.0001 
MPV 7.7±0.28 7.5±0.17 7.8±0.20 7.8±0.29 0.9900 
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Within group comparison in the treatment group between day 1 and day 2 also showed a 
significant difference for Hct (p < 0.001), RBC (p < 0.001), MCV (p < 0.001), MCH (p < 
0.05), red blood cell distribution width (RDW, p < 0.01) and mean platelets volume (MPV, p 
< 0.001) (supporting information table 5). However, the absolute difference between the 
means of day 1 and day 2 (table 4) is very small.  
The mean values of males both on day 1 and day 2 in control and treated groups were within 
the reference range (table 5) before and after dosing of vehicle or test compound. Statistical 
analysis showed a difference for Hct, MCV, MCH and platelets count in the male population 
on day 1 and day 2. Nonetheless, further investigation within the group variation showed that 
only Hct (p < 0.05) and MCV (p < 0.01) for the control group and MCV (p < 0.05), MCHC (p 
< 0.05) and RDW (p < 0.05) for the test group were statistically different (supporting 
information table 6). 
Table 6. Mean and p values (ANOVA) for the control group and treatment groups (female rats, 
N=5).  Comparison was made on data from day 1 and day 14. 
 control group treatment group p values 
Females day 14 day 1 day 14 day 1 day 14  
Hct 0.45±0.01 0.45±0.01 0.44±0.03 0.45±0.01 0.4817
RBC count 7.4±0.28 7.6±0.18 7.9±0.53 8.3±0.41 0.0206
MCV 58.0±0.68 58.2±0.73 56.0±1.89 54.2±2.07 0.0044
MCH 19.4±0.15 19.1±0.31 18.8±0.72 18.8±0.49 0.2978
MCHC 33.4±0.25 32.9±0.68 33.6±0.57 34.8±0.55 0.0001
RDW  12.1±0.41 12.1±0.40 12.5±0.47 12.0±0.69 0.6004
WBC count 10.4±1.43 10.4±1.98 11.5±2.11 12.3±1.32 0.8228
Platelets count 601.3±246.75 763.6±121.07 828.6±138.64 790.4±101.61 0.2465
MPV 7.5±0.22 7.6±0.27 7.4±0.12 7.5±0.22 0.6239
 
Hematology results for females showed that there was a statistical difference between day 1 
and day 14 for RBC count, MCV, and MCHC (table 6). But within group comparison for the 
control and test groups showed that only MPV (p < 0.05) for control and MCV (p = 0.05) 
showed a significant difference between day 1 and day 14 (supporting information table 7). 
The mean values of males both on day 1 and day 14 in treated and control groups were within 
the reference range (table 7) before and after dosing of vehicle or test compound. 
Nevertheless, comparison on data from day 1 and day 14 for the groups showed a significant 
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difference for Hct, RBC, MCV and MCHC. Upon further investigation the difference was 
found to be due to the variability of Hct (p = 0.05), RBC (p = 0.05), MCV (p = 0.05) and 
RDW (p = 0.01) in the control and MCV (p < 0.01) in the test group between day 1 and day 
14 (supporting information table 8). 
Table 7. Mean and p values (ANOVA) for the control group and treatment groups (male rats, N=5). 
Comparison was made on data from day 1 and day 14.  
 control group treatment group p values 
Males day 14 day 1 day 14 day 1 day 14  
Hct 0.42±0.02 0.45±0.02 0.42±0.01 0.43±0.02 0.0581
RBC count 7.0±0.20 7.6±0.24 7.2±0.09 7.6±0.29 0.0004
MCV 60.0±1.16 58.5±1.76 58.1±1.58 56.3±1.13 0.0081
MCH 19.5±0.25 19.1±0.58 19.0±0.46 18.7±0.41 0.0897
MCHC 32.4±0.31 32.5±0.42 32.7±0.46 33.2±0.19 0.0192
RDW  13.3±0.46 12.8±0.54 13.6±0.33 13.2±0.51 0.1436
WBC count 13.6±2.22 15.4±4.20 14.1±1.97 14.3±3.89 0.9989
Platelets count 723.2±50.56 707.2±72.95 759.6±41.39 737.0±94.67 0.6672
MPV 7.6±0.30 7.6±0.18 7.6±0.11 7.6±0.23 0.9255
 
4.5. Clinical chemistry 
The clinical chemistry results are presented in tables 8 to 11. The mean values for the acute 
toxicity in control and test groups in female rats on day 1 and day 2 were within the reference 
range (table 8) except for potassium and ALT levels. Potassium concentration was lower and 
ALT level higher than the reference range in all groups but not significantly different in any 
of the groups on any day. Urea level was significantly different. Bicarbonate level on day 2 
showed a significant deviation from day 1 in the control group (p < 0.05). None of the 
biochemical parameters in the treatment group showed a significant deviation after dosing 
(supporting information table 9).  
The potassium and ALT level for the male groups in the acute toxicity study were out of 
reference range. In addition, sodium concentration and chloride (for control group), and anion 
gap, bicarbonate level (treatment group) were out of reference range. Between groups 
comparison (unpaired t-test) on day 1 for males gave significantly different chemistry values 
except for potassium, urea and ALT (supporting information table 10). Moreover, the weight 
of the two groups on day 1 differed significantly (390.2±23.6 g versus 260.5±9.8 g for control 
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and test groups respectively, p < 0.0001). Therefore, any difference that could be observed on 
day 2 between the two groups did not have any clinical significance as the two groups were 
different at the start of the study. Due to limited number of metabolic cages, the test male 
group were kept in individually ventilated cages for longer days than the control group. This 
could be the reason for the observed difference in weight as male rats are known to gain 
weight very rapidly during their early developmental age. The paired t-test for the control 
group showed a difference between day 1 and day 2 only for bicarbonate concentration. The 
results for the test group showed a significant difference between day 1 and day 2 for a 
number of chemistry parameters (sodium, chloride, bicarbonate, anion gap, and creatinine). 
However, the maximum percentage change observed was (-) 8 % for bicarbonate, followed by 
3 % for albumin and less than 2 % for the remaining of significantly different parameters. 
Except biocaerbonate, the other parameters are within the total allowable variation (table 15).  
Table 8. Mean and p values (ANOVA) of chemistry results for the control group and treatment 
groups (female rats, N=10). Comparison was made on data from day 1 and day 2.  
 control group treatment group p values 
Females day 2  day 1 day 2  day 1 day 2  
Sodium 144.7±1.84 144.5±1.08 145.8±2.99 145.7±1.55 0.5937
Potassium 4.2±0.39 4.5±0.46 4.3±0.60 4.1±0.21 0.4261
Chloride 99.8±1.50 99.7±1.71 101.6±3.24 102.6±1.36 0.0667
Bicarbonate 18.2±1.31 21.3±1.74 20.4±3.21 20.4±0.99 0.3518
Anion gap 31.2±2.23 28.0±2.42 28.1±2.73 26.9±1.26 0.0704
Urea 28.8±8.67 30.4±8.32 32.7±5.68 36.1±5.95 0.0001
Creatinine  0.27±0.03 0.26±0.02 0.26±0.02 0.26±0.01 0.7091
Albumin 44.9±1.64 42.9±1.36 44.0±2.87 43.6±3.20 0.6729
AST 70.8±7.56 67.8±7.26 81.3±25.97 77.1±12.66 0.4882
ALT 48.2±14.64 45.0±16.32 57.5±22.01 58.4±19.31 0.5057
 
The clinical chemistry results for the female groups of extended toxicity study were out of 
reference range for potassium and ALT level in both control and treatment groups (table 10). 
Sodium, potassium and albumin level were significantly different (table 10). The paired t-test 
showed that differences were caused by the variation in values on day 14 in the control group 
but there was no significant variability in the treatment group (supporting information table 
11). Comparison between female control and test group on day 1 showed some difference 
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(bicarbonate, anion gap and albumin) and on day 14 (sodium, chloride, bicarbonate, anion gap 
and albumin). Nonetheless, the day 14 difference between the groups could not be attributed 
to the test compound as the two groups showed differences on day 1 and also the day 14 
results of the control group was different from day 1. 
Table 9. Mean and p values (ANOVA) of chemistry results for the control and treatment groups 
(male rats, N=10). Comparison was made on data from day 1 and day 2. 
 control group treatment group p values 
Males day 2 day 1 day 2 day 1 day 2  
Sodium 152.6±2.01 149.8±2.15 141.5±0.68 144.3±0.58 0.0001
Potassium 4.7±0.31 5.7±1.65 4.5±0.59 4.6±0.19 0.0835
Chloride 107.4±1.72 104.7±2.77 100.7±1.55 102.1±0.92 0.0001
Bicarbonate 19.7±1.15 21.9±1.01 25.9±2.12 23.7±1.06 0.0001
Anion gap 30.1±1.22 28.9±1.88 19.4±1.42 23.0±0.82 0.0001
Urea 36.0±7.44 36.6±5.53 39.6±8.26 41.2±6.10 0.0001
Creatinine  0.33±0.03 0.28±0.06 0.23±0.09 0.23±0.02 0.0100
Albumin 42.4±3.24 43.0±2.08 38.5±1.11 39.6±0.75 0.0001
AST 78.4±5.32 107.6±50.26 68.7±8.67 68.4±4.33 0.0111
ALT 63.1±14.44 72.3±11.27 50.1±6.66 49.8±3.15 0.0001
 
Table 10. Mean and p values (ANOVA) of chemistry results for the control and treatment groups 
(female rats, N=5). Comparison was made on data from day 1 and day 14. 
 control group treatment group p values 
Females day 14  day 1 day 14  day 1 day 14  
Sodium 145.9±.35 150.3±2.52 142.9±2.17 143.3±0.88 0.0040
Potassium 4.8±0.38 4.1±0.41 4.3±0.22 4.6±0.35 0.0327
Chloride 102.3±1.77 106.2±2.12 94.6±13.08 100.6±1.28 0.1438
Bicarbonate 20.1±0.67 19.9±1.01 23.0±0.18 22.2±1.03 0.7278
Anion gap 28.4±1.84 28.1±0.70 23.9±1.12 25.1±0.72 0.0575
Urea 38.0±5.40 37.4±3.14 34.0±0.00 40.6±4.92 0.1175
Creatinine  0.22±0.01 0.30±0.10 0.23±0.02 0.24±0.02 0.1807
Albumin 46.2±1.63 46.9±1.44 43.8±1.32 43.8±2.22 0.0364
AST 76.0±11.30 75.0±26.28 74.8±12.07 68.0±4.05 0.8840
ALT 55.4±9.73 65.4±12.69 55.8±3.87 61.6±8.40 0.3820
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The clinical chemistry results for the 14-day study in males showed out of reference range 
values for some parameters (potassium and ALT level) for both control and test groups. 
Anion gap also was out of reference range for the test group. Among all groups, a significant 
difference was observed for sodium, chloride, albumin and AST level between day 1 and day 
14 measurements (table 11). The control male group showed a significant difference for 
sodium (p = 0.01), chloride (p = 0.05), anion gap (p = 0.01) and urea (p = 0.05) between day 1 
and day 14 (supporting information table 12). However, only the anion gap (p = 0.05) and 
urea value (p = 0.05) of the test groups showed a significant difference on day 14. Since these 
differences were also observed in the control group, the effect was not attributed to the test 
compound. 
Table 11. Mean and p values (ANOVA) of chemistry results for the control and treatment groups 
(male rats, N=5). Comparison was made on data from day 1 and day 14.   
 control group treatment group p values 
Males day 14 day 1 day 14 day 1 day 14  
Sodium 145.1±1.79 150.0±0.92 141.6±1.56 143.1±0.57 0.0001
Potassium 5.1±0.20 5.2±0.60 4.9±0.26 4.8±0.39 0.3788
Chloride 102.6±0.90 105.4±1.39 100.4±1.62 99.9±1.39 0.0001
Bicarbonate 21.2±0.66 21.6±1.08 23.4±0.68 22.9±1.18 0.4900
Anion gap 26.4±0.64 28.3±0.62 22.7±0.62 24.9±0.96 0.1258
Urea 32.4±2.88 44.2±6.06 30.8±5.02 36.8±4.15 0.9957
Creatinine  0.20±0.01 0.23±0.05 0.20±0.00 0.21±0.00 0.3060
Albumin 41.1±1.49 42.3±1.10 40.8±0.87 40.0±0.71 0.0327
AST 73.0±2.00 69.2±7.40 77.8±3.49 64.6±8.80 0.0325
ALT 62.0±7.58 62.6±13.87 66.8±3.77 71.5±5.68 0.3880
 
5. Discussion and conclusion 
An extended toxicity study in Wistar rats was performed based on the 'microdose' principle. 
Tables 12 and 13 list the respective reference ranges for the hematology and clinical 
chemistry parameters compiled from three sources [6-9]. 
There are some issues associated with the use of published ‘normal’ values that first need to 
be addressed so that the results of the current study can be interpreted properly. ‘Normal’ 
values are affected by the type of the rat species (strain), food, and housing conditions. As our 
pre-dosing data show, the ‘normal’ values also vary within a cohort of animals. Consequently, 
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the reference ranges should only be used as a point of reference. Therefore, reference ranges 
should never be relied upon as the sole means of making judgments concerning the biological 
importance of a test material–related effect [6]. Furthermore, because reported normal values 
vary widely, ‘values outside of the reference range also do not necessarily indicate an 
abnormal condition and values within the reference range do not necessarily signify a normal 
condition’ [6]. Occasionally, very small statistically significant differences occur between 
control and treated groups in toxicology studies, and unfortunately, the mechanism for the 
difference is usually not apparent (emphasis here). Although the mechanism for the difference 
cannot be pin pointed with certainty, it is possible to identify some experimental 
conditions/manipulations and instrument related issues that could potentially affect the 
variability within same groups or between different groups. 
Table 12. Hematology parameters reference region from different sources for rats 
aged less than 6 months. 
  CRL7 Dirikolu L et al6 
Parameters unit Females Males Females Males 
Hct % 34-42 32-40 42.3±1.3 41.2±1.7 
RBC count 1012/L 6.2-7.6 5.8-7.1 7.7±0.3 7.1±.3 
MCV fL 52-59 53-59 55.1±1.6 58.3±1.5 
MCH pg 19-21 18-22 19.5±0.6 20.4±0. 7 
MCHC g/dL 34-39 33-41 35.4±0.2 35.0±0.5 
RDW %     
WBC count 109/L 4.2-9.7 5.1-12.2 10.5±2.3 14.6±4.3 
Platelates count 109/L 700 700   
MPV fL     
7CRL: Charles Rivers Laboratories adapted from reference [7];6adapted from reference [6] 
During the course of the experiment, repeated pricking was necessary in some rats to access a 
tail vein and at the same time massaging of the tail was done in order to have sufficient 
volume of blood (1 mL). These two handling procedures could potentially result in micro-
clotting (as blood was collected in droplets) and hemolysis. Micro-clotting has potential 
effects on RBC count, platelets count, Hct, ALT and AST in two ways. A first possibility is 
that micro-clot(s) could be counted as aggregates and this could potentially result in lower 
number of platelets without affecting the RBC count and the second effect is through 
blockage of blood analysis instruments by micro-clot which results in a variable RBC count 
which also affects the Hct [Davy Kieffer, Clinical Laboratory, UZ Leuven, personal 
communication]. Hemolysis affects the RBC count and consequently the Hct value together 
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with platelets counts. In the case of a decrease in platelet count without any accompanying 
decrease in RBC count, micro-clotting is the potential culprit for the variation. Repeated 
needle pricking could also be a stimulus for inflammation and initiation of clotting and this 
could potentially affect blood parameters such as WBC count or platelets count.   
Table 13. Clinical chemistry parameters reference region from different sources for rats of less than 6 
month. 
  CRL7 Dirikolu L et al6 Boehm et al8 
Parameters unit F M F M F M 
Na+ mmol/L 140-147 140-146 142.8±1.6 141.1±1.2 135-157 131-142 
K+ mmol/ L 5.8-7.3 6.1-7.7 5.4±0.5 6.1±0.4 4.3-5.6 3.9-6.5 
Cl- mmol/ L 99-108 99-106 101.3±1.4 98.0±1.0    
HCO3- mmol/ L   21.0±2.8 26.8±1.3    
Anion  mEq/L   24.9±2.8 22.4±1.8   
Urea mg/dL     41.3-67.9 24.0-55.9 
Creatinine  g/ L   0.3±0.1 0.2±0.0   
Albumin g/dL 36-46 30-44 47.6±1.8 44.7±0.9   
AST U/ L 47-88 37-94   61-153 50-96 
ALT U/ L 8-37 4-44 36.4±6.4 36.3±5.2 23-67 24-49 
7CRL: Charles Rivers Laboratories adapted from reference [7]; 6adapted from reference [6]; 8adapted from 
reference [8]; Na+: Sodium, K+: potassium; Cl-: chloride; HCO3-, bicarbonate; Anion: Anion gap 
The other potential issue that could introduce variability in observed results is instrument 
related. The blood analysis instruments (Sysmex XE-5000, Sysmex Europe, Hoeilaart, 
Belgium) used were dedicated for analysis of human blood/plasma samples and calibrated 
accordingly. Most laboratory animal hematology and chemistry samples are analyzed by 
dedicated instruments such as Coulter Counter (Model ZBI-6). This difference could 
potentially result in variation between the reference range in our results (a notable example 
being platelets count). The other possible difference arising from the type of instrumentation 
is the measurement method of blood parameters. Hematocrit is a good example here. In our 
blood analysis, the Hct was directly measured where as in other instruments like the Coulter 
Counter (Model ZBI-6), Hct is calculated from MCV and RBC count which can potentially 
introduce variability. Calibration of instruments is done every 3 months and there could be 
deviation in instrument measurement between calibrations. All these source of variations 
(both biological and instrument with and among laboratories) lead to the development of 
guidelines on ''Optimal specification for total error, imprecision, and bias, derived from intra -
and inter-individual biologic variations'' (tables 14 and 15) [10, 11]. Therefore, it was 
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expected that all these factors add up and could result in statistically but not clinically 
significant difference in observed values.  
Another potential confounding factor that could introduce variability in observed 
hematological data is stress effect and sampling technique [9, 12]. The effect of stress is 
highly variable, dependent on individuals, sex, age, and time. The complex nature of the 
effect of stress on hematological data introduces a highly random and difficult to predict noise 
in the observed results which could potentially result in a significant difference between or 
within groups.     
Table 14. Hematological desirable specifications for imprecision, inaccuracy, and total allowable 
error, calculated from data on within-subject and between-subject biologic variation [9]. 
Analyte Biological variation Desirable specification 
 CVw CVg I (%) B (%) TE (%) 
Hct 2.7 6.41 1.35 1.74 3.97 
RBC count 3.2 6.3 1.6 1.7 4.4 
Hemoglobin 2.85 6.8 1.43 1.84 4.19 
Mean corpuscular volume (MCV) 1.4 4.85 0.7 1.26 2.42 
Mean corpuscular hemoglobin (MCH) 1.4 5.2 0.7 1.35 2.5 
Mean corpuscular hemoglobin 
concentration (MCHC) 1.06 1.2 0.53 0.4 1.27 
Red cell distribution wide (RDW) 3.5 5.7 1.8 1.7 4.6 
Leukocytes count 11.4 21.3 5.73 6.05 15.49 
Platelets count 9.1 21.9 4.6 5.9 13.4 
Mean platelet volume (MPV) 4.3 8.1 2.15 2.29 5.84 
CVw = within-subject biologic variation (coefficient of variation); CVg = between-subject biologic 
variation (coefficient of variation); I = desirable specification for imprecision; B = desirable specification 
for inaccuracy; TE = desirable specification for allowable total error 
Therefore, all these factors need to be taken into account for interpretation of data and the 
percentage variation in mean values should be considered together with the statistical test in 
order to reach a clinically sound conclusion.   
The rationale behind using ANOVA as a statistical tool was that if the rats for the experiment 
were taken from the same population then hematology and biochemical parameters should not 
be significantly different among the control and test group unless in case of a pronounced 
effect of vehicle and/or test compound. However, when a significant difference was detected; 
both Tukey's post test and within group comparison (paired t-test) was further employed to 
identify the source of variation. 
NMVardenafil Toxicity Study 
181 
 
5.1. Histopathology/necropsy 
Since the liver is the primary organ that detoxifies toxins, a liver function test is an important 
indicator of the safety of NMVardenafil. There is no evidence for liver damage or impaired 
liver function in the test group except for one rat which showed ischemic liver necrosis on 
histopathological analysis. Nonetheless, in this rat the results of all liver function tests and the 
maintained body mass indicated no in vivo liver damage while the rat was alive and therefore 
necrosis is expected to have occurred after dissection. This could arise if the storage 
conditions during transportation were not optimal (for example if the liver was not completely 
submerged in the formaldehyde solution). In vitro ischemic liver necrosis due to handling of 
organ samples during storage and transportation is a frequent phenomenon in histopathology 
examination (Raphael Sciot, Department of Imaging and Pathology, personal 
communication). Other than the single incidence of potentially in vitro liver necrosis, there 
was no evidence for the organ toxicity of NMVardenafil. 
Table 15. Biochemical desirable specifications for imprecision, inaccuracy, and total allowable 
error, calculated from data on within-subject and between-subject biologic variation [9]. 
Analyte Biological variation Desirable specification 
 CVw CVg I (%) B (%) TE (%) 
Sodium 0.6 0.7 0.3 0.23 0.7 
Potassium 4.6 5.6 2.3 1.81 5.6 
Chloride 1.2 1.5 0.6 0.5 1. 
Sodium Bicarbonate 4.8 4.7 2.4 1.7 5.6 
Anion gap 9.5 10.1 4.8 3.5 11.3 
Urea 12.1 18.7 6.05 5.57 15.55 
Creatinine 5.95 14.7 2.98 3.96 8.8 
Albumin 3.2 4.75 1.6 1.43 4.0 
Aspartate aminotransferase (AST) 12.3 23.1 6.15 6.54 16.69 
Alanine aminotransferase (ALT) 19.40 41.6 9.7 11.48 27.48 
CVw = within-subject biologic variation (coefficient of variation); CVg = between-subject biologic variation 
(coefficient of variation); I = desirable specification for imprecision; B = desirable specification for 
inaccuracy; TE = desirable specification for allowable total error 
5.2. Hematology 
Reference ranges for hematology values are obtained from Dirikolu et al [6] and Charles 
River Laboratories [7]. Reliable strain, age and sex matched reference ranges could not be 
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found for RDW, platelets count and MPV. Hence, means of within and between groups were 
compared to derive any inference.  
On the first day of the experiment, almost 1 mL of blood was drawn before dosing for 
hematology and chemistry analysis. This was almost 6 % of the whole blood volume for an 
average 227 g weighing rat. Hence, it was anticipated that this might have an effect on the 
hematology analysis results such as RBC count and hemoglobin measured on the subsequent 
day. Consequently, these could have further impact on blood parameters that implicitly or 
explicitly depend on RBC count or hemoglobin level such as Hct, MCV, MCH and MCHC.  
Although hematology results showed statistically significant differences on day 2 within 
female control and test groups, none of the mean values were out of reference ranges. 
However, WBC count showed the highest coefficient of variation in control groups both on 
day 1 and day 2 (30.8 % and 26.8 %, respectively). The test groups also showed similar 
variability in WBC count as that of the control group with 29.7 % and 26.4 % coefficient of 
variation for day 1 and day 2, respectively. The slightly higher variability both in control and 
test groups on day 1 could potentially be due to acute metabolic cage stress effect. For both 
the control and test group of female rats, there was a general trend that the day 2 values (Hct, 
RBC, MCV, MCH, and MCHC) were lower than the day 1 values. This could be due to the 
effect of blood drawn on day 1 or to a natural biological variability. Both control groups and 
test group rats were pooled from the same general population of rats, therefore, the 
hematology results of control and test groups were compared (unpaired Student's t-test). The 
results showed that there was no significant difference between control and test group on day 
1 except for MPV (p < 0.001). Also on day two there was no significant difference between 
the two groups except for MCHC (p < 0.05). The comparison between the two groups showed 
that even before dosing there was a sporadic variation. Hence, it was deduced that there was 
no statistically significant difference that could be attributed to the test compound. 
The hematological findings in males of interim sacrificed groups did not show any consistent 
treatment-related effects and all hematology results were in the reference region. One-way 
ANOVA of WBC count for control and test groups on day 1 and day 2 showed no statistical 
difference (p = 0.97) between samples taken on different days and among different groups. 
The hematology results for both control and treatment female groups on day 14 were in the 
reference region except for Hct of both groups. The averages of Hct for all groups are, 
nevertheless, within the allowed total variability of 3.97 % (Table 14). In addition, one-way 
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ANOVA on all Hct data samples from the control and test group showed no statistically 
significant difference (p = 0.4817). Therefore, there is no evidence that the hematological 
findings in females show any consistent treatment-related effects on day 14. The hematology 
results of day 1 and day 14 showed no treatment-related effects in the male groups and all the 
results were in the reference region. The control group showed sporadic variability on day 14 
compared to day 1, albeit all results were in the reference region except the Hct and this was 
also in the allowable variability region.  
5.3. Clinical chemistry 
Reference ranges for clinical chemistry values were compiled from Dirikolu et al [6], Charles 
River Laboratories [7] and Boehm et al [8]. Reliable strain, age and sex matched reference 
ranges could not be found for bicarbonate, anion gap, urea and creatinine. Hence, means of 
within and between groups were compared to derive any inference. 
Clinical chemistry analysis of plasma showed that all groups had mean potassium level lower 
than and mean ALT level higher than reference regions given by Charles Rivers Laboratories.  
This might be due to several factors such as genetic shift from the initial Wistar rats colony or 
feedings (example dietary choline deficiency). Within group comparison for the control did 
not show any statistically significant differences except for the ALT level in the female 
control group of day 14. Therefore, any changes observed for the potassium and ALT level 
was not associated with the test compound.  
Biochemical results of the female groups (on day 2) showed no treatment-related variation, 
but the means of potassium level and ALT in both control and treatment groups were out of 
the reference range. Since within group comparison did show significant difference for both 
groups, the variability in potassium level was not treatment-related. NMVardenafil treated 
male rats showed sporadic variation for some parameters though the means stayed within the 
reference region.  
In the 14 day study groups both female and male control rats showed significant difference 
between day 1 and day 14 for some chemistry results, however, this pattern was not repeated 
in the test group except for the anion gap and urea for test male groups. We could not explain 
the cause for the variation in means for the control group.  
In conclusion, although there have been statistically significant differences both within and 
across groups for some hematology and biochemical parameters, no systematic, consistent 
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and treatment-related effects were observed. The results of the biological parameters 
evaluated in this study in order to establish the safety of NMVardenafil are highly variable 
and dependent on several factors including but not limited to age, sex, stress, weight, 
experimental handling and, instrument allowed total variability in precision. In addition, 
hematological results show both intra-and inter-individual variability and any statistically 
significant difference might be clinically not relevant and/or significant. Taking into account 
the fact that the amount of NMVardenafil which has to be used in humans for a clinical trial 
with [11C]NMVardenafil is less than a thousandth of the dose used for this toxicity study on 
weight basis, any kind of pharmacological toxicity is not anticipated.  
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Chapter V – Supporting Information 
Table 1. Weight (g) of rats and the percentage gain or loss during the experimental 
period. Control group of the interim sacrifice.  
Qrt day Day 1 a% gain/loss Day 2 b% gain/loss c% gain/loss 
      
rat 1 240 239 -0.4 240 0.4 0.0
rat 2 219 211 -3.7 218 3.3 -0.5
rat 3 246 240 -2.4 249 3.8 1.2
rat 4 240 213 -11.3 205 -3.8 -14.6
rat 5 242 222 -8.3 231 4.1 -4.5
rat 6 250 227 -9.2 234 3.1 -6.4
rat 7 240 232 -3.3 239 3.0 -0.4
rat 8 235 235 0.0 238 1.3 1.3
rat 9 237 226 -4.6 228 0.9 -3.8
rat 10 233 228 -2.1 233 2.2 0.0
rat 11 397 398 0.3 401 0.8 1.0
rat 12 390 378 -3.1 381 0.8 -2.3
rat 13 421 423 0.5 422 -0.2 0.2
rat 14 435 394 -9.4 405 2.8 -6.9
rat 15 440 423 -3.9 426 0.7 -3.2
rat 16 410 382 -6.8 378 -1.0 -7.8
rat 17 450 380 -15.6 385 1.3 -14.4
rat 18 365 343 -6.0 335 -2.3 -8.2
rat 19 416 401 -3.6 396 -1.2 -4.8
rat 20 375 380 1.3 381 0.3 1.6
Qrt: Quarantine, apercentage weight gain or loss between quarantine day and day 1, 
bpercentage weight gain or loss between day 1 and day 2, cthe overall percentage weight 
gain or loss between quarantine day and day 2; rats 1 to 10 are female and rats 11 to 20 
are male. 
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Table 2. Weight (g) of rats and the percentage gain or loss during the experimental 
period. Treatment groups of the interim sacrifice.  
Qrt day Day 1 a% gain/loss Day 2 b% gain/loss c% gain/loss 
      
rat 1 244 235 -3.7 243 3.4 -0.4
rat 2 251 250 -0.4 251 0.4 0.0
rat 3 237 231 -2.5 238 3.0 0.4
rat 4 256 255 -0.4 258 1.2 0.8
rat 5 237 232 -2.1 239 3.0 0.8
rat 6 243 236 -2.9 234 -0.8 -3.7
rat 7 243 249 2.5 251 0.8 3.3
rat 8 244 255 4.5 250 -2.0 2.5
rat 9 231 230 -0.4 240 4.3 3.9
rat 10 240 241 0.4 242 0.4 0.8
rat 11 254 261 2.8 270 3.4 6.3
rat 12 260 268 3.1 271 1.1 4.2
rat 13 258 257 -0.4 258 0.4 0.0
rat 14 260 245 -5.8 270 10.2 3.8
rat 15 255 257 0.8 271 5.4 6.3
rat 16 240 250 4.2 254 1.6 5.8
rat 17 267 275 3.0 277 0.7 3.7
rat 18 271 273 0.7 277 1.5 2.2
rat 19 260 265 1.9 267 0.8 2.7
rat 20 255 254 -0.4 268 5.5 5.1
Qrt: Quarantine, apercentage weight gain or loss between quarantine day and day 1, 
bpercentage weight gain or loss between day 1 and day 2, cthe overall percentage weight 
gain or loss between quarantine day and day 2; rats 1 to 10 are female and rats 11 to 20 
are male. 
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Table 3. Weight (g) of rats and the percentage gain or loss during the experimental 
period. Control group of day 14. 
  Day 1 Day 2 a% 
gain/loss
Day 8 b% 
gain/loss
Day 14 c% 
gain/loss 
d% 
gain/loss
rat 1 177 1.130 201 12.291 243 20.896 37.288
rat 2 178 183 2.809 204 11.475 255 25.000 43.258
rat 3 192 190 -1.042 204 7.368 246 20.588 28.125
rat 4 190 191 0.526 222 16.230 276 24.324 45.263
rat 5 192 196 2.083 221 12.755 238 7.692 23.958
rat 6 246 250 1.626 313 25.200 362 15.655 47.154
rat 7 255 263 3.137 322 22.433 350 8.696 37.255
rat 8 253 263 3.953 305 15.970 343 12.459 35.573
rat 9 246 250 1.626 249 -0.400 305 22.490 23.984
rat 10 248 254 2.419 307 20.866 353 14.984 42.339
apercentage weight gain or loss between day 1 and day 2, bpercentage weight gain or loss 
between day 2 and day 8, cpercentage weight gain or loss between day 8 and day 14, dthe 
overall percentage weight gain or loss between day 1 and day 2; rats 1 to 5 are female and 
rats 6 to 10 are male. 
 
Table 4. Weight (g) of rats and the percentage gain or loss during the experimental 
period. Treatment group of day 14. 
  Day 1 Day 2 a% 
gain/loss
Day 8 b% 
gain/loss
Day 14 c% 
gain/loss 
d% 
gain/loss
rat 1 185 187 1.081 223 19.251 237 6.3 28.1
rat 2 192 191 -0.521 208 8.901 184 -11.5 -4.2
rat 3 183 185 1.093 194 4.865 213 9.8 16.4
rat 4 184 183 -0.543 203 10.929 227 11.8 23.4
rat 5 185 185 0.000 203 9.730 212 4.4 14.6
rat 6 265 268 1.132 325 21.269 384 18.2 44.9
rat 7 259 262 1.158 322 22.901 380 18.0 46.7
rat 8 253 255 0.791 301 18.039 356 18.3 40.7
rat 9 264 264 0.000 326 23.485 382 17.2 44.7
rat 10 257 258 0.389 303 17.442 340 12.2 32.3
apercentage weight gain or loss between day 1 and day 2, bpercentage weight gain or loss 
between day 2 and day 8, cpercentage weight gain or loss between day 8 and day 14, dthe 
overall percentage weight gain or loss between day 1 and day 2; rats 1 to 5 are female and 
rats 6 to 10 are male. 
 
Clinical hematology  
The results are divided into control group (sacrificed day 2 or day 14) and Treatment groups 
(sacrificed day 2 or day 14). These groups were further divided into two, based on sex (female 
vs male). Comparison was made within group on data obtained on day 1 before administration 
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of vehicle or NMVardenafil and day 2 (or day 14) after administration of vehicle or 
NMVardenafil (paired t-test). 
Between groups comparison (unpaired t-test) was made on data of the control and test group 
on the first day (day 1) and on the day of sacrifice (day 2 or day 14). 
Table 5. p values for the control group and treatment groups (female rats, N=10). Comparison 
was made on data between day 1 and day 2. 
Females day 2  Within group comparison 
Between groups 
comparison 
   control group treatment group  Day 1 Day 2 
Hct  0.002 0.000 0.399 0.597
RBC count  0.001 0.000 0.124 0.983
 MCV 0.000 0.000 0.307 0.401
 MCH 0.014 0.002 0.729 1.000
 MCHC 0.001 0.834 0.061 0.026
 RDW  0.279 0.002 0.331 0.089
WBC count  0.115 0.846 0.628 0.595
Platelets count  0.210 0.413 0.778 0.839
 MPV 0.177 0.000 0.001 0.681
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Table 6. p values for the control group and treatment groups (male rats, N=10 per group). 
Comparison was made on data between day 1 and day 2. 
Males day 2  Within group comparison Between groups comparison 
   control group treatment group  Day 1 Day 2 
Hct  0.044 0.566 0.082 0.002
RBC count  0.101 0.851 0.965 0.035
 MCV 0.008 0.001 0.001 0.000
 MCH 0.072 0.030 0.000 0.000
 MCHC 0.781 0.006 0.026 0.742
 RDW  0.157 0.004 0.801 0.966
WBC count  0.886 0.665 0.883 0.525
Platelets count  0.425 0.044 0.000 0.011
 MPV 0.822 0.421 0.007 0.085
 
Table 7. p values for the control group and treatment groups (female rats, N=5).  Comparison was made 
on data between day 1 and day 14. 
Females day 14  Within group comparison Between groups comparison 
   control group treatment group  Day 1 Day 14 
Hct  0.784 0.658 0.770 0.561
RBC count  0.172 0.342 0.136 0.016
 MCV 0.562 0.030 0.077 0.006
 MCH 0.108 0.898 0.164 0.302
 MCHC 0.188 0.073 0.463 0.002
 RDW  0.865 0.108 0.260 0.771
WBC count  0.985 0.539 0.422 0.149
Platelets count  0.406 0.533 0.147 0.743
 MPV 0.034 0.528 0.441 0.575
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Table 8. p values for the control group and treatment groups (male rats, N=5). Comparison was made 
on data between day 1 and day 4. 
Males day 14  Within group comparison Between groups comparison 
   control group treatment group Day 1 Day 14 
Hct  0.013 0.207 0.969 0.169
RBC count  0.012 0.056 0.033 0.825
 MCV 0.040 0.010 0.058 0.046
 MCH 0.129 0.211 0.065 0.243
 MCHC 0.721 0.138 0.354 0.012
 RDW  0.009 0.178 0.411 0.312
WBC count  0.401 0.848 0.738 0.674
Platelets count  0.456 0.573 0.248 0.592
 MPV 1.000 0.305 0.589 0.882
 
Clinical chemistry 
Table 9. p values of chemistry results for the control group and treatment groups (female 
rats, N=10). Comparison was made on data between day 1 and day 2. 
Females day 2 Within group comparison Between groups comparison 
  control group treatment group Day 1 Day 2 
Sodium 0.692 0.956 0.476 0.141 
Potassium 0.079 0.391 0.759 0.035 
Chloride 0.943 0.512 0.255 0.004 
Bicarbonate 0.027 1.000 0.325 0.213 
Anion gap 0.233 0.200 0.140 0.252 
Urea 0.692 0.156 0.245 0.148 
Creatinine  0.621 0.910 0.446 0.393 
Albumin 0.176 0.644 0.504 0.684 
AST 0.317 0.592 0.400 0.156 
ALT 0.532 0.920 0.412 0.207 
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Table 10. p values of chemistry results for the control and treatment groups (male rats, 
N=10). Comparison was made on data between day 1 and day 2.   
Males day 2 Within group comparison Between groups comparison 
  control group treatment group Day 1 Day 2 
Sodium 0.083 0.000 0.000 0.000 
Potassium 0.178 0.751 0.439 0.058 
Chloride 0.098 0.003 0.000 0.019 
Bicarbonate 0.001 0.005 0.000 0.004 
Anion gap 0.128 0.000 0.000 0.000 
Urea 0.884 0.594 0.388 0.138 
Creatinine 
(IDMS-trac.) 0.084 0.840 0.019 0.026 
Albumin 0.685 0.001 0.005 0.000 
AST 0.201 0.906 0.021 0.034 
ALT 0.222 0.897 0.030 0.000 
  
Table 11. p values of chemistry results for the control and treatment groups (female rats, 
N=5). Comparison was made on data between day 1 and day 14.   
Females D14 Within group comparison Between groups comparison 
  control group treatment group Day 1 Day 14 
Sodium 0.021 0.759 0.098 0.001 
Potassium 0.071 0.258 0.040 0.074 
Chloride 0.046 0.382 0.277 0.002 
Bicarbonate 0.639 0.317 0.000 0.012 
Anion gap 0.752 0.375 0.007 0.000 
Urea 0.836 0.055 0.233 0.305 
Creatinine 
(IDMS-trac.) 0.191 0.460 0.561 0.266 
Albumin 0.056 0.981 0.050 0.049 
AST 0.905 0.272 0.888 0.613 
ALT 0.037 0.109 0.941 0.631 
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Table 12. p values of chemistry results for the control and treatment groups (male rats, 
N=5). Comparison was made on data between day 1 and day 14. 
Males day 14 Within group comparison Between groups comparison 
  control group treatment group Day 1 Day 14 
Sodium 0.007 0.099 0.012 0.000 
Potassium 0.597 0.441 0.348 0.220 
Chloride 0.037 0.567 0.031 0.000 
Bicarbonate 0.610 0.160 0.001 0.156 
Anion gap 0.008 0.027 0.000 0.001 
Urea 0.036 0.019 0.554 0.085 
Creatinine 
(IDMS-trac.) 0.300 0.058 0.347 0.365 
Albumin 0.105 0.092 0.726 0.005 
AST 0.322 0.061 0.029 0.428 
ALT 0.946 0.131 0.241 0.280 
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1. Overview of radiolabeled PDE5 inhibitors 
Phosphodiesterases are a superfamily of intracellular enzymes that are involved in the 
degradation of second messenger cyclic nucleotides (cAMP and cGMP). Phosphodiesterase 5 
(PDE5) is a cGMP-specific phosphodiesterase present for example in, smooth muscle cells 
and pulmonary vasculature. PDE5 is implicated in a number of pathologies including 
pulmonary arterial hypertension and heart failure/cardiomyopathies. Since the first discovery 
and approval of the PDE5-specific inhibitor sildenafil for treatment of male erectile 
dysfunction, many more PDE5 specific inhibitors have been reported and a few more 
(vardenafil, avanafil and tadalafil) have been approved for human use. 
Despite the apparent role of PDE5 in a multitude of diseases, there have not been many 
reports on developing imaging probes labeled with short lived radionuclides to non-invasively 
assess and visualize PDE5 expression levels in PDE5-related pathophysiological processes.   
Molecular imaging is a rapidly emerging field, providing non-invasive quantitative and 
reproducible information on fundamental biological processes in intact living subjects. 
Fundamental biomedical research benefits considerably from advances in molecular imaging 
and technologies such as microMRI and microPET can be easily translated to the clinics and 
may provide clinical benefit through improved patient care. Integrating molecular imaging 
and molecular medicine in combination with system-biology approaches to better understand 
disease complexity, is very promising to provide predictive, preventive and personalized or 
patient-centered medicine that will transform healthcare in the future. Therefore, developing 
PDE5-specific PET radioligands would allow to quantify and evaluate changes in PDE5 
expression, select patients that would benefit from PDE5 inhibitors early during disease stages 
and assess PDE5 occupancy and optimize dose regimens in patients treated with PDE5 
inhibitors. 
In order to achieve this goal, several PDE5 specific inhibitors that have been reported in the 
literature were selected, synthesized, radiolabeled and evaluated in animal models. The 
structure of different PDE5 inhibitors that have been selected for radiolabeling and further 
investigation in this dissertation are given in figure 1. These nine radiolabeled compounds can 
be grouped into four clusters based on core structural similarities: pyrazolopyrimidinone 
(sildenafil ([11C]14), [11C]33 and [11C]37), imidazotriazine (NMVardenafil ([11C]7), [11C]8 
and [18F]11), benzyl amino-quinolin ([11C]21) and pyridopyrazinones ([11C]12 and [18F]17).   
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Figure 1. Structures of radiolabeled PDE5 inhibitors. 
Selection of PDE5 inhibitors for radiolabeling and biological evaluation was based on 
reported in vitro PDE5 inhibitory activity (IC50), selectivity (specificity) for PDE5, ease of 
synthetic pathways of precursors and references, and amenability for radiolabeling with 
carbon-11 or fluorine-18.  
Precursors and standard non-radioactive compounds (reference compounds), were 
successfully synthesized and the latter were sent to Janssen Pharmaceuticals (Beerse, 
Belgium) to determine their in vitro PDE5 inhibitory activity. The in vitro PDE5 inhibitory 
activity of most compounds showed deviations from values reported in the literature except 
for 7 which showed similar IC50 values (table 1).  
Carbon-11 was produced in a cyclotron as [11C]CH4 and was converted to the more reactive 
[11C]methyl iodide and subsequently [11C]methyl triflate. Labeleing was achieved by standard 
nucleophilic substitution. Fluorine-18 was produced in a cyclotron as [18F]F-. [18F]F- was used 
in the tosyl substitution to get [18F]17. But converted to 2-[18F]fluoroethyl bromide and 
subsequently to 2-[18F]fluoroethyl triflate which was used in nucleophilic substitution to 
produce [18F]11.  
The radiochemical yield for [11C]7, [11C]8, [11C]14, [11C]21, [11C]33, [11C]37 were acceptable 
for biological evaluation. The labeling of [11C]12 was not reproducible and consistent and this 
was reflected in the high standard deviation (20±13). The labeleing of [18F]11 was not also 
reproducible. The labeling of [18F]17 yielded the highest absolute activity upto 6 GBq per 
General Discussion 
199 
 
batch. The crude reaction mixture was purified by RP-HPLC in all cases and subsequently 
formulated for animal experimentation. However, [11C]37 was further purified with C-18 
cartridge in order to get rid of the acetonitrile in the eluting mobile phase and re-formulated. 
Before animal experimentation, the (radio)chemical purity of the radiolabeled formulation 
was determined with analytical RP-HPLC. The identity of the radiolabeled compound was 
confirmed by co-injection with the non-radioactive standard.   
Table 1. Experimental results for different radiolabeled tracers. IC50 (nM), lung uptake (SUV±SD, 
n = 4), blocking (% reduction),   heart retention in PDE5 TG mice (SUV±SD, n = 4). 
 IC50a IC50b Lungsc Blockd Hearte ffold gL/B 
Tracers other names nM nM SUV % SUV   
[11C]-7 [11C]NMVardenafil 0.6 0.8 5.9±1.0 87 12.8±2.1 18.3 11 
[11C]-8 [11C]PVardenafil NA 1.1 3.2±0.4 ND ND ND 17 
[18F]-11 [18F]Fluorovardenafil NA 0.7 6.4±1.6 ND ND ND 7 
[11C]-14 [11C]Sildenafil 3.5 17.3 1.0±0.1 ND ND ND 3 
[11C]-21 [11C]RBQ08 NA 8.1 0.7±0.1 ND ND ND 2 
[11C]-33 [11C]JC4687 0.89 163.6 1.7±0.3 ND ND ND 11 
[11C]-37 [11C]JC4714 0.7 3.2 4.4±1.2 45 3.6±0.9 3.3 32 
[11C]-12 [11C]RPP07B NA 6.6 3.1±0.6 32 7.5±0.9 8.3 19 
[18F]-17 [18F]FRPP07 NA 6.5 2.3±0.3 70 21.4±1.7 16.5 4 
aIC50: literature reported value for non labeled cold compounds; bIC50: values in our assay for non labeled 
cold compounds; clung retention in healthy mice at 30 min pi (SUV±SD); dpercentage reduction of lung 
retention at 30 min pi in healthy mice due to pre-treatment with tadalafil (10 mg/kg, sc); eheart retention in 
PDE5 TG mice at 30 min pi (SUV±SD); fpercentage increase in uptake of tracers in the myocardium of 
PDE5 TG mice compared to control at 30 min pi (based on SUV); gL/B: lung to blood radioactivity ratio 
(based on SUV); ND: not determined; NA: not available. 
 
Initial biological evaluation of radiolabeled tracers was investigated in healthy NMRI mice at 
several post injection (pi) time points (at least at 2 and 30 min pi for all tracers and in some 
cases additional studies were performed at 10 and 60 min pi). Their retention/uptake in the 
lungs at 30 min pi was considered indicator of tracers’ binding to PDE5 because this enzyme 
is abundantly expressed in lung tissue. Comparison of retention between different tracers, 
animal models and conditions (treated and non-treated groups) was made on retention of 
tracers at 30 min pi. The 30 mi pi was selected because it avoids the early perfusion effect and 
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it was considered long enough to allow radioligands reach maximal retention. In addition, the 
selection was partly based on the microPET results of [11C]7 where the tracer reaches 
dynamic equilibrium only after 25 min. Only when tracers retention in the lungs of NMRI 
mice was found to be relatively high,  binding specificity of the tracers to PDE5 was assessed 
by pre-saturating the enzyme (pre-blocking study) with a known structurally unrelated PDE5 
specific inhibitor (tadalafil was generally used for this purpose). 
Comparison of lung retention of several radiolabeled tracers at 30 min pi showed that the 
highest retention in the lungs was observed for vardenafil derivatives [11C]7 and [18F]11 
followed by [11C]37, [11C]8, and [11C]12. [18F]17 retention in lungs was only moderate 
whereas other investigated compounds [11C]14, [11C]21 and [11C]33 showed low retention 
in lungs which is in agreement with their lower PDE5 in vitro inhibitory activity (table 1). 
However, further investigation of binding of radioligands to PDE5 in the lungs of tadalafil 
pre-treated mice showed mild for [11C]12 (32 %), moderate for [11C]37 (45 %), and marked 
for [11C]17 (70 %) and [11C]7 (87 %) reduction in lung retention based on % injected dose (% 
ID). The limited reduction of lung retention for [11C]12 and [11C]37 can be due to non-
specific binding of the tracers to cellular compartment or tissues, but further investigation is 
required to confirm this hypothesis. The in vivo lung retention of the different tracers largely 
paralleled the in vitro PDE5 inhibitory activity (figure 2).   
 
Figure 2. Lung retention of different radiolabeled tracers in healthy NMRI mice in relation to their in 
vitro PDE5 inhibitory activity. pIC50 (= -logIC50), % ID (% injected dose). For the corresponding names 
of the numbers, please refer to Appendix at the end of this chapter. 
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Some of the more promising tracers ([11C]7, [11C]12, [18F]17 and [11C]37) were further 
evaluated in transgenic mice with cardiomyocyte-specific PDE5 over-expression (PDE5 TG) 
to firmly assess their affinity and specificity for the PDE5 enzyme. The mice were generated 
at the Department of Cardiovascular Sciences, KU Leuven (Collaboration with Professor 
Stefan Janssens) and graciously supplied to us. The PDE5 TG mice are characterized by an up 
to 10-fold increase in PDE5 protein expression and a 10-fold increase in sildenafil-inhibitable 
cGMP hydrolysis specifically in the cardiomyocytes of these mice compared to wild type 
littermates. Therefore, it was anticipated that any difference observed in the retention of 
radiotracers administered to the PDE5 TG mice would arise from the increased myocardial 
(bovine) PDE5 expression level. However, there are no reports describing the difference in 
affinity of PDE5 inhibitors for bovine and mouse PDE5 as the catalytic core is a highly 
conserved region across species.  
In PDE5 TG mice, [11C]7 and [18F]17 showed the highest increase in myocardial retention 
(18-fold and almost 17-fold, respectively) compared to the retention in wild type (WT) mice 
at 30 min pi.  Similar to previous results, [11C]12 (8-fold) and [11C]37 (3-fold) showed only 
moderately increased myocardial retention in PDE5 TG mice (figure 3, left). In contrast to 
myocardial uptake, the retention of the tracers in the lungs of PDE5 TG mice decreased 
significantly (figure 3, right) compared to WT mice: [11C]37 (60 %), [11C]12 (50 %), [11C]7 
(45 %), and [18F]17 (32 %) based on SUV. It was hypothesized that the reduction in lung 
retention in PDE5 TG mice was due to the ‘‘stealing effect’’ of the high myocardial uptake 
and lower availability of circulating tracer in the blood. 
 
Figure 3. Left: The myocardium of the PDE5 TG mice showed a marked increase in retention 
compared to WT mice. Right: The lungs of PDE5 TG mice showed a marked reduction in retention 
compared to WT mice. SUV (standardized uptake value). 
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Thus far, we have discussed invasive methods to evaluate the affinity and specificity of 
different radiolabeled tracers for PDE5. However, the objective of this research work was to 
develop radioligands suitable for in vivo visualization of PDE5 with positron emission 
tomography (PET).  PET is a non-invasive molecular imaging technique used in nuclear 
medicine to explore the biochemical process at molecular levels. Therefore, the suitability of 
the different radioligands for PET imaging was evaluated in different animal models. For this 
purpose, dynamic microPET imaging of all synthesized radiotracers was performed in PDE5 
TG mice. To address specific and reversible binding of the radiolabeled tracers to PDE5, mice 
were treated with tadalafil prior to administration of the tracers or given tadalafil 
intravenously (iv) at a specific time (10, 20 or 30 min) after tracer administration, 
respectively. Tadalafil was chosen for both pre-treatment and chase studies because it is 
structurally unrelated to the radioligands we have evaluated, hence minimizing the chance of 
having similar off-target binding patterns.   
In the microPET dynamic studies, it was anticipated that a PDE5-specific radioligand would 
show significantly enhanced accumulation in the myocardium of PDE5 TG mice compared to 
WT mice. In contrast, tadalafil pre-treated mice should show a significant decrease in tracer 
accumulation whereas chase experiments were expected to result in displacement of the 
radioligand from PDE5 catalytic site by the presence of high concentrations of tadalafil if 
radioligand binding was PDE5 specific and reversible. Radiolabeled tracers with low affinity 
for PDE5 were not expected to show any significant accumulation in the myocardium of 
PDE5 TG mice.  
Dynamic microPET imaging results of [11C]7 and [11C]37 are shown in figure 4. 
The radioactivity concentration in the myocardium as a function of time after tracer 
administration was expressed as standardized uptake value (SUV). The time–activity curves 
(TAC) for the myocardial region after administration of [11C]37 showed that there was no 
significant accumulation in  PDE5 TG mice (figure 4, left). This is a typical TAC 
demonstrating low tracer binding due to a too low ratio of PDE5 expression (Bmax) and tracer 
binding affinity (Kd). The TACs reconstructed for [11C]14, [11C]8, [11C]21 and [11C]33 were 
similar to the TAC of [11C]37 (figure 4, left).  
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Figure 4. Left: Time activity curves of myocardium in three PDE5 TG mice (Control) after iv administration of 
[11C]37. Right: Myocardial time activity curves in three PDE5 TG mice after iv administration of [11C]7 (Ct: Control; 
Pt: mouse pre-treated with tadalafil 10 mg/kg, sc; and Ch: mouse given intravenous tadalafil (10 mg/kg, iv after 20 
min of tracer injection) 
On the other hand, TACs on the right panel of figure 4 represent a scenario in which 
radiotracers have a high affinity for PDE5 resulting in a higher Bmax/Kd ratio. The control 
mice showed a steady accumulation of radioactivity in the myocardium until a maximum 
uptake at 30 min pi followed by slow tracer washout. Accumulation of radioactivity in the 
tadalafil pre-treated mice was significantly reduced and maximal uptake was achieved earlier 
compared to the control condition. Myocardial tracer uptake was quickly displaced after 
intravenous administration of tadalafil in the chased mouse. The TACs reconstructed for 
[18F]11 showed a similar patterns as the ones observed for [11C]7 albeit with prolonged 
plateau starting from 20 min and declining after 60 min. [11C]12 and [18F]17, however, 
showed much faster kinetics with a maximal myocardial uptake that was reached about 5 min 
after tracer injection.  
The use of PDE5 inhibitors has been described to be beneficial in improving memory, for 
treating stroke and has effects on object recognition and avoidance learning in different 
animal models. Nonetheless, all these claims are not without controversies. Therefore, 
developing radiolabeled PDE5 specific tracer(s) with the ability to cross the blood-brain 
barrier (BBB) will enable to assess the spatial distribution, the expression levels and the 
physiological role of PDE5 in the brain. Some of the PDE5 inhibitors, we evaluated, have 
been described to cross the BBB. However, in our study none of the radiolabeled tracers 
showed any significant uptake and retention in the brain except for the pyridopyrazinone 
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family ([11C]12 and [18F]17). In vitro autoradiography experiments showed that the 
pyridopyrazinones [11C]RPP07B and [18F]FRPP07 had a self-displaceable binding in brain 
slices to a certain degree but their binding could not be blocked to any significant level with 
other PDE5 specific inhibitors such as tadalafil. In addition, in vivo dynamic microPET 
imaging of rat brain after administration of [11C]12 or [18F]17 showed a uniform and 
significant distribution of both tracers. Nevertheless, their retention could not be blocked by 
pre-treatment with cold 12 or 17, hence providing evidence that their binding were not PDE5-
specific. From our studies, the binding target of the radiolabeled pyridopyrazinones in brain 
tissue could not be determined and future studies are needed to determine the binding site. 
Based on the results of in vitro and in vivo evaluation results, we can affirmatively conclude 
that among the biologically evaluated radiolabeled tracers, the vardenafil derivatives [11C]7 
and [18F]11 showed the highest affinity and specificity for the PDE5 enzyme followed by the 
tracers of the pyridopyrazinone family [11C]12 and [18F]17. Although initial biological 
evaluation of the pyrazolopyrimidinone derivative [11C]37 showed favorable properties with 
45 % inhibitable binding in the lungs of wild type mice; further investigation in PDE5 TG 
mice showed only a moderate increase in myocardium retention compared to control mice at 
30 min pi. The other investigated compounds [11C]7, [11C]14, [11C]21 and [11C]33 showed 
lower retention in lungs and accordingly there was no significant accumulation in the 
myocardium of PDE5 TG mice.   
Based on our preclinical results, [11C]7 has been selected for further clinical investigation in 
selected end-stage heart failure patients awaiting cardiac transplantation. In order to use 
[11C]7 in human, a single dose toxicity study of 7 was conducted in rats according to the 
recommendation of the International Conference on Harmonization (ICH) Topic 3 guideline 
on Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. 
Necropsy, hematology and clinical chemistry parameters were fully investigated to determine 
the safety of 7. 
In the toxicity study, sporadic variation was detected that were statistically but not clinically 
significant in some cases both in control and test groups treated with 7 for some hematology 
and biochemical parameters. Nevertheless, systematic, consistent and treatment-related effects 
were not observed. The toxicity study has paved the path to further pursue the application of 
[11C]7 in humans. 
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2. Limitations and future perspectives 
Selection of PDE5 inhibitors was based on reported in vitro PDE5 inhibitory activity (IC50), 
selectivity (specificity) for PDE5, amenability for radiolabeling and synthetic pathways to 
obtain precursor and reference compounds. Though in vivo affinity is a more relevant 
predictive parameter for a potential PET radioligand, the in vitro PDE5 inhibitory activity 
(IC50) of PDE5 inhibitors is generally reported in literature, particularly in articles or patents 
of high-throughput screening experiments as the latter is more relevant for potential 
therapeutic use. 
The selection of the benzyl aminoquinoline derivative (22, Chapter II - figure 3) was based on 
its extremely low IC50 (50 pM) and high selectivity for PDE5 (at least 7800 times more 
selective for PDE5 vs PDEs 1 to 6). However, attempts to demethylate 22 with different 
classical reagents capable of breaking the aryl methyl ether bond (ArOMe) to provide the 
phenolic precursor for radiolabeling were not successful. It was hypothesized that every 
attempt to break the ArOMe bond with a Lewis acid also resulted in debenzylation of the 
compound at the amine bridge (figure 5). A similar boron tribromide mediated debenzylation 
mechanism was also proposed by Paliakov and Strekowski for a similar compound [118]. 
Therefore, we selected 21 a close analogue of 19 (Chapter II, figure 3) reported by the same 
group albeit with lower in vitro PDE5 inhibitory activity (0.7 nM) for radiolabeling and 
further biological evaluation. Hence, the results of the biological evaluation of [11C]21 might 
not be representative of the family. Had [11C]22 been successfully radiolabeled and evaluated, 
a different results might have been obtained. The same limitation (unsuitability of the lead 
compound for radiolabeling) applies to the pyrazolopyrimidinone derivative [11C]37 as the 
structure of the parent compound reported by Tollefson et al differs slightly. However, our in 
vitro PDE5 inhibitory assay showed similar IC50 values (3.2 nM) for both compounds 35 and 
37 (Chapter II, figure 4).  
We first investigated the affinity and specificity of the radiolabeled tracers with different in 
vitro and ex vivo techniques. However, once a radioligand is proven to have high affinity and 
specificity for the target enzyme (receptor) the natural course would be evaluating this tracer 
in animal models of diseases relevant to the intended use of the radioligands in humans. 
However, due to the lack of a well characterized animal model for the intended purpose, our 
investigation of the suitability of the radiotracers was limited to proof of concept evaluations. 
Though some of the radioligands were validated in PDE5 TG mice with cardiomyocyte PDE5 
Chapter VI 
206 
 
over-expression, it remains to be determined how the expression level of PDE5 in the PDE5 
TG mice correlates to PDE5 expression levels in patients with cardiomyopathies and other 
PDE5 related pathologies.   
 
Figure 5. Proposed mechanism of debenzylation of 22 by Lewis acids (LA).  
Nonetheless, in light of the interest from different groups to investigate particularly [11C]7 in a 
selected group of cardiac patients and patients with pulmonary hypertension;  the inability to 
evaluate this tracer in relevant animal models of disease might not preclude the application of 
this tracer in the preceding pathologies. In addition to the well known role of PDE5 in PAH 
and cardiac hypertrophy, there have been numerous reports of its direct or indirect 
involvement in pathologies such as apoptosis, hypercholesterolemia and atherosclerosis, 
Raynaud’s phenomenon, cystic fibrosis, stroke, and benign prostatic hyperplasia. Future 
studies in animal models using radiolabeled inhibitors with favorable in vivo properties, might 
shed more light onto the possible role of PDE5 in other diseases/processes that are still under 
investigation such as apoptosis where the impact of labeled PDE5 tracers might be even 
higher. PET tracers are advantageous in this regards as it is possible to use them directly in 
humans once their safety is established unlike bulk pharmaceutical active ingredients where 
clinical trial takes years of strenuous effort.   
Finally, with respect to the 4-benzylaminoquinoline derivates, it might be worth trying to 
search for alternative methods to provide the phenolic precursor for radiolabeling and 
biological evaluation. This also holds true for 14 though its close analogue [18F]17 showed a 
high affinity for PDE5 albeit with fast kinetics. It was anticipated that the exchange of 
hydroxyl in the 2-hydroxyethylpiperazine moiety by fluoride would not have much effect on 
the affinity of the molecule for PDE5. In support of this hypothesis is Hughes’ report that in 
X-ray crystallographic studies, the piperazine substituent points towards the solvent and 
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therefore, modifications to this region of the molecule would likely have minimal effect on 
PDE5 affinity and selectivity [72]. 
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